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Abstract
The ionotropic receptors including nicotinic acetylcholine (nAChR), y-aminobutyric 
acid type A  and C (G A B A a/c), serotonin (5HT-3) and glycine receptors (GlyR) all 
comprise the cys-loop receptor family. A pentameric configuration is adopted by 
these receptors featuring a large extra cellular domain, four transmembrane (M) 
spanning domains and an intracellular compartment primarily contributed from the 
M3-4 loop. The recent advent of an X-ray crystal structure of the related ACh 
binding protein from snail, Lymnaea stagnalis, and an electron micrograph nearing 
atomic resolution of the transmembrane domains for the Torpedo nAChR provide 
the opportunity to homology model the structures of all cys-loop ligand-gated 
receptors and investigate critical elements of receptor function with unprecedented 
accuracy.
By using homology modelling to guide site-directed mutagenesis in combination 
with whole-cell patch clamp electrophysiology, molecular elements that mediate the 
biphasic modulation of glycine receptors by Zn2* were investigated. The structure 
of a previously identified low sensitivity inhibitory Zn2+ site was clarified revealing 
critical determinants of GlyR subtype selectivity for Zn2* mediated inhibition. 
Intriguingly these experiments also revealed a novel functional asymmetry at this 
site suggesting that one specific side of the site directs downstream transduction of 
the inhibitory Zn2^  effect. This enabled the elucidation of a hydrophobic pathway 
leading directly through the core of the GlyR from the inhibitory Zn2+ site to the 
agonist binding site suggesting a mechanism for Zn2* mediated inhibition.
This study also investigated the structural basis for Zn2* enhancement of GlyR 
function. A comparative study of GlyR a l  and a2 followed by a directed 
mutagenesis regional scan led to the identification of a complete and novel site for 
Zn2+ potentiation. Further studies also elucidated a potential mechanism of action 
for this site by identifying an important gating component of the GlyR, which 
exhibited a strong interaction with this novel potentiation site for Zn2+.
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These studies demonstrate the power of a homology modelling strategy to resolve 
key elements of cys-loop ligand-gated receptor function. Identifying and 
understanding receptor modulation by allosteric effectors is a key requisite to 
understanding receptor function. This work describes the key structural 
determinants involved in the biphasic Zn2+ modulation of GlyRs both in terms of 
actual binding sites and downstream effector mechanisms.
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Chapter 1 
Introduction
Inhibitory neurotransmission: The glycine receptor
Of all the molecules so far identified as neurotransmitters, the simplest is glycine. 
This achiral amino acid is vital for all known life and is the most basic building block 
of all amino acids. Despite its apparent simplicity glycine forms a critical 
component of many cellular proteins endowing peptide backbones with extra 
flexibility and unique functions. This simplicity is also able to code for multiple 
modes of neurotransmission. Glycine can act as an agonist for strychnine-sensitive 
inhibitory glycine receptors (Lynch, 2004) and as a co-agonist, or modulator, of 
excitatory N-methyl-D-aspartic acid (NMDA) receptors (Mayer and Armstrong, 
2004). Furthermore, glycine is a crucial ingredient for many metabolic processes 
including nucleotide biosynthesis. With regards to mammals this molecule comes 
under the title of a non-essential amino acid as it can be synthesised within cells and 
is not required from the diet. This process requires the enzyme serine 
hydroxymethyl transferase, which acts on another amino acid, serine, itself obtained 
from a glycolytic intermediate (Voet and Voet, 1996). Since the requirement for this 
most simple of organic building blocks began, glycine has shaped the properties of 
almost all proteins and been a major driving force in the progression of metabolic 
processes and neurotransmission.
The race to identify the chemical correlates of neurotransmission, which included 
glycine, came about from the initial impetus generated in the 1950s. Within this 
period it became clear that neurotransmission in higher vertebrates required 
communication between central nervous system (CNS) neurones that were not 
physically touching and that this process was primarily chemically mediated (Nicoll, 
1988). The consensus towards glycine acting as a specific neurotransmitter was 
cautious due to the abundant number of cellular processes this molecule was already 
known to be involved in. Howeve^opinion began to change upon the publication in 
1965 of a paper by Aprison and Werman, which showed that glycine fulfilled the 
first criterion of any substance that is classified as a neurotransmitter. The four
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requirements, listed below, are considered to be important for designating a chemical 
as a conventional neurotransmitter (Ottersen and Storm-Mathisen, 1990).
1. The presynaptic criterion -  In order for a molecule to elicit a rapid 
communication event across a synaptic junction it must initially be present 
within the presynaptic cell.
2. Release criterion -  Upon depolarisation of the presynaptic cell the 
neurotransmitter in question must be released in quantities sufficient for it to 
mediate a downstream effect.
3. Identity of action criterion -  Exogenous application of the putative 
transmitter substance should mimic the effects on the postsynaptic neurone.
4. Removal criterion -  If transmission is to retain a dynamic status then the 
system must reset rapidly for subsequent incoming signals and this therefore 
requires an efficient neurotransmitter removal service.
The landmark paper of Aprison and Werman, (1965) along with follow-up studies 
(Graham, Jr. and Aprison, 1966; Johnston, 1968) demonstrated the presence of both 
glycine and GABA at significant levels through a cross section of the cat spinal cord. 
This research was given further credence when measurements of the glycine content 
was correlated with a number of small neurones present in the spinal cord (Davidoff 
et al., 1967a;DavidofT et al., 1967b). Finally, the advent of autoradiography and the 
loading of neurones with [3H]glycine allowed the distribution of this amino acid to 
be observed using electron microscopy, firmly establishing the presence of glycine in 
synaptic vesicle structures and presynaptic terminals (Hokfelt and Ljungdahl, 
1971;Ljungdahl and Hokfelt, 1973;Matus and Dennison, 1971;Price et al., 1976).
Verification of the release criterion for glycine proved more difficult to attain. These 
techniques primarily relied upon the loading of neuronal tissue, in this case 
hemisected or slices of spinal cord,with [14C]glycine and then electrically stimulating 
the tissue to evoke release. Several studies all achieved success in selectively 
measuring [14C]glycine release over non-specific release such as that of loaded 
[3H]insulin (Aprison, 1970a,b; Roberts and Mitchell, 1972;Osbome et al., 
1973;Mulder and Snyder, 1974). These studies^ however, met with limited success 
perhaps as a result of the efficient reuptake of this neurotransmitter upon synaptic 
release (Mulder and Snyder, 1974).
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The postsynaptic action criterion, was demonstrated using electrical recordings 
accompanied by iontophoretic applications of exogenous glycine. Early studies 
demonstrated that stimulation of presynaptic cells from the lumbosacral spinal cord 
produced membrane responses in motoneurones directly comparable to those elicited 
by exogenous glycine application (Werman et al., 1967;Werman et al., 1968). The 
measurements using applied glycine produced a fall in membrane resistance, a rapid 
membrane hyperpolarisation and an inhibition of electrogenesis, all of which are now 
attributed to actions via the GlyR. Latter studies reproducing these results also 
revealed that (3-alanine, another agonist of the GlyR, could also act in a similar 
fashion, though at the time it was not known that its action was mediated via the 
same receptor (Curtis et al., 1968;ten Bruggencate and Sonnhof, 1972).
With regards to a rapid removal system for glycine from the synaptic cleft after its 
release, initial evidence supported a selective reuptake mechanism. Neal (1969) 
reported a rapid uptake of labelled glycine by rat spinal cord slices. Furthermore, in 
keeping with the observation that the spinal cord seemed to possess far higher levels 
of glycine than the brain (Kelly and Kmjevic, 1969) it was revealed that the spinal 
cord maintained both high and low affinity glycine reuptake processes while the 
brain retained only a low affinity uptake mechanism (Johnston and Iversen, 
1971;Logan and Snyder, 1972). The rate of this uptake in the spinal cord was 
measured using [U-14C]glycine into synaptosomes and was shown to occur against a 
large concentration gradient suggesting an active uptake mechanism (Aprison and 
McBride, 1973). Thus by the middle of the 1970s all four criteria for glycine as a 
neurotransmitter had been established to a sufficient level to strongly implicate 
glycine as a genuine chemical neurotransmitter.
It should also be noted that these studies were complimented by experiments 
demonstrating a selective blockade of the GlyR. Such a selective blockade of spinal 
cord motoneurones mediating inhibitory synaptic transmission was identified early 
on in response to the application of the alkaloid strychnine. This naturally occurring 
molecule is derived from the Indian tree Strychnos nux vomica and was shown to 
selectively inhibit the response elicited via GlyRs, only inhibiting GABAaR 
mediated responses at much higher concentrations (Davidoff et al., 1969;Curtis et al.,
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1971). This important discovery enabled receptor distribution studies using 
[3H]strychnine, which revealed comparable staining patterns to those for the agonist 
glycine at postsynaptic inhibitory locations in the spinal cord and brain stem (Young 
and Snyder, 1973;Young and Snyder, 1974). Eventually this high affinity ligand was 
used to initiate the first direct selective purification of GlyRs via affinity purification 
columns paving the way for biochemical characterisation and subsequent cloning 
studies (discussed later).
The physiology of glycine receptors
Distribution
The spinal cord was the ideal preparation for many of the original distribution studies
for GlyRs. However, even early glycinergic neurotransmission studies eluded to the
possibility that active GlyRs may exist elsewhere, most notably the hindbrain,
including the medulla oblongata, and the pons (Werman et al., 1968; Aprison et al.,
1968;Aprison et al., 1969;Galindo et al., 1967;ten Bruggencate and Sonnhof, 1972).
Meanwhile the presence of glycine and therefore the prospect of putative glycinergic
transmission appeared low in higher brain regions including the cerebral cortex
(Kelly and Kmjevic, 1969). Distribution studies of mRNA levels across a range of
developmental stages up to adulthood revealed that the GlyR family exhibits a broad
distribution of potentially functional receptors throughout the CNS (Kuhse et al.,
1991;Malosio et al., 1991a;Nikolic et al., 1998). The relative importance of these
receptors in synaptic communication is likely to vary between tissue preparations
with studies identifying direct inhibitory synaptic responses mediated by GlyRs in
cerebellar golgi cells, retinal ganglion cells and auditory pathway medial superior
olive cells (Dieudonne, 1995;Protti et al., 1997;Tian et al., 1998;Smith et al., 2000).
Whereas, other reports have only validated functional GlyR responses following
exogenous agonist application with the significance of synaptic receptors not
addressed, such as in cortical and amygdala neurones, and oligodendrocytes
(Belachew et al., 1998;Okabe et al., 2004;Danober and Pape, 1998). At the other
extreme, recordings from hippocampal neurones and rat dopaminergic neurones of
the substantia nigra suggest GlyRs from these regions are exclusively extrasynaptic
with no spontaneous activity observed and whole-cell glycinergic currents are only
recorded in response to exogenous agonist application (Mangin et al., 2002;Mori et
al., 2002). The synaptic GlyR expression patterns are also in close agreement with
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the reported distribution of the two selective plasma membrane glycine transporter 
proteins. These sodium/chloride-dependent transporters, GLYT1 and GLYT2 
(Guastella et al., 1992;Liu et al., 1993), are localised to the spinal cord and the brain 
stem with GLYT1 also present in the diencephalon and retina and GLYT2 expressed 
in the cerebellum (Kim et al., 1994;Zafra et al., 1995).
The role o f the glycine receptor
Given the prevalence of this receptor in intemeurones and motoneurones throughout 
the spinal cord and brain stem this suggested that the GlyR played an important role 
in the coordination of skeletal muscle movements. Most notably, lamina la spinal 
intemeurones, which are regulated via a strong glycinergic input, play a critical role 
in mediating reciprocal inhibition in stretch reflex circuits allowing for relaxation of 
the antagonist muscle (Lodge et al., 1977;Kandel et al., 2000). A role for a 
glycinergic component in motor control circuits is demonstrated by selective 
disruption upon consumption of strychnine, a potent convulsing agent, and also in 
the rare hereditary disease, hyperekplexia. This disorder is a result of detrimental 
mutations within the GlyR protein family leading to dysfunctional glycinergic 
neurotransmission, which is manifest in patients as an overly pronounced startle 
response to unexpected stimuli (Rajendra and Schofield, 1995a). The patient startle 
response stereotypically involves facial grimacing, hunching of shoulders, flexure of 
arms and clenching of fists, most notably this is due to an increase in muscle rigidity, 
known as hypertonia throughout the body of the patient. Animal models of this 
syndrome also exist, which are again due to faulty glycinergic signalling following 
receptor mutations. These include the oscillator, spasmodic and spastic mouse lines 
and myoclonus in dogs, horses and cows, all of which feature a loss of muscle 
coordination and hypertonia (Holland et al., 1970;Lane et al., 1987;Gundlach et al., 
1988;Gundlach et al., 1993;Buckwalter et al., 1994).
Besides the important contribution of GlyRs to motor coordination these receptors
also play significant roles in other neuronal pathways. The GlyR is expressed
throughout the lateral and medial superior olive and the medial nucleus of the
trapezoid body, and evidence suggests this glycinergic circuitry is critical for
tonotopic map formation and sound localisation by the auditory apparatus (Kungel
and Friauf, 1997;Smith et al., 2000;Kapfer et al., 2002;Kim and Kandler, 2003). In
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addition, motor coordination is not the only process that obtains feedback via the 
spinal cord as the peripheral sensation pathways including those that mediate pain 
also communicate with higher brain regions in this manner. GlyRs are prevalent in 
spinal cord lamina I and II, where modification of the inhibitory apparatus can alter 
the strength of the mediated chronic inflammatory pain response and it has recently 
been shown that a specific GlyR plays a vital role in this process (Ahmadi et al., 
2002;Ji et al., 2002;Harvey et al., 2004).
In addition to an inhibitory neurotransmitter role for glycine, a large body of 
evidence now suggests GlyRs also play important roles in neuronal development by 
regulating differentiation and neurite outgrowth, via an excitatory action of the GlyR. 
Due to the depolarised nature of the chloride equilibrium potential in embryonic 
tissues, GlyRs elicit depolarising potentials at these stages. An electrophysiological 
study using microelectrodes on hemisected spinal cords demonstrated the strongest 
excitatory effect by GlyRs and GABAaRs at embryonic day 16 (E l6), with gradual 
weakening and finally a reversal of excitation by postnatal day 2 (P2) (Wu et al., 
1992). This excitatory effect may instigate downstream developmental processes via 
activation of Ca2+ transients as activation of GlyRs in neocortical cells and in 
neonatal lateral superior olive cells caused elevations of intracellular Ca2+ (Flint et 
al., 1998;Kullmann et al., 2002) and excitatory embryonic spinal cord GlyRs have 
also been shown to influence both intracellular calcium and neurite outgrowth (Tapia 
et al., 2001). It has not yet been possible though to show that differentiation and 
neurogenesis is a direct consequence of GlyR modulation of Ca2+ transients. Studies 
investigating the differentiation of retinal photoreceptor precursor cells and cortical 
neurogenesis suggest GlyRs acting via this depolarising mechanism may contribute 
crucially to these developmental events (Zhou, 2001; Young and Cepko, 2004;Flint et 
al., 1998).
Glycine receptor synaptic signalling partners
Experiments to address how glycinergic inhibitory neurotransmission is integrated
within the vast complexity of neuronal systems have revealed a number of interesting
ways in which this neurotransmission may be modulated. Perhaps of most
significance is the potential partnership that exists between the GlyR and the
GABAaR. Both these receptors are present in lamina I and II of the spinal cord, the
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brain stem and in cerebellar Golgi cells. In each case they are capable of co- 
localising at the same synapses to induce mixed inhibitory postsynaptic potentials 
with mixed decay components, a faster glycinergic decay and a slower GABAergic 
decay (Jonas et al., 1998;Chery and de Koninck, 1999;0'Brien and Berger, 
1999;Donato and Nistri, 2000;Dumoulin et al., 2001;Keller et al., 2001;Russier et al., 
2002). This suggests that these two receptor families may work together to 
coordinate and regulate motor control. This supposition is supported by the effective 
treatment of patients with hyperekplexia upon administration of phenobarbitone or 
clonazepam, both enhancers of GABAaR function (Andermann and Andermann, 
1988). The mechanism of GlyR and GABAaR synergy may not always be exactly 
equivalent across different tissue preparations. In lamina I of the spinal cord, GlyRs 
are localised on the postsynaptic membrane directly opposing the presynaptic 
terminals while GABAaRs are positioned further away in the periphery around the 
GlyRs (Chery and de Koninck, 1999). In the case of retinal photoreceptor cell 
maturation, which again requires the activation of both GlyRs and GABAaRs, the 
two receptor types are instead thought to be activated by the common agonist, taurine 
(Young and Cepko, 2004). Another interaction identified between the GlyR and the 
GABAaR is a negative feedback loop whereby activation of one receptor type will 
reduce the amplitude and increase the rate of desensitisation of the subsequently 
activated alternate receptor type. In the spinal cord dorsal horn this inhibition is 
phosphorylation dependent and is asymmetric with pre-activation of GlyRs inhibiting 
subsequent activation of GABAaRs more strongly than vice versa (Li et al., 2003).
The interaction between the neurotransmitters GABA and Gly is not only restricted
to the postsynaptic membrane however, with presynaptic GABAbRs of the auditory
brainstem nucleus able to attenuate the amplitude of postsynaptic glycinergic
potentials by reducing glycine release (Lim et al., 2000). On the other hand
presynaptic spinal GlyRs in the dorsal commissural nucleus and metabotropic
glutamate receptors from rat hypoglossal motoneurones have been shown to enhance
the amplitude and frequency of glycinergic postsynaptic transmission, respectively
(Donato and Nistri, 2000;Jeong et al., 2003). Interestingly though, type II mGluRs
have also been shown to reduce the frequency of glycinergic transmission in
mechanically dissociated rat spinal cord neurones (Katsurabayashi et al., 2001).
Finally, GABA neurotransmission is unlikely to be the only factor influencing
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glycinergic neurotransmission as activation of presynaptic purinergic P2 X2 receptors 
has also been suggested to enhance the frequency of postsynaptic glycinergic 
signalling in a Zn2+ dependent manner (Laube, 2002a).
Intracellular signalling interactions with the glycine receptor 
Besides a rapid extracellular modulation of glycinergic neurotransmission 
postsynaptic GlyR function can also be regulated by a number of intracellular 
processes. One of these is phosphorylation. The GlyR was first demonstrated to be a 
substrate for both cAMP-dependent protein kinase (PKA) and protein kinase C in 
1990 (Song and Huang, 1990). PKA has been shown to significantly enhance the 
amplitude of GlyR mediated responses (Ruiz-Gomez et al., 1991;Katsurabayashi et 
al., 2001) and both protein tyrosine kinases and calcium-calmodulin dependent 
protein kinase II are capable of enhancing glycinergic neurotransmission (Xu et al., 
1999;Caraiscos et al., 2002). Interestingly, the GlyR also appears capable of directly 
interacting with a G-protein py dimer, which increases the channel open probability 
in response to glycine, potentially allowing GlyR modulation by a whole host of G- 
protein coupled receptors (Yevenes et al., 2003). Another potential contribution to 
GlyR enhancement may arise via an as yet unreported cytoplasmic factor, which can 
mediate the effects of Ca2+ influx to increase the apparent affinity of the GlyR 
(Fucile et al., 2000). These modulatory processes are presumably of physiological 
significance, though their exact role remains unreported.
GlyR subtypes: Their respective distributions, properties and functions
Isolation o f glycine receptor subtypes
The isolation of the first pure component of the glycinergic signalling pathway was 
achieved in 1982 when Pfeiffer et al purified a glycine receptor complex from the 
spinal cord using affinity chromatography. The purification, using a strychnine 
derivative bound to a column, yielded a protein complex comprising of three 
different molecular weights, 48 kD, 58 kD and 93 kD. Subsequent analysis revealed 
that the 48 kD component retained properties consistent with GlyRs from native 
tissues, namely a high affinity for the antagonist strychnine and displacement of this 
binding by three GlyR agonists, glycine, p-alanine and taurine.
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Molecular cloning of a GlyR subunit from the rat followed five years later revealing 
that the GlyR a l  shared significant sequence homology with the nAChR family 
(Grenningloh et al., 1987b) and the GABAa receptor family (Grenningloh et al., 
1987a). Owing to the conserved presence of two cysteine residues at a fixed distance 
of 13 amino acids apart, the three families were consigned to a new receptor 
superfamily known as the cys-loop family of ligand-gated ion channel receptors 
(Karlin and Akabas, 1995). Subsequent studies identified the human (h) GlyR a l  
orthologue and another hGlyR variant designated a2, which retained 76 % amino 
acid sequence identity to its a l  counterpart (Fig 1.1; Grenningloh et al., 1990a). 
These studies were further complimented when the rat cDNA sequence 
corresponding to the 58 kD protein was determined (Grenningloh et al., 1990b) and 
later verified in human form (Handford et al., 1996). This subunit had a significantly 
increased molecular weight and lacked the ability to bind strychnine (Pfeiffer et al., 
1982). Unsurprisingly therefore, this protein had a lower sequence identity to the a l  
subunit of 47 % and was therefore classified as GlyR p.
21
hGlyRal --- MYSFNTLR- -LYLSGAIVFFSLAASKEAEAARSATKPMSPSDFLDKLMGRTSG  23
hGlyRa2 MNRQLVNILTALFAFFLETNHFRTAFCKDHDSRSGKQPSQTLSPSDFLDKLMGRTSG  30
hGlyRa3 -MAHVRHFRTLVSGFYFWEAALLLSLVATKETDSARSRSAPMS PSDFLDKLMGRTSG-- 23
uanGlyRa4       MS PSDFLDKLMGRTSG-- 16
hGlyRp MKFLLTTAFLILISLWVEEAYSKEKSSKKGKGKKKQYLCPSQQSAEDLARVPANSTSNIL 39
hGlyRal ----- YDARIRPNFKGPPVNVSCNIFINSFGSIAETTMDYRVNIFLRQQWNDPRLAY-N 76
hGlyRa2A ----- YDARIRPNFKGPPVNVTCNIFINSFGSVTETTMDYRVNIFLRQQWNDSRLAY - S 83
hGlyRa2B IA - a2B variant
hGlyRa3 ------YDARIRPNFKGPPVNVTCNIFINSFGSIAETTMDYRVNIFLRQKWNDPRLAY-S 76
nnnGlyRa4 ----- YDARIRPNFKGPPVNVTCNI FINSFGSVTETTMDYRVNVFLRQQWNDPRLAY-R 69
hGlyRP NRLLVS YDPRIRPNFKGIPVDVWNI FINS FGSIQETTMDYRVNIFLRQKWNDPRLKLPS 99
Pi-2 loop
hGlyRal EYP-DDSLDLDPSMLDSIWKPDLFFANEKGAHFHEITTDNKLLRISRNGNVLYSIRITLT 135
hGlyRa2 EY P - DPSLDLDPSMLDSI WKPDLFFANEKGANFHDVTTDNKLLRISKNGKVLYSIRLTLT 142
hGlyRa3 EYP-DDSLDLDPSMLDSIWKPDLFFANEKGANFHEVTTDNKLLRIFKNGNVLYSIRLTLT 135
mmGlyRa4 EYP-DDSLDLNPSMLESI WKPDLFFANEKGANFHEVTTDNKLLRIFKNGNVLYSIRLTLI 129
hGlyRp D FRGSDALTVD PTMYKC LW KPD L F FAN E KSANFHDVTQENILLFIFRDGDVLVSMRLSIT 158
loop A
hGlyRal LACPMDLKNFPMDVQTCIMQLESFGYTMNDLIFEWQEQGA-VQVADGLTLPQFILK-EEK 193
hGlyRa2 LSCPMDLKNFPMDVQTCTMQLESFGYTMNDLIFEWLSDGP-VQVAEGLTLPQFILK-EEK 200
hGlyRa3 LSCPMDLKNFPMDVQTCIMQLESFGYTMNDLIFEWQDEAP-VQVAEGLTLPQFLLK-EEK 193
xmnGlyRa4 LS CPMDLKNFPMDIQTCTMQLES FGYTMNDLMFEWLEDAPAVQVAEGLTLPQFILR-DEK 187
hGlyRP LSCPLDLTLFPMDTQRCKMQLESFGYTTDDLRFIWQSGDP-VQLEK-IALPQFDIKKEDI 216
cys-loop loop B P8-9 loop
hGlyRal DLRYCTKHYN-TGKFTCIEARFHLERQMGYYLIQMYIPSLLIVILSWISFWINMDAAPAR 252
hGlyRa2 ELGYCTKHYN-TGKFTCIEVKFHLERQMGYYLIQMYIPSLLIVILSWVSFWINMDAAPAR 259
hGlyRa3 DLRYCTKHYN-TGKFTCIEVRFHLERQMGYYLIQMYIPSLLIVILSWVSFWINMDAAPAR 252
mmGlyRa4 DLGYCTKHYN-TGKFTCIEVKFHLERQMGYYLIQMYIPSLLIVILSWVSFWINMDAAPAR 246
hGlyRp EYGNCTKYYKGTGYYTCVEVIFTLRRQVGFYMMGVYAPTLLIWLSWLSFWINPDASAAR 276
loop C Ml
hGlyRal v|LG I IrviTMTTQBsGS RASLPKVS YVKAIDI wflvCLLFVFSALLEYAAVNFVS  308
hGlyRa2 \JlG iBtvItMTT J S G S RASLPKVSYVKAIDHMVCLLFVFAALLEYAAVNFVS 315
hGlyRa3 \^GI|T vItMTTQ|SGSRASLPKVSYVKAIDIWiJ vCLLFVFSALLEYAAVNFVS  308
nanGlyRa4 V'MLGIBTVwrMTTQBSGSRASLPKVSYVKAIDIWNMVCLLFVFAALLEYAAVNFVS  302
hGlyRP V§LGl|svfSLASE§TTLAAELPKVSYVKALDVWLjACLLFGFASLVEYAVVQVMLNNPK 336
M2 M2-3 loop M3
hGlyRal RQHKELLRFRRKRRHHKSPMLNLFQ------ EDEAGEGRFNFSAYGMGPACLQAKD  358
hGlyRa2 RQHKEFLRLRRRQKRQNKE-------------EDVTRESRFNFSGYGMG - HCLQVKD  358
hGlyRa3 RQHKELLRFRRKRKNK§EAFALEKF^RFfp3MDDEVRE|RFSFTAYGMGP-CLQAKD  363
mmGlyRa4 RQHKE FMRLRRRQRRQRME-------------EDI IRESRFYFRGYGLG-HCLQARD  345
hGlyRP RVEAEKARIAKAEQADGKG-------------GNVAKKNTVNGTGTPVHISTLQVGETRCK 384
INTRACELLULAR M3-4 DOMAIN
hGlyRal  GISVKGANNSNTTNPPPAPSKSPEEMRK 986
hGlyRa2 --------------------------------- GTAVKATP - AN - PLPQPP—  KDGDAIKK |82
hGlyRa3 --------------------------------- GMTPKGPNHPVQVMP KSPDEMRK $96
mmGlyRa4 ------ gephyrin binding site GGPMEGSS -1YSPQPPTPLLKEGETMRK 374
hGlyRp KVCTSKSDLRSNDFSIVGSLPRDFELSNYDCYGKPIEVNNGLGKSQAKNN— KKPPPAKP 442
hGlyRal LFIQRAKKIDKISRIGFPMAFLIFNMFYWIIYKIVRREDVHNQ  429
hGlyRa2 KFVDRAKRIDTISRAAFPLAFLIFNIFYWITYKIIRHEDVHKK  425
hGlyRa3 VFIDRAKKIDTISRACFPLAFLIFNIFYWVIYKILRHEDIHHQQQD 432
xmnGlyRa4 LYVDRAKRIDTISRAVFPFTFLVFNIFYWWYKVLRSEDIHQAL-- 408
hGlyRp VIPTAAKRIDLYARALFPFCFLFFNVIYWSIYL-------------  47 5
M4
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Figure 1.1 GlyR family amino acid alignment. From the beginning the domains 
are; signal peptide, which is cleaved from the mature protein (aquamarine), 
extracellular domain and extracellular M2-3 loop (black), transmembrane helices 
(blue) and intracellular M l-2 and M3-4 domains (green). The regions and individual 
amino acids attributed with aspects of receptor function are highlighted as follows: 
agonist binding (purple), gating (red -  with the exception of the GlyR P subunit 
gephyrin binding domain, which is labelled), splice variations (yellow background), 
picrotoxin potency (red background), alcohol and anaesthetic potency (green 
background), the proposed channel gate (grey background), GlyR a3 
phosphorylation residues (light blue background). See also Table 1.1 for a more 
detailed breakdown on transmembrane domain residue functions.
With the rapid rise of molecular cloning techniques two further receptor subtypes 
have since been reported, GlyR a3 from rats and humans (Kuhse et al., 
1990a;Nikolic et al., 1998) and GlyR a4 from mouse (Harvey et al., 2000). Of the 
four a  and the single P genes now discovered GlyR a l  - 3 have all been shown to 
express themselves in two alternative splice variant forms (Fig 1.1). GlyR a l  and 
a3 both exhibit variation in the form of an extra exon either presenter absent, from 
the transmembrane (M) 3 - 4  intracellular loop of the protein and are thus referred to 
as short (S) or long (L) variants (Malosio et al., 1991b;Nikolic et al., 1998). The 
GlyR a2 gene, by contrast, carries two alternate versions of exon 3 identified in rat, 
which result in a section of the N-terminus being expressed in two possible forms 
that differ by a divergent dual amino acid substitution (Kuhse et al., 1991b). Though 
the specific requirement within an organism for all five of these GlyR subunits is not 
known, this diversity is extended outside the mammalian lineage to the zebrafish, a 
teleost, suggesting maintenance of these divergent orthologues is physiologically 
significant (Imboden et al., 2001).
Glycine receptor a l -  The rapid responder
An obvious question with regard to the apparent complexity of variable GlyR
subtypes is what functional consequences this might have on the organism. Such
information has been obtained by identifying distinct receptor expression patterns
and unique functional properties as well as by discovering naturally occurring
receptor mutations and evaluating the consequences of artificially manipulating these
receptors in vivo. The role of the GlyR a l  subunit is clearly a critical one with
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several naturally occurring mutations being responsible for the genetic condition of 
hyperekplexia (Zhou et al., 2002;Lynch, 2004). The broad expression pattern of this 
subunit within the spinal cord and certain brain regions (Malosio et al., 1991a) along 
with the absence to date of naturally occurring mutations in any of the other 
a  subunits, suggests that GlyR a l  may be the predominant functional isoform in 
mammals. Furthermore, the auxiliary nature of the p subunit and its almost 
ubiquitous expression throughout the central nervous system suggests this variant is 
unlikely to be able, by itself, to confer functional specificity. However, despite these 
observations recent evidence does point to specific roles for the other a  subunits in 
vivo.
Several studies have suggested there is a developmental switch around the time of 
birth from an embryonic expression pattern where GlyR a l  and a4 predominate to 
the predominant postnatal forms, GlyR a l  and a3. This raises the possibility that 
differing receptor isoforms may perform specific roles during development. These 
initial studies were collated from RNA in situ hybridisation experiments on GlyR 
a  1-3 (Malosio et al., 1991a;Watanabe and Akagi, 1995) and protein quantification 
comparing the relative amounts of the 48 kD (a l)  and 49 kD (a2) species (Becker et 
al., 1988) during development. However, further support was also obtained from a 
functional study by Takahashi et al, (1992) where single channel studies revealed 
distinct distributions of amplitudes and open times for recombinant rat GlyR a l  and 
a2, which correlated with those recorded from native GlyRs in the juvenile P I6 and 
embryonic E l8 rat, respectively. These observations were tentatively linked to a 
shift in the kinetics of evoked IPSCs with embryonic tissues exhibiting a more 
diffuse IPSC that displayed slower rates of onset and offset compared to evoked 
IPSCs in more mature tissues. This may mean that the embryonic GlyR a2 is not as 
suited to the rapid response dynamics required for receptors positioned at the synapse 
(Mangin et al., 2003) and therefore during post-natal development, where the 
organism requires more precise and rapid movement, the spinal cord up regulates to 
the more rapidly responsive GlyR a l . Another prime example of the requirement for 
a highly coordinated and rapid signalling complex is provided by the central auditory 
system, a system which receives a strong regulatory control from GlyRs and where 
GlyR a l  is not expressed until birth when it undergoes rapid up regulation at the
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protein level according to immunostaining with a selective a l  antibody (mAb 2b) 
(Kungel and Friauf, 1997).
A recent study by Mangin et al (2003) analysing recombinant GlyR a2 in a synaptic 
context, by rapidly applying brief 1 ms pulses of Gly to macropatches, revealed that 
even at 1 mM concentrations, GlyR a2 was only able to activate minimally within 
this time scale. This suggested that the GlyR a2 subtype is not capable of supporting 
rapid transmission at synapses and indeed may not be localised to the synapse. 
Though the slow activation kinetics of GlyR a2 makes this receptor unsuitable for 
dynamic synaptic integration it is unlikely that the GlyR a2 subunit is entirely 
extrasynaptic. Takahashi et al (1992) electrically evoked glycinergic IPSCs, 
presumed to be mediated by a2 receptors, in embryonic tissue. Even as early as E l6, 
acute recordings from the rat dorsal root exhibited glycinergic synaptic activity (Wu 
et al., 1992). Furthermore rat spinal cord cultures, that are known to undergo only a 
minimal transition from the a2 to a l  subtype during maturation (Hoch et al., 
1989;Hoch et al., 1992), still exhibit robust synaptic activity (Bloomenthal et al., 
1994;Laube, 2002a). The auxiliary P-subunit is, however, highly expressed during 
culture maturation and this subunit is also an important anchoring protein to ensure 
efficient expression of GlyRs (Moss and Smart, 2001). In certain systems such as 
the basolateral amygdala the receptor subtype is predominantly a2 and its 
pharmacology is mostly in keeping with expression as an a2p heteromer (McCool 
and Farroni, 2001). Thus it may be that the P subunit can co assemble with a l  
receptors and increase their activation kinetics (unfortunately not tested by Mangin et 
al., 2003) sufficiently to be operable at the synapse, though probably still less 
responsive than the GlyR a l  (Takahashi et al., 1992).
Glycine receptor a2 -  The developmental subunit
Any advantage that the GlyR a l  subunit offers over a2 in mature tissues must 
presumably be complimented by a beneficial effect conferred by a l  receptors in the 
embryo. With regards to the proposed suitability of GlyR a l  to extrasynaptic 
localisation at embryonic stages this may indeed have important consequences for 
neuronal development in response to tonic stimuli. The presence of extrasynaptic
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GlyRs in cortical plate neurons during embryonic development has been 
electrophysiologically validated in the neocortex with taurine the most likely agonist 
responsible (Flint et al., 1998). A subsequent study combining RT-PCR and 
electrophysiology confirmed these cortical receptors to be GlyR a l  (Okabe et al., 
2004). Previously, taurine deprivation of kittens in utero has been shown to cause an 
apparent disruption of normal cortical migration and differentiation (Sturman, 1986), 
in accord with a developmental role for GlyRs. Indeed, taurine acting via GlyR a l  
encourages differentiation of precursor cells into rod photoreceptors in retinal 
cultures (Young and Cepko, 2004). Developmental regulation by GlyR a l  subunits 
may also potentially be fine tuned by varying the relative expression of the two a l  
receptor splice variants, which exhibit a 4-fold variation in their sensitivity to taurine 
regardless of co-expression with the p subunit (Miller et al., 2004). This is a 
particularly tantalising hypothesis as neurones possess two genes encoding NOVA-1 
and 2 spread across the spinal cord and brain, which have the capacity to control the 
relative ratios of receptor splice variants, including GlyR a2A and 2B (Jensen et al., 
2000;Ule et al., 2003).
Although GlyR a l  is the predominant receptor during embryogenesis it may also 
play some specialised roles in adult tissues. Though the receptor subtype has not 
been validated, non synaptic GlyR mediated tonic noise, a role seemingly suited to 
GlyR a l , has been demonstrated in the postnatal hippocampus from P7 onwards 
(Mori et al., 2002). Additionally, RT-PCR studies in the amygdala demonstrate that 
GlyR a l  is the predominant GlyR in this adult preparation (McCool and Farroni, 
2001). Thus it would appear that GlyR a l  can remain in certain adult tissues, a 
suggestion supported by the identification of GlyR a l  transcripts that are retained at 
least until juvenile stages of rat spinal cord progression (Jensen et al., 2000).
Glycine receptor a3 -  The bearer o f great pain
The expression pattern of GlyR a3 is highly localised using in situ hybridisation and
Northern blot studies detecting mRNA transcripts in adults at low levels in the
cerebellum, frontal lobe, temporal lobe and putamen and no evidence of a3 in the
spinal cord (Malosio et al., 1991a;Nikolic et al., 1998). Two further non-functional
studies have both revealed that GlyR a3 is also localised to the adult mammalian
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retina (Greferath et al., 1994;Haverkamp et al., 2003). It has a distinct staining 
pattern from the a l  subunit suggesting that a3 may mediate specific retinal 
pathways in vivo, though this function can be compensated by apparent up regulation 
of other GlyR subunits in the a3 knockout animal (Haverkamp et al., 2003). Of most 
significance though is a recent study demonstrating that despite previous mRNA 
studies (Nikolic et al., 1998) GlyR a3 is in fact expressed at the protein level in a 
highly localised manner in spinal cord lamina II of the dorsal hom (Harvey et al., 
2004). This region plays an important role in mediating inflammatory pain and 
allodynia (Basbaum, 1999). GlyR a3, which retains a unique serine residue in the 
intracellular domain, underwent phosphorylation in response to activation of the 
PGE2 signalling cascade and the a3 mediated inhibitory input was subsequently 
attenuated (Harvey et al., 2004). GlyR a3 knockout mice retained significant GlyR 
mediated IPSC input at lamina II but failed to down regulate the inhibitory input in 
response to PGE2 mediation with the result that these mice were resistant to 
inflammatory pain when the PGE2 pathway is activated (Harvey et al., 2004). This 
pain-induced pathway was shown in a previous overlapping study to be selective 
specifically to the prostaglandin PGE2 (Ahmadi et al., 2002). Another study, which 
interfered with anionic homeostasis in nearby lamina I also supports the importance 
of inhibitory input into the dorsal hom for responsiveness to neuropathic pain (Coull 
et al., 2003). Thus it would appear that there is a specific role for GlyR a3 in 
mammals and this role cannot easily be compensated for by other ligand-gated 
receptors.
Glycine receptor a4 -  The enigma
The a4 subunit has, as yet, received only an elementary functional analysis 
demonstrating that the recombinant homomer bears similarity with a l  GlyRs 
(Harvey et al., 2000). The same study went on to show with mRNA in situ 
hybridisation that this receptor has an embryonic distribution akin to a2 and is 
localised primarily to the spinal cord and sympathetic neurones, as well as the testis, 
suggesting it may contribute to the development of sensory and motor pathways.
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Gephyrin and the glycine receptor /3-subunit
Evidence to support a specific functional role for the p-subunit in GlyR physiology 
currently revolve around its ability to interact with a synaptic anchoring protein 
called gephyrin allowing the p subunit to selectively target ap  GlyR heteromers to 
inhibitory synapses (Meyer et al., 1995;Kneussel et al., 1999;Moss and Smart, 2001). 
When the GlyR was initially isolated, it was part of a complex featuring a 
cytoplasmic protein component with mass 93 kD (Pfeiffer et al., 1982). This 
component, named gephyrin, was found to exist in at least 5 different splice variant 
mRNA products in the brain (Prior et al., 1992) though 7 have now been detected in 
the spinal cord (Meier et al., 2000) and 10 neuronal iso forms have been found in 
humans (Rees et al., 2003). Even more may exist in both neuronal and non-neuronal 
tissues since 8 of its 29 exons so far verified from cDNA sequencing, have the 
potential to generate splice variants (Ramming et al., 2000). As suggested from the 
potential wide array of variant isoforms, expression analysis of gephyrin transcripts 
reveals a tissue distribution far beyond that of the GlyR (Prior et al., 1992;Kirsch and 
Betz, 1993;Ramming et al., 2000). This is in agreement with proposed additional 
roles for gephyrin in molybdoenzyme activity in non-neuronal tissues (Feng et al.,
1998) and providing a critical interaction with RAFT1 (rapamycin and FKP12 target 
1) for rapamycin immunosuppressant mediated signalling (Sabatini et al., 1999). 
Also of interest, expression of the p subunit in aP heteromers halves single channel 
conductance (Bormann et al., 1993) and reduces sensitivity to picrotoxin (Pribilla et 
al., 1992), though this has not yet been attributed with any functional significance. 
Kinetics and desensitisation 
Kinetics
Studies of the kinetics of ion channels usually either attempt to measure parameters 
of burst openings, closures and conductance states using single channel recordings, 
or to evaluate the rates of current onset and offset when using ultrafast perfusion 
systems on small receptor populations in macropatches. The first kinetic studies on 
GlyRs utilised single channel studies from neuronal systems owing to the lack of 
ultrafast perfusion techniques and molecular cloning strategies available to attain 
pure GlyR populations of receptors. These early studies focused on the channel 
conductance and revealed that GlyRs could adopt a number of different conductance 
states, always at least two, and though there was a large variation in the sizes of the
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conductance states due to variations in holding potentials and driving forces the most 
commonly occurring conductance state was generally the largest, in the range 80 -  
90 pS (Hamill et al., 1983;Bormann et al., 1987;Twyman and Macdonald, 1991). 
Although these studies used spinal cord neurones, multiple conductance states with 
the predominant one being the largest have now been obtained in recombinant 
systems (Takahashi et al., 1992;Grewer, 1999;Lewis et al., 2003;Beato et al., 
2002;Beato et al., 2004). Intriguingly, the most recent and thorough studies to date 
suggests that multiple conductance states are far less prolific in pure recombinant 
populations, with the largest conductance being predominant for over 80 % of all 
channel openings and the second smaller conductance state being rarely visited 
(Beato et al., 2002;Beato et al., 2004;Lewis et al., 2003). Thus, variable conductance 
states might primarily reflect receptor heterogeneity in native tissue.
The first quantitative single channel study to attempt to elucidate an activation 
scheme for spinal cord GlyRs using open-shut time durations within bursts was 
carried out by Twyman and Macdonald (1991). This study, using low agonist 
concentrations, revealed three different mean open times within bursts, an 
observation reproduced in rat spinal cord slices and in zebrafish homomeric a l  
receptors (Takahashi et al., 1992;Fucile et al., 1999). Furthermore, for both rat and 
zebrafish GlyRs, the mean open time durations remained the same but the frequency 
of the longer burst duration relative to the shortest burst duration increased with 
increasing glycine concentrations (Twyman and Macdonald, 1991;Fucile et al.,
1999). Recently, an extra very short open-time duration, has been revealed for the 
homomeric GlyR a l  (Beato et al., 2002). In addition, only the frequency of channel 
openings again increased with agonist concentration with unchanged mean open time 
durations over a 30-fold concentration range. This property is consistent with a 
kinetic scheme where each individual liganded state switches between open and 
closed but the open states are discrete, i.e. a sequential binding model (Fig 1.2).
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Figure 1.2 Kinetic schemes of GlyR activation. A, The simplest Markov model of 
receptor activation, which assumes that either there is only one activated state (AR*) 
for the receptop or that all activated states are equivalent (AR represents the bound 
inactive state). B, A sequential binding model, which assumes that different 
numbers of agonist molecules bound to a receptor induce discrete activation states, 
reflected in single channel recordings by distributions composed of multiple open 
durations. C, The complex sequential binding model (Beato et al, 2004) where 
activation states with the same number of agonists bound are not necessarily 
phenotypically equivalent, dependent on the positions of the sites occupied by 
agonist. This suggests that the receptor displays allostery i.e. that binding of an 
agonist molecule may influence the affinity of subsequent binding events. D, A 
modified Markov model with one activation state and two desensitised states as 
proposed for GlyR a2 by Mangin et al, 2003. AD! represents a fast desensitised 
state that can occur before the receptor activates and is dependent on a receptor with 
a low number of agonist molecules bound, while AD2 represents the standard 
desensitisation that the GlyR may undergo after activation. Note that desensitised 
states were not included in the other schemes as this process is poorly understand 
and cannot be accurately accounted for in these schemes.
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To date an in depth single channel study to elucidate the activation mechanism of the 
more physiological heteromeric ap  GlyR has not been reported, but such a 
mechanism is now available for a l  homomers (Beato et al., 2004). In the presence 
of a range of glycine concentrations from 10 pM to a saturating 1000 pM dose, open 
and shut time distributions from within bursts revealed that this data could best be 
explained by a cooperative model favouring up to three agonist binding events per 
receptor to achieve maximal activation. This model assumes that initially the 
binding sites are equivalent, the obvious assumption for a homopentamer. Then with 
each agonist binding event, the efficacy for receptor activation increased from 
approximately 0.4 to 8 to 40 for 1, 2 and 3 agonist molecules bound with no further 
increase upon binding of 4 or 5 agonist molecules. This model was considered from 
the perspective of both a linear sequential binding model where the positions of the 
subunits bound by agonist do not matter and from a situation where the subunit 
selected for the second binding step does matter, though both models provided good 
fits to the data (Fig 1.2). At a saturating application of glycine, with an E value of 40 
the P0 is 0.98, suggesting glycine is an efficient agonist activating 98 % of a receptor 
population or keeping a single channel open for 98 % of its burst duration. Of 
particular interest, this model required a certain degree of agonist cooperativity, 
which the authors suggest is best suited by the initial singly liganded state causing an 
effect on the binding affinity of subsequent binding events but not necessarily the 
second binding event affecting the third. Though it was not possible to determine the 
exact nature of any allostery even whether it was positive, or negative,depending on 
where and how the agonists bind, this study is important as it supports cooperativity 
in GlyRs and suggests 3 agonist bindings are maximally efficacious for 
homopentameric receptors. It should be noted that prior studies assessing the kinetic 
scheme for GlyR a l  activation applied a sequential kinetic model where there is 
effectively just one activation state (a Markov model; Fig 1.2) to simplify matters 
(Walstrom and Hess, 1994;Grewer, 1999;Laube et al., 2000). However both 
Twyman and Macdonald, (1991) and Beato et al, (2002 and 2004), demonstrated that 
the GlyR clearly contains 3 distinct open states representative of a sequential 
activation model. Additionally, studies using exponential curve fits of current onsets 
in response to ultrafast drug applications are unlikely to be able to attain the 
resolution necessary to predict all the exponential components within the rising phase
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of the macroscopic activation, particularly the fastest component (Grewer, 1999). 
Therefore the study of Beato et al (2004) is to date the highest temporal resolution 
study addressing the activation dynamics of the GlyR.
This activation mechanism may provide a guide for the GlyR <*P heteromer as the 
a  subunit is thought to directly bind the agonist and so it is possible that the binding 
sites could remain equivalent. Current studies to elucidate a kinetic model for the 
heteromeric GlyR have resulted in the proposal of a model with two open states and 
a reluctant gating step (Legendre, 1998). This proposal, which adopted ultrafast 
macroscopic perfusion techniques to record from M-cells in zebrafish that 
predominantly express ap  heteromers (Legendre, 1997) will, however, be an 
oversimplification as single channel studies on presumed ap heteromers has 
previously revealed that 3 separate open states exist (Twyman and Macdonald, 
1991). Certainly, from a macroscopic point of view, the evidence suggests that the 
p subunit does not affect activation; or inactivation rates, with these two parameters 
remaining comparable for a l  homomers and ap  heteromers using ultrafast perfusion 
studies on macropatches (Mohammadi et al., 2003). This is also supported by 
comparisons of recombinant a l  single channel burst durations, which when 
summated could be directly overlaid with presumed ap  native receptor IPSCs 
(Takahashi et al., 1992;Legendre, 1998).
Kinetic experiments have also recently been carried out to compare the mechanism 
of action elicited by the three primary GlyR agonists, glycine, p-alanine and taurine 
using both ultra-fast perfusion techniques and single-channel analysis (Lewis et al.,
2003). These studies, on GlyR a l  homomers, also revealed three distinct open states 
that were distinguishable for all three agonists. Whilst the open time durations and 
amplitudes did not vary between the agonists the closed time durations did vary. 
This was reflected in the ultrafast macroscopic currents by slower activation and 
faster relaxation rates of currents evoked by saturating concentrations of p-alanine 
and taurine compared to glycine. As the mean open time durations, a direct 
reflection of the closing rate, did not differ, this suggested that the closing rate 
constants represented an intrinsic property of the receptor. In addition to this relative
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estimates of the agonist efficacies were obtained with glycine, P-alanine and taurine 
having E values of 16, 8 and 3.4.
As has been previously mentioned an ultrafast perfusion study carried out on GlyR 
a2 revealed that this receptor exhibits a slower activation rate compared to studies on 
a l  (Takahashi et al., 1992;Legendre, 1998;Mangin et al., 2003). In addition the 
relaxation and desensitisation rates were also slower and, of particular interest, an 
estimate of glycine efficacy at the GlyR a2 revealed a high value of 200, 5-fold 
higher than that for GlyR a l  (Lewis et al., 2003;Beato et al., 2004). This suggests 
that a l  and a l  have significant differences in terms of their kinetics, a fact supported 
by the delayed GlyR a2 channel openings after exposure to agonists, which were 
suggested to represent transitions between a ligand bound-closed state and a 
desensitised closed state prior to channel opening (Fig 1.2; Mangin et al., 2003). 
This delayed opening, which occurred at low agonist concentrations suggesting it 
represented low-level liganded receptors, was absent at a saturating concentration of 
agonist, presumably due to multiple agonist binding events occurring before the 
receptor could desensitise. Thus in this higher liganded state the receptor would 
always open (Mangin et al., 2003).
Desensitisation
The reason and mechanism for receptor desensitisation remains enigmatic. Most 
studies show that desensitisation consists of two components at high glycine 
concentrations but just one component at lower agonist concentrations (Mohammadi 
et al., 2003). A proposed physiological role for GlyR desensitisation has so far been 
suggested to be unlikely with the time course of both desensitisation components 
being too slow to impact on IPSC kinetics. Even with rapid re-stimulation using 
ultrafast perfusion techniques akin to a train of GlyR IPSCs, no paired-pulse 
desensitisation is observed (Legendre, 1998;Lewis et al., 2003). This is in contrast to 
certain GABAa receptor subtypes and nAChRs which exhibit much more rapid rates 
of desensitisation capable of influencing physiological functions (Burkat et al., 
2001;Pidoplichko et al., 1997). Studies to recreate recombinant GlyR populations 
more representative of their neuronal counterparts have shown that incorporation of 
the p subunit does cause a significant increase in the rate of desensitisation
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(Mohammadi et al., 2003) as does inducing the clustering of receptors using 
gephyrin (Legendre et al., 2002) raising the possibility that this process could have 
some impact physiologically.
Structure-Function studies
General topology
The general topology of the GlyR was originally predicted using hydropathy analysis 
and was placed in the context of a common general architecture shared by all cys- 
loop ligand-gated ion channels. The a  and p subunits contain approximately 420 and 
470 amino acids respectively. Starting from the N-terminus the structures comprise a 
large extracellular domain of around 200 -  250 residues, four transmembrane 
domains (M1-M4) and a sizable 80 -  100 amino acid intracellular loop between 
M3-M4 (Fig 1.1; Grenningloh et al., 1987b). Also consistent with the proposed 
quaternary structure of other cys-loop receptors, the GlyR is predicted to co- 
assemble into a pentamer. This was initially based on sedimentation analysis and 
treatment with chemical cross-linking reagents. The molecular weight measured was 
260, 000, which is best accounted for by the inclusion of three 48 kD a  subunits and 
two 58 kD P-subunits into the pentamer (Langosch et al., 1988). Evidence in support 
of this general tertiary and quaternary topology is based on medium and high 
resolution electron micrographs at 9A, 4.6A and 4A levels of whole Torpedo nAChRs 
(Miyazawa et al., 1999;Miyazawa et al., 2003;Unwin, 1993;Unwin, 1995). Here 
globular centres of electron density based around a pseudo 5-fold axis of symmetry 
were observed corresponding to the five extracellular domains of the receptor 
pentamer. This perimeter allowed for the presence of a large central water filled 
vestibule, through which ions could easily gain access to the extracellular side of the 
membrane lining ion channel. In each subunit, 4 predicted a-helical transmembrane 
domains could also be distinguished as well as a globular intracellular domain. The 
intracellular domains appeared to link together to form a basin such that ionic 
conductance was proposed to occur via pores present at the side interfaces between 
each of the subunits (Fig 1.3). The great challenge for structure-function studies is to 
decipher how this general topological representation encodes for the principal 
functional properties of agonist binding, receptor activation, modulation 
desensitisation, ion conductance and selectivity.
34
A.
ECD
M3 M2
Ml
M3-4
Figure 1.3 Representative model of the monomeric (.A) and pentameric (B) 
GlyR. A, Each subunit consists of an N-terminal extracellular domain (ECD) of 
approximately 200 -  250 amino acids, four transmembrane regions (M1-M4) of 
approximately 20 amino acids, and two intracellular loops, M l-M2 
(approximately 10 amino acids) and M3-M4 (approximately 80 - 100 amino 
acids). B, Each monomer co-assembles into a functional pentameric receptor. 
The pentamer draws together the five M2 domains into the interior of the protein 
at the level of the membrane to form a functional gate and channel to control ion 
influ^ or efflux. The most likely routes for ion entry and exit through the 
solution exposed components of the GlyR are via the large extracellular 
vestibule, and on the intracellular side, via gaps between the subunit side 
interfaces (marked by arrows).
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The agonist binding site
Preliminary experiments to isolate the important protein determinants of agonist 
binding used the technique of peptide mapping in conjunction with [3H]strychnine. 
The assumption made in these experiments was that glycine and the competitive 
antagonist strychnine bind to the same part of the receptor. Modelling studies reveal 
that despite the obvious structural disparity between these two compounds they do 
share a common element allowing them to potentially interact with some of the same 
binding site residues (Fig 1.4, Aprison et al., 1987). Moreover [3H]strychnine was 
able to displace glycine binding (Young and Snyder, 1973). Focusing on the ligand 
binding a-subunit, covalent incorporation of [3H]strychnine occurred between amino 
acids 170 and 220 of the N-terminal extracellular domain (Graham et al., 1983;Ruiz- 
Gomez et al., 1990). Subsequent site-directed mutagenesis studies, targeting 
residues in and neighbouring this region, identified two discrete domains that were 
able to influence the potency and selectivity of the agonist binding site.
Strychnine
Glycine
Figure 1.4 Chemical groups present in glycine and strychnine, 
highlighting the structural similarity of glycine (red) with one subsection of 
the strychnine molecule (blue), which might explain the ability of strychnine 
to act as a competitive antagonist at the GlyR.
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In the first discrete motif, subsequently termed loop B, substitution of GlyR a l  G160 
and Y161 with Glu and Ala mutations respectively, produced receptors with 
substantially reduced sensitivity to strychnine (Vandenberg et al., 1992a). An 
equivalent G167E substitution in a l  generated a receptor with a dramatically 
reduced glycine and strychnine potencies (Kuhse et al., 1990b). It was also 
demonstrated that introduction of conserved equivalents from the GABAaR, to 
create GlyR a l  F159Y and Y161F mutated subunits, shifted the relative order of 
agonist potencies from; glycine > P-alanine > taurine for the wild-type receptor to 
one where p-alanine was most potent and the GABA potency was also enhanced 
(Schmieden et al., 1993). This suggested that these three agonists bind to a common 
site, as was already suspected from their common structural determinants. 
Furthermore the ability of F I59 and Y161 to determine agonist selectivity makes 
these residues ideal candidates to face into the agonist-binding site. In accordance 
with this hypothesis, which infers that G160 may instead be acting as a structural 
linker, introduction of a more conserved alanine instead of a glutamate at G160 does 
not significantly alter glycine/  or strychnine, potency (Vandenberg et al., 1992a). 
Additionally, though substantial perturbation of this FGY motif reduces the potency 
of strychnine, the more subtle F159Y and Y161F mutations do not, suggesting this 
domain can influence strychnine binding but not to the same degree as for the 
agonists (Schmieden et al., 1993).
The second discrete domain, termed loop C, encompasses residues between GlyR 
a l ,  C l98 and C209, a cys-loop bridge domain unique to GlyRs. This is not the same 
as the absolutely conserved cys-loop present in all cys-loop ligand-gated receptors 
(Fig 1.1 -  discussed later). Replacement of either of the bridging residues with 
chemically similar serines produced non-functional receptors. Thus, the unique 
ability of cysteine residues to form a disulphide bridge in this region would appear to 
be critical for receptor function (Rajendra et al., 1995b). The introduction of alanine 
residues at the even numbered positions K200, Y202 and T204 severely attenuated 
agonist and antagonist binding. Substitution of K200 reduced strychnine binding, 
perturbation of Y202 reduced strychnine and glycine binding, and mutation of T204 
selectively reduced glycine potency (Vandenberg et al., 1992b;Rajendra et al., 
1995b). In addition to this, chemical evaluation of the candidate residues labelled by
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[3H]strychnine identified two potential tyrosines as prime candidates, Y197 and 
Y202. As disruption of Y 197 does not affect strychnine potency (Vandenberg et al., 
1992b) this strengthens the supposition that the loop including Y202 is physically 
capable of ligand binding (Ruiz-Gomez et al., 1990). Also of interest is the pattern 
of disruption with only alternate mutations between C l98 and the potential ‘kinking’ 
residue G205 affecting agonist and antagonist potency. This is consistent with a (3- 
strand orientation for these residues.
Though [3H]strychnine covalently labelled residues in the region a l  170 -  220, a 
third and final loop, positioned earlier on in the primary sequence and so termed loop 
A, has also been implicated in agonist binding. This region spans from 193 to G105 
in the GlyR a l  subunit and the individual residue substitutions, 193A, A101H and 
N102A, caused reductions in glycine potency (Vafa et al., 1999). Furthermore the 
most significant reductions in agonist potency, involving substitutions of A101 and 
N102 did not reduce the maximal currents of the lower potency agonist taurine, 
suggesting this effect was selective to binding, not gating. The potency of strychnine 
was only moderately reduced suggesting this loop participates primarily in agonist 
binding. A follow-up study also demonstrated that an N102C mutant exhibited a 
drastically reduced agonist potency. However an A101C mutation failed to attenuate 
agonist potency and instead cysteine substitution of the opposing neighbour E l03 
induced a disruptive effect on receptor function (Han et al., 2001). This suggests that 
N102 is the primary binding residue in this loop. In the case of 193, a mutation to 
cysteine was not tested, but the previously reported I93A mutation also reduced 
agonist maximal currents suggesting this residue may be exerting other secondary 
effects rather than being engaged in agonist binding (Vafa et al., 1999).
To further strengthen the role of loops A-C in agonist binding, there is good 
agreement between the GlyR studies and those carried out on other cys-loop 
receptors, most notably the GABAaR and the nAChR. Identified residues in the 
Torpedo nAChR a l  subunit loop B include W149 and Y151, which align perfectly 
with GlyR a l  F I59 and Y161. In loop C, prime binding site candidates for the 
nAChR a l  include Y190, C l92 and C l93, which are analagous to GlyR a l  K200, 
Y202 and T204, (Fig 1.5). These five nAChR residues can all be covalently tagged
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in response to photoaffinity labelling with the competitive antagonist (N,N-dimethyl) 
aminobenzenediazonium fluoroborate (DDF) (Dennis et al., 1988;Galzi et al., 
1990;Galzi et al., 1991a). In the case of the GABAaR p subunit, comparable 
residues Y157 and T160 from loop B and T202 and Y205 from loop C also exhibit 
properties consistent with roles in ligand binding (Fig 1.5; Amin and Weiss, 1993). 
Finally, regarding loop A, the GlyR a l  N102 may play a similar role to W86 and 
Y93 in the a l  nAChR (Cohen et al., 1991;Galzi et al., 1990;Galzi et al., 1991d;Galzi 
et al., 1991b), and to HI 01 of the GABAaR a l  (Wieland et al., 1992;Duncalfe et al.,
1996) and R100 of GABAaR a6 subunits (Korpi and Seeburg, 1993), as well as Y97 
and L99 of the GABAaR p2 subunit (Boileau et al., 2002; Fig 1.5). These potential 
agonist binding site residues in the nAChR are also thought to play a direct role in 
agonist coordination (Mu et al., 2003;Sullivan and Cohen, 2000;Celie et al., 2004).
The experiments discussed here provide evidence for a conserved set of loops, A-C, 
that are involved in agonist binding by cys-loop ligand-gated receptors. However,in 
the case of nAChR, GABAaR and 5 HT3R there is evidence for the existence of five 
to six loops involved in agonist binding (for reviews see Cromer et al., 2002;Reeves 
et al., 2003). These loops contribute to an intersubunit binding site. For example,in 
the case of a GABAaR containing a  and p subunits, residues are contributed from 
loops A-C on the p subunit and loops D-F on the a  subunit (Cromer et al., 2002). 
Currently for GlyRs, a contribution from loops D-F, in a  and p subunits, to the 
agonist binding process has not been reported and it may be that the agonist glycine 
is small enough such that loops A-C from the a-subunit are wholly sufficient to 
mediate the necessary binding interactions.
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Figure 1.5 Cys-loop receptor family amino acid alignment. The conserved 
locations of the agonist binding residues in loops A-C are highlighted; GlyR a l  
in yellow, nAChR a  in blue, GABAaR P2 in purple.
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Such functional studies support a conserved location for the agonist-binding site in 
the cys-loop family of receptors; however, they do little to increase our 
understanding of the structure of this site, or inform us how each residue contributes 
to the binding process. Medium resolution electron micrographs of the Torpedo 
nAChR revealed the presence of a potential agonist pocket located about halfway up 
the extracellular domain of each subunit. This pocket was surrounded by twisted P- 
sheet strands at the interface of neighbouring subunits but was not of sufficient 
resolution to determine the locations of binding loops A, B and C (Fig 
1.6/l)(Miyazawa et al., 1999). These data have since been superseded by what is 
unquestionably the most significant breakthrough in our understanding of the 
structure of cys-loop receptors. Brejc et al, published in 2001, a high 2.6A resolution 
crystal structure of a cys-loop receptor related protein known as the acetylcholine 
binding protein from the snail Lymnaea stagnalis. This soluble protein shares a low 
but significant 20 % homology with the N-terminal, extracellular domain of the cys- 
loop receptor family and importantly it places loops A, B and C in proximity to act as 
ideal coordinators of agonist binding (Fig 1.6B,C & 1.7/1, B). The location of this site 
is equivalent to the previously identified pocket in medium resolution electron 
micrographs suggesting that the AChBP does retain a comparable overall topology to 
the extracellular domain of cys-loop receptors. This structure presents the 
extracellular domain as an initial a-helix, which then runs into two parallel sheets of 
P-strands where the two sets of p-strands run perpendicular to each other (Fig 1.6A & 
1.7/1,B). In the case of the AChBP it has been possible to crystallize this protein 
coordinated to three different ligands including the agonists, carbamylcholine and 
nicotine, to give precise insight into the exact structural interactions that occur during 
agonist binding (Celie et al., 2004). Due to the low homology this protein shares 
with the GlyR it is not possible to gain such an exact insight into the glycine binding 
site, however this homology model has already served as a powerful structural guide 
in future studies to determine the importance of domains spread throughout the cys- 
loop receptor extracellular regions.
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Figure 1.6 Current structural assumptions that can be made about the GlyR 
extracellular domain. A, A longitudinal section through an intermediate resolution 
structure (4.6 A electron micrograph) of the torpedo nAChR a  subunit. The 
highlighted extracellular domain (dashed green box) of a potential ligand binding 
cavity half-way up the domain from the membrane (arrow; adapted from Miyazawa 
et al, 1999). B, A homology model (see Materials and Methods) from the inside face 
(from the vestibule; see inset) of the GlyR a l  subunit based on the crystal structure 
of AChBP (Brejc et al, 2001). Starting with an initial helix (brown) this structure 
then forms two parallel sheets of p-strands, which run perpendicular to each other 
creating inside (pink strands) and outside (white strands) facing sheets. Notable 
features include; the agonist binding domain consisting of loop A (red), loop B 
(orange) and loop C (yellow), again predicted to reside half way up the extracellular 
domain (arrow); the gating domain consisting of the p i-2 loop (green), cys-loop 
(light blue) and P8-9 loop (dark blue). C and £), Close-up of the agonist binding 
domain from a side on perspective (C; see inset) and gating domain from the outside 
face perspective (Z); see inset) with important residues displayed and labelled. 
Colour schemes of ribbons are as in (B). For reference, alternate nomenclature from 
Brejc, et al, is as follows; P1-P2 -  L2, cys-loop -  L7, p8-p9 -  L9.
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Figure 1.7 Position of the agonist binding site in the pentameric extracellular 
homology model. A, Three neighbouring subunits (white, green and blue) from a 
pentamer, viewed from the outside face (see inset). The binding site from the white 
subunit consists of loop A (red), loop B (orange) and loop C (yellow). The agonist- 
binding site is most likely accessed from the outer face of the subunit and at the 
intersubunit boundary (marked by arrow). B, Profile of the whole pentamer, viewed 
from above (see inset), displaying the same information.
The transduction process
Deciphering components specifically involved in the receptor activation process has 
benefited significantly from the availability of the AChBP crystal structure. This is 
due to the difficulties that arise in differentiating between components that are 
influencing the initial agonist-binding event to the closed receptor and those which 
determine the subsequent effectiveness of channel opening. Thus, a structural 
appreciation of the receptor aids in predicting and isolating residues that have a 
genuine significance in ligand-binding and channel-gating. Unfortunately, no 
unliganded crystal structures of the AChBP have so far been resolved (Celie et al.,
2004). This means there is no measurement yet of the movements that loops A to C 
undergo upon agonist binding. However, medium resolution electron micrographs of 
the Torpedo nAChR have been obtained in the agonist-bound and unbound states 
(Miyazawa et al., 1999;Unwin, 1993;Unwin, 1995). These studies revealed that the 
agonist-bound a-subunit experiences a ‘local disturbance’ of the binding site. In 
addition the extracellular domain underwent a set of small axial rotations presumably 
to transmit activation to the channel region. Of particular interest was the realisation
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that the a  subunit transition, upon binding ligand, converted it to an orientation 
similar to that already assumed by the P and y subunits, which experienced only 
minimal reorganisation during receptor activation. This situation may be analogous 
to the GlyR where the a  subunit is also the principal agonist binding subunit and so 
the GlyR p subunit may remain conformationally stationary at least from the 
perspective of its extracellular domain (Fig 1.8A,B). Using the AChBP crystal 
structure, a more recent study has attempted to map the movements that occur in the 
extracellular domain during agonist activation by fitting the most conserved p-strand 
regions to the 4.6A electron micrographs of the nAChR extracellular domains. This 
study revealed that the AChBP crystal structure, which has the putative agonist 
HEPES bound and therefore may be in the activated conformation already, could be 
overlaid with a good fit to the p, y and 5 subunits, but not the a  subunit of the 
unbound-closed nAChR (Unwin et al., 2002). This is also most consistent with the 
non-ligand binding p, y and 5 subunits existing in a conformation close to that of the 
activated state for the extracellular domain, whilst the a  subunit does not. It was 
possible to overlay the AChBP with the nAChR a  subunit surface topology by 
simply reorienting the set of p-strands that are on the inside face of the subunit 
relative to those on the outer face of the subunit. This simple 15 -  16 ° rotation of 
the inner face strands consequently means that the interface of the subunit 
undergoes a greater degree of movement compared to the *+’ interface of the subunit 
(nomenclature of Fu and Sine, 1996; Fig 1.8A,B). This reorientation may therefore 
be the driving force for downstream communication with the channel. Currently 
there is no such evidence to validate this information in the GlyR. Furthermore these 
studies were unable to address the primary movements that occur in the immediate 
vicinity of the agonist binding site due to the more flexible nature of the loops A to 
C. With regards to these initial movements the information is relatively speculative, 
though a mutation in the GABAaR P subunit in a position equivalent to GlyR a l 
A101 of loop A does produce a spontaneously open receptor (Boileau et al., 2002). 
Also of interest is a Psi value analysis of a nine amino acid segment overlapping with 
and immediately following on from the A loop in nAChR a  subunits. This technique 
attempted to measure the order of domain movements during receptor activation and 
revealed that the nine amino acid segment moves early on in the activation process
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(Chakrapani et al., 2003). Thus it may be that the A loop is the actuator that enables 
downstream extracellular movements.
A. Closed state B. Open state
y i  9r
Figure 1.8 Hypothesis for cys-loop receptor activation, based on rotation of the 
extracellular agonist binding a  subunit of the GlyR. A , Closed and B, Open 
conformations of the GlyR. The pentamers, viewed from above the receptor, 
represent cartoons of the rotation that is undertaken specifically by the agonist 
binding a subunit (red). The non-ligand binding p subunits (blue) are proposed to 
already reside in the active conformation. The green rectangles denote the a-helix 
present in each extracellular subunit domain for extra definition of each subunits 
orientation. The green circles represent the approximate axis of rotation for the a  
subunits during activation. The homology models reflect enlargements of a single 
a l  subunit from the cartoon pentamer in the same alignment (red box; also viewed 
from above). The green circles represent the axis of rotation and demonstrate that 
during the 15 -  16 ° rotation of the inner sheet relative to the outer sheet (indicated 
by black arrow), the internal *-* side of the subunit will undergo a greater movement 
than the internal *+* side of the subunit. This rotation of the extracellular domain of 
the GlyR a  subunit is proposed to transmit downstream to the helical bundle and 
induce channel opening.
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One limitation of the combined AChBP-electron micrograph analysis is that it does 
not indicate which are the critical regions for transmitting the agonist binding effect 
down to the channel. Initial mutagenesis experiments targeted residues predicted to 
reside close to the transmembrane interface based on primary sequence due to the 
absence of a high-resolution structural model. Likely candidates to mediate 
communication from this interface to the extracellular domain consist of the section 
immediately prior to M l, the M2-M3 linker domain or the C-terminal tail from M4. 
The significant size of the 12-13 amino acid M2-M3 linker, its apparent central 
location and its direct link to two membrane segments including M2, the pore lining 
helix (discussed later) makes this the most likely candidate. Early functional studies 
did indeed point to the M2-M3 linker as part of the gating mechanism. Initially a 
naturally occurring mutation was identified in patients with the human startle disease 
that replaced a positively charged GlyR a l  R271 with an uncharged leucine or 
glutamine (see review Rajendra, 1995a). Subsequent functional studies revealed that 
these receptors had significantly reduced sensitivities to glycine and the higher single 
channel conductance states were abolished sufficient to reduce whole-cell currents 
by 90 % (Langosch et al., 1994;Rajendra et al., 1995c). Furthermore the cell surface 
receptor expression levels, assessed by [3H] strychnine binding, were not reduced 
and glycine binding, as assessed by its ability to displace [3H]strychnine, was only 
reduced by 50 -  100 fold, in comparison to glycine potency, which was reduced by 
230 -  410 fold. Further evidence supporting a role for this arginine residue in gating 
was the abolition of p-alanine and taurine evoked currents. By contrast, the 
sensitivity of the receptor to these compounds, measured in terms of their ability to 
inhibit glycine mediated currents, was unaffected suggesting that the efficacy of 
p-alanine and taurine had been reduced to such an extent that they were now unable 
to activate the receptor (Rajendra et al., 1995c). Since identification of R271, a 
functional scan of the M2-M3 loop has identified further residues that influence 
receptor function in a manner consistent with an involvement in gating (Lynch et al.,
1997). Moreover, substituted cysteine accessibility mutagenesis (SCAM) 
experiments in this region on the open and closed receptor conformations revealed a 
differential pattern of accessibility supporting a movement of this domain during 
activation (Han et al., 2001). In the context of the original structural evidence on 
nAChRs, suggesting the ligand binding a  and structural P subunits do not undergo
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comparable movements during receptor activation, a second SCAM study on the 
GlyR p-subunit yielded no obvious effects on receptor potency when p subunit M2- 
M3 residues were mutated to cysteines. In addition there were no obvious effects on 
function upon application of a cys-modifying reagent in the open,or closed,receptor 
conformations to ap  heteromeric receptors containing Cys mutated p subunits in the 
M2-M3 region (Shan et al., 2003). In accord with the evidence that the M2-M3 
linker is a critical gating component, naturally occurring mutations and site-directed 
mutagenesis studies on this domain in nAChRs and GABAaRs also revealed 
impaired receptor function in a manner consistent with an influence on gating 
(Campos-Caro et al., 1996;Kusama et al., 1994;Sigel et al., 1999;Baulac et al., 2001). 
Also of interest is the characterisation of two nearby GlyR a l  residues Q266 and 
S267, both present on the extracellular side of the M2 domain. These residues when 
mutated to create Q266H and S267Q GlyRs impair function in a manner consistent 
with gating (Moorhouse et al., 1999;Findlay et al., 2003).
Due to the juxtaposition of the M2-M3 linker to the channel it is easy to appreciate 
how this domain can influence receptor activation but prior to resolving the AChBP 
structure it was not clear how components of the extracellular ligand-binding domain 
communicate across to the M2-M3 linker. The AChBP crystal structure provided a 
possible solution as the p-strands and loops located at the base of this structure could 
now be identified and would be in an ideal location to interact with the 
transmembrane segments and the M2-M3 loop (Brejc et al., 2001) (Fig 1.9A,B). A  
recent study proposed an electrostatic interaction between two loops at the base of 
the extracellular domain and the M2-M3 linker (Kash et al., 2003a). Charge 
reversals at GABAaR a l  D57 from the p i -2 loop, D149 from the cys-loop and K279 
from the M2-M3 linker, all disrupted receptor function in a manner consistent with 
gating. However, paired charge reversal of the M2-3 linker, K279D, with either the 
p i -2 loop D57K, or the cys-loop D149K mutation, the GABAaR regained a large 
degree of receptor function. This suggested that these domains interacted regardless 
of charge orientation. Since this study a high 3A resolution electron micrograph of 
the M1-M4 segments including the M2-M3 linker has been reported (Miyazawa et 
al., 2003). This structure was paired up with the extracellular domain and predicted
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that the pi-2 loop, the cys-loop and the M2-M3 linker are in prime orientation for 
communication (Fig 1.9A,B).
Figure 1.9 Interactions between the extracellular domain and the 
transmembrane domains. The structure is based on a homology model of the 
AChBP (Brejc et al, 2001) and the torpedo nAChR transmembrane domains 
(Miyazawa et al, 2003) paired together. A, Whole subunit and B, close-up of the 
gating interactions. The pi-2 loop (green) and the cys-loop (light blue) of the 
extracellular domain are closely apposed to the M2-3 loop (red) and the top two 
turns of the M2-3 helices (purple; individual helices are labelled on the diagram) 
which rise out above the membrane (white dashed line). Residues in the 
interacting domains that influence receptor properties consistent with gating are 
displayed and labelled.
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In the context of the GlyR individual alanine substitutions have been made 
throughout the cys-loop domain. This approach identified a number of residues 
including a l  D148 (corresponding to GABAaR a l  D149), that significantly reduced 
glycine potency and maximal currents, as well as taurine potency and relative 
efficacy, consistent with an effect on channel gating (Schofield et al., 2003;Schofield 
et al., 2004). Charge reversals introduced at the GlyR a l  pi-2 loop E53 and D57 
residues, also disrupted receptor function in a manner consistent with gating 
(Absalom et al., 2003). Furthermore a K143 residues in the cys-loop was shown to 
change its accessibility pattern in a SCAM study suggesting this domain, like the 
M2-M3 linker can change its conformation during activation (Absalom et al., 2003).
Howeve^it is unlikely that electrostatic communication between the p i -2 loop, the 
cys-loop and the M2-M3 linker can be generalised throughout the cys-loop receptor 
families as attempts to reproduce a similar correlation in the GABAaR P2 subunit 
and in the GlyR, failed (Absalom et al., 2003;Kash et al., 2003b). Also non-charge 
related substitutions in the pi-2 loop can cause subtle effects on receptor potency as 
was originally discovered for the spasmodic mouse, which has the A52S mutation in 
GlyR a l  (Ryan et al., 1994;Saul et al., 1994). This same location in the a l  subunit, 
which is the source of splice variance between a2A and a2B (Fig 1.1) also causes a 
reduction in glycine potency at the a2A subunit in a manner consistent with a gating 
effect as the relative efficacy of taurine is attenuated (Miller et al., 2004). 
Furthermore, a recent chimeric study generated a non-functional cys-loop receptor by 
pairing the extracellular domain of the AChBP to the transmembrane segments of the 
5-HT3AR. Function was then restored to this receptor by progressively substituting 
each of the three loops at the base of the extracellular domain, the p 1 -2 loop, the cys- 
loop and the P8-9 loop, with those of the 5-HT3AR. Only when all three of these 
loops, not just the two identified previously by Kash et al (2003a) were restored, was 
there an effective return of the receptor’s gating properties (Bouzat et al., 2004). In 
the case of the nAChR, the hydrophobic V44 from the p i-2 loop is predicted to be in 
close apposition with the M2-M3 domain (Miyazawa et al., 2003). These authors 
propose that this residue docks into a hydrophobic pocket at the end of the M2-3 loop 
and upon activation the rotation of the extracellular domain twists this residue
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exerting an effect on the M2-M3 loop to induce channel opening. Together this 
evidence suggests that the gating process is most likely a combination of charged 
polar and apolar interactions that can occur between the three base loops of the 
extracellular domain and the M2-M3 linker.
The ion channel and its opening mechanism
A large body of evidence, accumulated from the nAChR, supports the view that the 
M2 domain of cys-loop receptors is responsible for forming the channel and contains 
the gate responsible for opening and shutting of this channel (for review see 
Devillers-Thiery et al., 1993). The M2 segment of the cys-loop receptor family is the 
most conserved domain between subunits, highlighting the important nature of its 
role. For GlyRs, a mutagenesis study identified a residue on the intracellular cusp of 
M2 that is critical for determining the maximal conductance state. A G254A 
substitution in GlyR a l  increased its maximal conductance state in symmetrical 
chloride solutions from 86 pS to 107 pS bringing it in line with GlyR a l  and a3, 
which have an alanine at this position and have maximal conductance states of 111 
and 105 pS, respectively (Bormann et al., 1993). One major difference between the 
channels of the GlyR and the nAChR is their ionic selectivity. Whilst the nAChR 
favours cation conductance, the GlyR channel has an anion permeability sequence of 
SCN>r>N0 3  >Br>Cr>HCO">acetate>F‘>propionate (Bormann et al., 1987) and 
the responsible M2 residues have now been identified (Galzi et al., 1992;Keramidas 
et al., 2000). It is beyond the scope of this introduction to describe the multitude of 
experiments that have been carried out to discern the architecture of the channel and 
its ability to determine selectivity of anionic conductance in the GlyR (for review see 
Rajendra et al., 1997;Lynch, 2004). However^ from the perspective of receptor 
activation and possible allosteric modulation there are a number of relevant points to 
be raised. The general structure of the pore for the Torpedo nAChR suggests that 
M l-4 exist as membrane spanning a-helices with M2 positioned on the interior face 
such that the pentamer contains an inner ring of five M2 helices (Fig 1.10A,B; 
Miyazawa et al., 1999;Miyazawa et al., 2003). These M2 helices are 40 A long with 
two turns of each helix rising out above the extracellular membrane face. These are 
connected via a short M2-M3 linker to the M3 segment, which also protrudes above 
the membrane face by two turns of an a-helix (Fig 1.9A,B; Miyazawa et al., 2003).
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Each of the five subunits align the M2 helices to display residues of the 
corresponding location at the same position thus creating rings of residues in register 
spanning across the membrane. The exact location of the gate is still contentious but 
is probably located just over halfway down the pore towards the intracellular side, 
corresponding to an 8 A stretch of helix, where the pore diameter is less than 3.5 A. 
This section includes a critically conserved ring of hydrophobic leucines (nAChR a l  
L251; GlyR a l  L261 in Fig 1.10,4,5) and just over one helical turn above this a ring 
of Val 255 residues (Labarca et al., 1995;Miyazawa et al., 2003). In this context the 
location L251 in the closed state, represents a ring of residues that form what 
is effectively a ‘hydrophobic girdle’ between the M2 helices. This 
hydrophobic girdle operates by creating an energetic barrier for ion permeation as 
ions must shed their hydrated water shell before being able to fit through such a 
small pore.
With regards to the activation mechanism, the current hypothesis is that the gate, and 
therefore the location of the leucine and valine rings, opens up through a sideways 
rotation of each M2 helix (Miyazawa et al., 2003;Unwin, 1995). This may arise 
through each M2 segment moving individually to gradually weaken the stable closed 
channel state, or a synchronised group movement of all the M2 domains together. 
The basis of this hypothesis was in part due to the presence of two predicted flexible 
loops, the M l-M2 linker and M2-M3 linker, at either end of the pore lining helix 
(Fig 1.105). The relevance of the GlyR M l-M2 loop in gating is apparent from a 
hyperekplexia autosomal recessive mutation (I244N) that was identified in this 
region (Fig 1.10C; Rees et al., 1994). Mutant receptors exhibited decreased 
sensitivity to glycine and smaller maximal current responses, which could in part be 
attributed to an effect on channel gating. Thus it would seem that both flexible loops 
at either end of M2 can influence gating and may be acting as hinges. One potential 
problem with this hypothesis is that if the M2 leucine residues do form a tightly 
enclosed gate then where does the space arise from for the helices to each rotate to 
the side? Fortunately, the structural data does predict the presence of a sizeable 
water filled pocket on the back of M2 between M2 and M3 (Fig 1.10D), which 
allows space for M2 movement. In addition, experiments investigating a putative
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Figure 1.10 The transmembrane 
domains. A, Modelled M l-4
domains of a pentamer (from
above) showing their orientation
around the central ion channel pore, 
which is formed from the five M2 
domains (inside the yellow dashed 
circle). B, The Ml -4 domain of two 
opposing subunits (side profile), the 
green box highlights the hydrophobic girdle, which represents the gate
approximately two thirds of the way down the channel in the M2 domains,
corresponding to L261 in GlyR a l .  At either end of M2 is the M l-M2 (yellow) 
and M2-M3 (green) loops proposed to act as two hinges that allow the M2 
domain to rotate sideways and open the channel. C, Identification of residues 
involved in gating, conductance, desensitisation and sensitivity to alcohols, 
anaesthetics, picrotoxin and cyanotriphenylborate. The helices are colour coded 
and labelled (side profile). Due to the multiple roles of most of these residues, 
their functions are presented in Table 1.1. D, View from above of the four 
helices from a single subunit, highlighting the location of the water filled 
vestibule behind the pore lining M2 domain (white dashed circle). The two 
residues implicated in determination of alcohol and anaesthetic potency are also 
presented.
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GlyR a l  
residue
Location Influential roles References
A52 p i-2 loop PTX sensitivity, 
Gating
(Miller et al., 2004)
(Ryan et al., 1994;Saul et al., 
1994;Miller et al., 2004)
L142, 
F145, 
PI 46, 
D148
cys-loop Anaesthetic sensitivity, 
Gating
(Schofield et al., 2004) 
(Absalom et al., 2003;Schofield 
et al., 2003;Schofield et al., 
2004)
1244 Ml Desensitisation,
Gating
(Breitinger et al., 2001) 
(Breitinger et al., 2001)
A254 M2, (2’) Conductance, 
Desensitisation 
CTB sensitivity, 
PTX sensitivity
(Bormann et al., 1993)
(Zhang et al., 1994) 
(Rundstrom et al., 1994) 
(Pribilla et al., 1992) 
(ffrench-Constant et al., 1993)
T258 M2, (6’) PTX sensitivity (Gurley et al., 1995)
L261 M2, (9’) Channel gate (Unwin, 1993) 
(Labarca et al., 1995)
Q266 M2, Gating (Moorhouse et al., 1999)
S267 M2, (15’) Anaesthetic and 
alcohol sensitivity, 
Gating
(Mihic et al., 1997) 
(Findlay et al., 2003)
R271 M2, Conductance/Gating, 
PTX efficacy
(Rajendra et al., 1995) 
(Lynch et al., 1995)
A288 M3 Anaesthetic and 
alcohol sensitivity
(Mihic et al., 1997)
Table 1.1 The functions associated with residues in the GlyR transmembrane 
domains. Nearby residues from the p i -2 loop and cys-loop that influence the 
pharmacology of antagonists linked to the membrane region are also included. See 
Fig 1.10C,D for structural information on the location of these residues.
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binding site for alcohols between M2 and M3 revealed that altering the size of amino 
acid side chains present on M2 and M3 controls the ‘cutoff point for the size of 
alcoholic molecules that are able to enhance receptor function. This suggests that the 
size of the channel lumen is determined by the side chain moieties present (Wick et 
al., 1998). Another experimental observation that is consistent with the M2 rotation 
hypothesis was determined by labelling the nAChR p subunit at A267 of M2 
(equivalent to GlyR a l  Q266, Fig 1.1 OQ with a fluorophore tetramethylrhodamine. 
Upon agonist evoked receptor activation there was a shift in the fluorescence 
emission peak to lower wavelengths in accord with the fluorophore entering a more 
hydrophobic environment (Dahan et al., 2004). This is consistent with the M2 
domain twisting to move the A267 into a more hydrophobic location near M3 and 
M4. It is worth mentioning that although the GlyR p subunit may have a limited 
effect on gating via its M2-M3 linker (Unwin et al., 2002;Shan et al., 2003), the 
experiment above suggests that the M2 domains in the non-ligand binding subunits 
still undergo a conformational shift during receptor activation. In support of this, the 
mutation L285T, in the leucine gate of the GlyR P M2 domain, increases the glycine 
potency, presumably by destabilising the closed conformation (Shan et al., 2003).
The intracellular domain
The intracellular domain is associated with the most uncertainty as regards its 
structure. The only available insight into its structure is from a medium resolution 
4.6 A electron micrograph (Miyazawa et al., 1999) but this is of insufficient 
resolution to pinpoint individual amino acids. However, it does suggest that the 
intracellular domain is ordered and projects inwards from each subunit to form a cap 
with significant apertures between the sides of the subunit interfaces through which 
ions could flow (Fig 1.3). These apertures, though sizeable, may at least in the case 
of the 5 -HT3R, control channel conductance (Kelley et al., 2003).
For the GlyR, the intracellular domain has been attributed with three functions. 
Firstly, the P-subunit contains an 18 amino acid insert in this region that is vital for 
gephyrin binding and receptor anchoring (Meyer et al., 1995;Kneussel et al., 1999); 
secondly, both GlyR a l  and a3 have variable splice insertions in the M3-M4 
intracellular loop, which contain consensus phosphorylation sites capable of
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modulating channel function. In this regard, an M2-M3 S346 residue in the GlyR a3 
subunit is such a consensus, for PKA, which is vital for determining sensitivity to the 
PGE2 pain induced pathway (Harvey et al., 2004). Finally, the two intracellular 
M l-M2 and M3-M4 domains have also been shown to have an important influence 
on the rate of receptor desensitisation. This is supported by the fact that 
phosphorylation can modulate the rate of desensitisation for GlyR a l  (Gentet and 
Clements, 2002). In addition, a3 splice variants, which are distinguished by the 
presence or absence of a 15 amino acid insert in the M3-4 intracellular domain, have 
different desensitisation profiles. This property was primarily attributed to the 
presence of three hydroxyl groups within this domain located at T325, Y334 and 
S337 (Breitinger et al., 2002). Furthermore a study on residues throughout the 
M l-M2 loop shows that disruptions in this region influence the rate of receptor 
desensitisation (Breitinger et al., 2001).
In summary, the structure-function studies seem to support the presence of a 
localised agonist-binding domain formed by, in the case of the GlyR, loops A-C. 
The subsequent activation event from this site may possibly be mediated via loop A 
and the end result of this is a downstream predicted 15° rotation of the internal face 
of the extracellular domain GlyR a  subunit. This rotation exerts its effect on the 
three base loop regions, pi-2, the cys-loop and P8-9, which in turn reorganise the 
M2-M3 linker and this twists the M2 domain into an open conformation made easier 
by the flexible M l-M2 loop at the other end of M2 and a water filled lumen at the 
back of M2. As should be realised, this overall scheme remains relatively 
speculative and the fine details are only partially described. One aspect that is 
particularly evident from these studies is the limited identification of molecular 
components responsible for the different functional properties amongst GlyR 
subtypes. While studies now suggest that the GlyR a l  and 2 subtypes activate at 
different rates (Mangin et al., 2003) there have been no reports elucidating the 
molecular components responsible for this. Furthermore, though intracellular 
domains may be able to influence desensitisation there is no structural data on these 
regions and it is impossible to even speculate how this process is induced. In terms 
of single channel studies, residues have been identified which can account for 
subtype variations in the main conductance states, however there have been no
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molecular correlations to elucidate the residues responsible for different GlyR open- 
closed times and agonist efficacies. Thus, a vast repository of data is still required 
before those properties that enable receptors to exert unique physiological effects are 
determined from a molecular aspect and linked to the receptor activation process. In 
addition, relatively little is known about how principle GlyR modulators such as 
alcohols, anaesthetics, picrotoxin and Zn2+ exert their effects (Laube et al., 2002b). 
It is the job of structure-function studies to now attempt to decipher the molecular 
correlates of subtype specificity and modulator action and to place these in the 
context of the newly elucidated receptor binding-activation pathway. As the focus of
“S i
this study is on the modulator Zn , and how it can interplay with receptor function, 
the next section will deal with a few of the prime GlyR modulators and what is 
known of their mechanisms of action.
Pharmacology
Alcohols and anaesthetics
Anaesthetics and alcohols are able to potentiate both GABAaRs and GlyRs. This 
potentiation can occur at low nanomolar concentrations dependent on alcohol or 
anaesthetic structure (Downie et al., 1996; Wick et al., 1998). The evidence suggests 
these two classes of compound may act via a common site. Indeed, two critical 
determinants in the GlyR a l  subunit, S267 from M2 and A288 from M3, can 
determine whether or not alcohols and anaesthetics potentiate GlyRs (Mihic et al.,
1997). These two residues are located towards the extracellular side of the 
membrane and on either side of the predicted water filled lumen between M2 and 
M3, an ideal location for a binding site (Miyazawa et al., 2003; Fig 1.10C,£>). The 
presence of this region as a binding site for modulators is strengthened by the 
phenomenon of alcoholic ‘cutoff. This is characterised by an increased potency for 
the n-alcohols, as the chain length increases, which reaches a ceiling (Wick et al.,
1998) after which the potency stays unchanged, or begins to drop with longer chain 
lengths. This ‘cutoff varies between cys-loop receptors with the cutoff occurring 
earlier on the GABAaR p subunit than for the GlyR (Mascia et al., 1996;Mihic and 
Harris, 1996) and can be reversed by switching the differential identities of GlyR a l  
S267 and A288 with the equivalent residues from the GABAaR p subunit (Wick et 
al., 1998). This suggested that these residues altered the size of the cavity,
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supporting its potential as a binding site. From the location of this putative binding 
site it would seem sensible that in order for anaesthetics and alcohols to mediate their 
potentiating effects these molecules would facilitate the movement of the M2 domain 
either directly/ or by aiding the M2-3 hinge movement. SCAM experiments of 
residues from the a l  GlyR, including S267 and A288, revealed that the accessibility 
of both these residues increased upon receptor activation suggesting that this lumen 
does indeed undergo a conformational change during activation and that alcohols and 
anaesthetics could perhaps facilitate this process (Lobo et al., 2004). Intriguingly, 
individual alanine substitutions across the whole of the neighbouring GlyR cys-loop 
revealed a number of positions where potentiation by the anaesthetics halothane and 
isofluorane was ablated (Schofield et al., 2004). Thus, several facets of the GlyR 
gating apparatus appear to be able to influence anaesthetic modulation.
Picrotoxin (PTX) and cyanotriphenylborate (CTB)
These two molecules are both antagonists at GlyRs (Pribilla et al., 1992;Rundstrom 
et al., 1994;Miller et al., 2004) and highlight the caution that must be taken when 
ascribing a mechanism of action for an inhibitor based on the location of residues 
that determine its sensitivity. Originally, residues in M2 were identified that affected 
antagonist potency in both cases. The high sensitivity of GlyR a l  to CTB, compared 
to a2, was reversed by substituting G254 for the a2 alanine counterpart 
(Fig 1.10Q(Rundstrom et al., 1994). Similarly for PTX, replacing part of the 
P subunit M2 domain with a corresponding portion from the a l  subunit, markedly 
increased the sensitivity of ap  heteromers to PTX (Pribilla et al., 1992). The 
inhibition by CTB was in keeping with a direct action at M2 as CTB was use- 
dependent, uncompetitive, and the block was enhanced at positive membrane 
potentials (Rundstrom et al., 1994). The original conclusion for PTX also suggested 
this molecule was partially inhibiting receptor function by channel blockade (Pribilla 
et al., 1992). However the mechanism of PTX action at GlyR a l  has since been 
shown to act in a manner more consistent with competitive antagonism (Lynch et al., 
1995). Furthermore, GABAa receptors are rendered picrotoxin insensitive by 
introduction of the GlyR p residue F282 located towards the base of M2 (Gurley et 
al., 1995), which is a threonine in GABAa receptors and in the high sensitivity GlyR 
a l  (T258; Fig 1.10C). This suggests these two receptors share similar components
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for PTX action and also in GABAaRs, PTX does not have the profile of an open 
channel blocker. Another residue from the GABAaR corresponding to GlyR a l  
G254 located at the base of the channel beneath GlyRp F282, also influences the 
potency of PTX action by up to 100-fold (ffrench-Constant et al., 1993). This 
GABAaR residue has also been shown to be important in desensitisation (Zhang et 
al., 1994) and it has been proposed that PTX may act via an allosteric mechanism, 
preferentially binding activated receptors and stabilising them in agonist-bound 
closed conformations (for review see Hosie et al., 1997). In support of the M2 
region being a possible PTX binding site, SCAM studies on these residues showed 
that the GABAaR equivalent to GlyR a  G254 is less accessible in the presence of 
PTX (Xu et al., 1995). Despite this, disruption of the GlyR a l  R271 residue at the 
other end of M2 (Fig 1.1 OQ can also influence PTX modulation by switching the 
properties of PTX from competitive to non-competitive and even to a potentiator of 
glycine evoked responses at low concentrations (Lynch et al., 1995). Furthermore a 
residue in the extracellular gating domain p i -2 loop of the GlyR a l  receptor has also 
been shown to modestly influence the PTX potency (Fig 1.10C)(Miller et al., 2004). 
It should be noted that PTX is in fact a mixture of two separate components, 
picrotoxinin and picrotin, both of which have the same potency at the GlyR 
suggesting they mediate their effects in a similar manner (Pribilla et al., 1992).
Zinc
The molecular basis o f Zn2+ modulation o f glycine receptors
The first study to investigate the modulation of GlyRs by Zn , earned out by 
Bloomenthal et al, (1994) revealed a biphasic profile such that Zn exerted 
potentiation at low 0.1-10 pM concentrations and inhibition at higher concentrations. 
This profile was directly comparable between homomeric GlyR a2 and heteromeric 
GlyR a2p and was also similar for native GlyRs from rat spinal cord cultures 
(Bloomenthal et al., 1994). This data was later reproduced for GlyR a l  showing that 
the inhibitory site was selective for Zn2+ over Ca2+ and Mg2+ with only Ni2+, from the 
metal ions tested, able to replicate the Zn2+ mediated inhibition process (Laube et al., 
1995). Since these original reports, independent studies have verified the biphasic 
profile of modulatory Zn on native GlyRs in various neuronal preparations
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indicating that this phenomenon is most likely retained throughout the majority of, if 
not all, glycinergic systems (Li and Yang, 1999;Han and Wu, 1999).
The follow-up study by Laube et al (2000) identified a putative GlyR a l  D80 
residue as a plausible coordinating residue for Zn2+ potentiation (Laube et al., 
2000;Laube et al., 2002b; Fig 1.11). Though this moiety is acidic and is therefore 
one of the favoured chemical groups for Zn2+ coordination at binding sites, a 
subsequent independent study demonstrated that this residue only ablated Zn2+ 
enhancement of glycine evoked responses and not those of another endogenous GlyR 
agonist taurine, believed to bind to the same site as glycine (Lynch et al., 1998).
94-This suggested that D80 is unlikely to form part of a single Zn site necessary for 
agonist enhancement and instead is somehow linked either to glycinergic or zincergic 
transduction. In addition to this, the study by Lynch et al (1998) identified a number 
of residues in the GlyR M2-M3 linker region that also abolished Zn2+ enhancement. 
Though these residues did not bear the traits of classical Zn2+ binding moieties their 
location in the M2-M3 linker believed to be a pertinent component of the agonist 
gating apparatus (Lynch et al., 1997;Han et al., 2001;Kash et al., 2003a) suggested 
that Zn2+ potentiation may mediate its effect by influencing receptor gating. This 
assertion is also supported by the demonstration that Zn2+ was able to enhance the 
relative efficacy of the partial agonist taurine but did not increase the maximal 
response for the full agonist glycine, which as discussed previously has a P0 of 0.98 
(Laube et al., 2000).
Whilst advances in determining the molecular basis of Zn2+ enhancement have
94-essentially stagnated since these studies, reports to identify components of Zn 
mediated inhibition have continued to make progress. The first such study used the
94-histidine scanning technique to individually replace these potential Zn binding 
residues in the extracellular ligand binding portion of the protein with non-Zn2+ 
coordinating alanines. This led to the critical identification of GlyR a l  H I07 and 
H I09, as both GlyR a l H107A and GlyR a l H109A were resistant to 1 mM Zn2+ when 
co-applied with glycine (Harvey et al., 1999; Fig 1.11). Another report 
complemented these findings by demonstrating that alanine substitution of the 
nearby GlyR a l  T112, and also less profoundly El 10, reduced the sensitivity of
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GlyR a l  to Zn2+ mediated inhibition (Laube et al., 2000; Fig 1.11). Interestingly, the 
molecular basis of proton inhibition appears to overlay to some extent with the 
inhibitory site as Zn2+ inhibition has a lower potency when the concentration of 
protons is increased at pH 5.4 suggesting the two ions compete with each other for 
the same site (Harvey et al., 1999). A more recent study has identified GlyR a l 
HI09 and T112 as the critical components for proton inhibition, but not HI07, 
suggesting that though the sites overlap, the reliance on certain residues such as 
HI07 is different (Chen et al., 2004).
HI 07HI 09
Figure 1.11 Residues identified in the extracellular 
domain that influence Zn2+ potentiation and inhibition. 
Homology model from the inside face (see inset) of two 
neighbouring GlyR a l  subunit extracellular domains. 
Residues implicated in Zn2+ mediated potentiation, D80, and 
Zn2+ mediated inhibition HI07, HI09, El 10 and T112, are 
displayed and labelled. For ease of comparison with other 
characterised domains the extracellular domain is presented 
in a similar manner to previously as two parallel plates of P- 
strands, which run perpendicular to each other, the inside 
face in pink and the outside face in white. The agonist 
binding domain is also shown, consisting of loop A (red), 
loop B (orange) and loop C (yellow), as well as the gating 
domain, p i-2 loop (green), cys-loop (light blue) and P8-9 
loop (dark blue).
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Critically the importance of GlyR a l  H107, H109 and T112 in Zn2+ mediated 
inhibition have all been independently verified in the most up to date study on Zn2+ 
inhibition (Nevin et al., 2003). This report used a GlyR structural model based on 
the homologous AChBP protein (Brejc et al., 2001). The resultant model predicted 
that the inhibitory Zn2+ site between H I07 and H I09 could in fact form at the 
interface between two subunits (Fig 1.11) and the authors produced evidence in 
support of this by demonstrating that co-expression of a l H107A and a l H109A recovered
i • •  • • • •near wild-type sensitivity to Zn mediated inhibition. If the binding site was located 
solely within the confines of each individual subunit then co-expressing these 
mutated receptors to form mixed pentameric complexes would not recover Zn2+ 
inhibition as each individual site would still lack one of the Zn2+ binding residues. 
However if the site were interfacial then mixed pentameric complexes would 
produce receptors where some of the sites contained two non-binding alanines whilst 
others retained the full Zn2+ binding apparatus and could mediate Zn2+ inhibition. In 
addition to this the authors were unable to reproduce these results in the context of 
GlyR a l  T112 leading to the postulate that this residue has only an indirect bearing 
on the site of Zn2+ inhibition.
Zn2+ as a potential endogenous modulator o f glycine receptors 
Neurotransmitter release from a single synapse is generally considered to be a 
selective pairing between a specific neurotransmitter and its ligand-gated receptor; 
however in some circumstances, communication may be more complex. Such a 
situation can arise from the synaptic co-release of different neurotransmitters e.g. 
GABA and glycine in the spinal cord, which occasionally work together to 
simultaneously activate two types of postsynaptic receptors. This co-release property 
can also be extended to the paired release of a neurotransmitter with a receptor 
modulator, e.g., co-release of the NMDA receptor agonist glutamate and its 
synergistic partner, glycine (Johnson and Ascher, 1987;Corsi et al., 1996). A slight 
modification of this theme exists where the slow diffuse release of a modulator 
allows for long term modulation of postsynaptic receptors, e.g., in neurosteroid 
modulation of GABAa receptors (Belelli and Herd, 2003;Lambert et al., 2003;Stell 
et al., 2003). One prime candidate for the role of an endogenous modulator of 
neurotransmission is the transition metal cation Zn2+. The significance of this cation
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in neurotransmission and whether it participates in fast synaptic co-release, a slow 
diffuse release, or even simply exists as a background modulator present at a 
constant concentration as a ‘cationic veneer’ across the plasma membrane, is still 
debated.
The initial evidence favouring Zn as a physiologically relevant synaptic modulator
'Si #
relied on histochemical studies using Zn staining reagents such as Timms’ sulphide 
(Danscher, 1981), sodium selenite (Danscher, 1982) and fluorescent probes, to
'j,
establish the presence of Zn across many discrete brain regions (Danscher, 
1984;Danscher et al., 1985;Danscher, 1996;Frederickson et al., 1987;Frederickson, 
1989;Frederickson et al., 1992). Further studies revealed that Zn2+ is selectively 
packaged into numerous particular cell types, including: fibres from the perirhinal 
cortex to the neocortex and septum; amygdala (Perez-Clausell et al., 1989;Perez- 
Clausell, 1996); neurones of the dorsal cochlear nucleus (Frederickson et al., 1988), 
cerebellum, thalamus (Mengual et al., 2001), brain stem, spinal cord, retina and 
olfactory bulb (see Frederickson, 1989;Frederickson et al., 2000). The most famous 
example is the hippocampal mossy fibre innervation from the dentate gyrus to the 
CA3 pyramidal neurones (Haug et al., 1971;Crawford and Connor, 1972;Slomianka, 
1992). Though the concentration of free intracellular Zn2+ is believed to be very low, 
possibly picomolar for most cell types (Simons, 1991), the labelled ‘zinc-containing 
neurones’ (Frederickson et al., 2000) revealed intense Zn2+ staining in a pattern
^ i
consistent with the packaging of Zn into synaptic vesicles in axonal terminal
2+boutons. This fits with the principal characteristic required for Zn to act as a 
dynamic neuromodulator, its presence in a loosely bound, mobile form available for 
rapid release at the synapse (Frederickson et al., 2000).
In keeping with a zincergic action at synapses, an efficient reuptake and repackaging 
pathway is required. Though the exact molecular components of the initial reuptake 
stage from the extracellular space have not been determined a relatively high 
sensitivity, 0.3 -  20 pM saturable transport has been reported (Howell et al., 
1984;Wensink et al., 1988; Colvin et al., 2000a;Colvin et al., 2000b). The sensitivity 
of this process is unlikely to be relevant to the estimated nanomolar to picomolar 
background levels of extracellular Zn2+ (Kay, 2003) but may be sufficient to have an
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impact at the synapse where concentrated Zn2+ release could presumably reach much 
higher concentrations. Likely candidates for the downstream protein machinery of 
Zn2+ repackaging have^ however^ been elucidated with Zn2+ proposed, upon cellular 
re-entry, to bind proteins such as metallothionein ID, which may facilitate Zn2+ 
translocation to synaptic vesicles for sequestration via the Zn2+ transporter, ZnT-3 
(Palmiter et al., 1996). ZnT-3 is specific to the nervous system and testis and a 
ZnT-3 knockout mouse exhibits a complete absence of histologically-reactive 
vesicular Zn2+ in the brain (Palmiter et al., 1996;Cole et al., 1999;Wenzel et al., 
1997).
y.
Whilst the evidence so far suggests Zn is located and packaged at synapses, 
experiments to detect a genuine neuronal release and subsequent functional 
consequence mediated by Zn2+ have proved difficult to obtain. Initial studies 
attempting to address this issue loaded the hippocampal mossy fibre system with 
Zn and measured subsequent release into the superfusate upon depolarisation 
using high K+, kainate (Assaf and Chung, 1984), or electrical stimulation (Howell et
y  i
al., 1984). Measurements of the Zn concentration after such chronic treatment 
suggested this cation could attain 300 pM in the synaptic cleft. Further fluorescent 
assay based studies and atomic absorption spectroscopy suggested that depolarisation
j i
caused Zn to reach significant levels in the extracellular media (Budde et al., 
1997;Thompson et al., 2000;Li et al., 2001; Varea et al., 2001;Ueno et al., 2002). 
One report using the highly sensitive fluorescent Zn2+ probe, FluoZin-3, in
y ,
hippocampal slice preparations does, however, suggest that the levels of Zn 
released during synaptic transmission are far lower, even of the order 1 - 1 0  nM 
(Kay, 2003). This study even suggests that Zn2+ release may not be significant as a 
dynamic process and instead Zn exists at a low background level accumulated on 
extracellular membranes in the form of a veneer, which could modulate highly 
sensitive ligand-gated receptors. Functional studies using electrophysiology to
yi
address whether Zn is actually present at the synapse modulating neuronal 
receptors generally supports the assertion that indeed the concentrations of Zn are 
likely to be low, mainly because there is little evidence available for a Zn2+ mediated
y  I
effect. Two independent functional studies looking at synaptic Zn release in the 
hippocampus suggest that postsynaptic NMDA receptors can undergo modulation by
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synaptic Zn2+ that is possibly co-released with glutamate (Ueno et al., 2002;Vogt et 
al., 2000). Given the nanomolar sensitivity of some NMDA receptor subtypes in
94-these studies to Zn mediated inhibition, this suggests the concentrations of Zn 
released are also in this range. An additional study of Zn2+ modulation of tonic
94-GABAaR mediated currents, possibly by overspill of Zn into the extrasynaptic
94-space, also supported the claim that Zn can exist as a modulator of neuronal 
receptors (Ruiz et al., 2003). The sensitivity of these extrasynaptic GABAa 
receptors can be variable, suggesting Zn2+ concentrations of high to low micromolar 
(Brickley et al., 1999;Draguhn et al., 1990;Hosie et al., 2003). Furthermore, the
94-likely physiological relevance of synaptic Zn is in keeping with a modest role for 
this cation in neuromodulation as the Zn-T3 knockout mouse, which lacks synaptic 
vesicular Zn2+, is devoid of any obvious phenotype (Cole et al., 1999;Cole et al., 
2001). This suggests that either this phenomenon is unimportant or that receptors
94-can compensate for this normally subtle effect and that the reliance on Zn is only 
realised under certain confined circumstances (Cole et al., 2000).
With regards to any specific role this potential cationic modulator may play in GlyR 
synaptic activity, there are currently no direct functional studies to support such a 
claim. However, the receptor sensitivity, at least for Zn2+ mediated enhancement of 
recombinant GlyR responses, is high at 0.1 -  10 pM. This would be relevant to 
synaptic Zn2+ release, especially as the onset of potentiation is rapid (Suwa et al., 
2001). In addition to this, zinc-containing neurones are present throughout the spinal 
cord, the most concentrated home of the GlyR, and these zinc-containing vesicles 
have been identified side-by-side with glycine containing vesicles at presumed 
glycinergic axonal boutons (Birinyi et al., 2001 ;Jo et al., 2000;Velazquez et al., 
1999;Wang et al., 2001). It has also been shown in the zebrafish hindbrain that 
glycinergic EPSC currents maintain this high sensitivity to Zn2+ enhancement as 
application of a Zn2+ chelator increased the decay rate of the IPSC responses (Suwa
94-et al., 2001). This suggested very low, submicromolar concentrations of Zn are 
sufficient to enhance glycinergic neurotransmission by extending the IPSC decay
94-phase, though it does not prove that Zn was released synaptically as contaminating
• 94-nanomolar concentrations of Zn in the saline used are sufficient to account for this 
effect (Paoletti et al., 1997;Wilkins and Smart, 2002).
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Aims of the present study
Whilst some available data hints at potential regions of the GlyR that may be 
important for Zn2+ modulation of GlyRs there are still large gaps in our 
understanding of both the Zn2+ binding sites and any possible transduction pathways 
by which this modulator may act. Given the possible significance of Zn2+ as an 
endogenous modulator of GlyRs and the insight that determining the molecular basis 
of such events might bring, both in terms of how the GlyR operates and also how 
other cys-loop receptors may be allosterically modulated, this study aims to elucidate 
these specific molecular correlates. The techniques adopted revolve primarily 
around the established stratagem of site-directed mutagenesis to elucidate the
7+function of specific amino acids with regard to Zn binding and transduction. This 
approach was undertaken with structural homology modelling of the GlyR based on 
the homologous AChBP crystal structure, a tool that vastly enhanced the power of 
the site-directed mutagenesis strategy. In some cases, additional SCAM experiments 
were implemented to assess the accessibility of potential Zn binding sites. 
Furthermore pharmacological characterisations of spinal cord culture GlyRs were 
also carried out to link any recombinant pharmacological observations with in vivo 
receptor populations.
These techniques and tools have revealed a surprising wealth of information 
regarding Zn2+ modulation of GlyRs from both a binding and transduction 
standpoint. Firstly, the molecular basis of subtype divergence in sensitivity to both 
Zn2+ inhibition and enhancement was revealed. Secondly, original and novel 
candidates of the Zn2+ inhibition site were characterised and evaluated for their
7 ,
relative likely contributions to direct binding and transduction of Zn inhibition. 
Thirdly, the study uncovered a family of Zn2+ activated receptors, and through this 
discovery, it was possible to isolate a direct and specific hydrophobic pathway 
through the core of the GlyR a  subunit that could mediate transduction of the 
inhibitory Zn2+ site to reduce glycine binding and receptor activation. Fourthly, upon
7 .
determining the molecular basis of a differential potency for Zn between GlyR a l  
and a l  it was possible to identify a specific area of the GlyR as a strong candidate
7 , # t t
for a Zn potentiation site. As a consequence of this, a critical control element of
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this site was also determined, which implied that the Zn2+ potentiation site is able to 
exert its enhancement by affecting the cys-loop gating domain to increase the 
efficacy of the receptor.
Whilst these results will be of interest to those engaged in structure-function 
determinations of the GlyR and also other cys-loop receptor family members, this 
data unexpectedly offered potentially more than just an insight into the action of Zn 
itself. The hydrophobic pathway identified in this study and the nature of the process 
by which Zn is proposed to mediate its inhibitory effect suggest that this 
transduction pathway is an ideal structure to mediate the initial downstream 
conformational shift by which the GlyR and other cys-loop receptors may activate. 
Under such a proposition, agonist binding would induce a downstream collapse of 
the hydrophobic pathway allowing for destabilisation of polar interactions between 
the ‘+’ and subunit faces and subsequent twisting open of the extracellular domain 
of the receptor. In keeping with previous evidence, this twisting would move loops 
of the proposed extracellular gating domain which would impinge on the M2-M3 
loop and transmit to the M2 pore lining to elicit channel opening (Miyazawa et al., 
2003;Unwin et al., 2002;Kash et al., 2003b;Bouzat et al., 2004). Identification of 
such a candidate pathway was totally unexpected and highlights the importance of 
such studies as modulatory domains undoubtedly feed into agonist processing at 
some stage and therefore always offer insight into mechanisms of agonist action.
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Chapter 2 
Materials and Methods
Reagents
All laboratory reagents were purchased from Sigma and tissue culture reagents were 
purchased from GIBCO unless stated otherwise. Water for use in electrophysiology 
was filtered through an ELGA PURELAB Prima machine, whilst molecular biology 
grade water underwent a further purification process through an ELGA PURELAB 
ultra to remove trace ionic and organic impurities.
Molecular biology: Glycine receptor cDNAs
The work carried out in this project relied on the initial availability of a number of 
wild-type cys-loop ligand-gated receptor clones. Human (h) GlyR a lL , hGlyR a2A 
and rat (r) GlyR a3S cDNAs were cloned into the vector pCIS2 (obtained from Dr. 
R.J. Harvey). pCIS2 is a non-commercially available plasmid vector originally 
developed by H. Betz (Grenningloh et al., 1990) and this is a low copy number 
plasmid that contains an ampicillin resistance coding region. The splice variants 
selected for study from each GlyR subtype, a lL  (long) and a3S, contain or omit 
respectively, an intracellular TM3-4 loop amino acid insert compared to their spliced 
partners (Malosio et al., 1991b;Nikolic et al., 1998). This selection is unlikely to 
influence the subject of this study, the extracellular modulation by Zn2+, which 
previous evidence and the data presented here suggest is mediated through the 
extracellular domain of the protein. In the case of GlyR a2A, this splice variant does 
differ from its a2B counterpart in the extracellular domain by a two amino acid 
substitution. However the functional consequences of this substitution have been
• * 9+examined previously and do not have any obvious bearing on the property of Zn 
modulation of GlyRs (Miller et al., 2004). The human GlyR p cDNA was cloned 
into pcDNA3.i+ and provided by Dr. P.J. Groot-Kormelink. All other cDNAs used, 
namely murine (m) m5 -HT3Aiwas cloned into pRK5. Also, jellyfish enhanced green 
fluorescent protein (EGFP; in pEGFP-1) was obtained from Clontech. The GlyRp 
subunit was used in a different vector (PCDNA3.1+) so that high yields could be 
obtained upon purification, as highly saturating levels of this plasmid were required 
in transfections to ensure homogeneous expression of GlyR ap heteromers.
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Site-directed mutagenesis
During the course of this project more than 100 GlyRs containing single^or multiple; 
point mutations were generated and tested therefore only general details of the 
specific mutations made, or the oligonucleotide primers used^are included here. To 
insert an amino acid point mutation into a protein it is necessary to first substitute the 
corresponding nucleotide bases at the DNA level. This is done by hybridising a 
synthetic DNA primer containing the mutated base(s) of interest to a wild-type 
cDNA in a plasmid and then extending the primer with a polymerase to make a copy 
of the rest of the cDNA in its vector. This process is repeated in a manner similar to 
the cycling in PCR to amplify the vector containing the directed point mutant to 
sufficient levels for detection using bacterial cloning (scheme highlighted in Fig 2.1).
DNA melting (95 °C- 30 s)
Heat DNA plasmid to melt it 
▼ into two separate strands
Annealing phase (55 °C - 60 s)
O  Complementary synthetic forward and reverse primers containing the mutated bases of interest anneal to the wild type cDNA at the position where the mutation is to be inserted
I Extention phase (68 °C— 14 mins; 2 m ins/1 Kb o f DNA)
The DNA polymerase PfuTurbo extends oligonucleotide primers 
X using free deoxynucleotide triphosphates (dNTP) to create new 
mutated copies of the original wild-type cDNA plasmid
Cycling -1 8  times
Geometric amplification of mutated DNA 
to creates many copies of the mutated 
DNA plasmid for subsequent isolation
Figure 2.1 Schematic of the site-directed mutagenesis technique. Mutated cDNAs, 
which will later yield proteins with targeted amino acid substitutions for structure- 
function studies are generated by a three stage PCR amplification strategy involving
DNA melting, primer annealing and extention of the mutated primer in a cycle
repeated 18 times.
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Oligonucleotide primers (Invitrogen) were designed to be 24 -  34 nucleotides in 
length, ending and starting with cytosine or guanosine to improve the efficiency of 
hybridisation surrounding the unmatched region. At least six matching bases 
encompassed either side of the mutated base(s) of interest and where possible 
primers were designed to contain an even mixture of each of the four bases, dATP, 
dCTP, dGTP and dTTP, avoiding long stretches of any one base and possible 
sequences that may allow for hairpin loop formation within the oligonucleotide. In 
some instances an automated online oligonucleotide design engine was used, 
available from Stratagene (web address
http://labtools.stratagene.eom//Forms/SVLogin.php).
The site-directed mutagenesis protocol was modified from the Quikchange kit recipe 
(Stratagene):
PCR reaction mixture
5 pi of 10 x reaction buffer (Stratagene)
1 pi of 100 ng/pl double stranded cDNA plasmid template 
1 pi of 100 ng/pl forward synthetic mutated oligonucleotide primer 
1 pi of 100 ng/pl reverse synthetic mutated oligonucleotide primer 
1 pi of 40 mM dNTP mix (dATP, dCTP, dGTP and dTTP)
40.5 pi dH20
0.5 pi of PfuTurbo DNA polymerase (Stratagene)
This reaction mixture underwent the following PCR cycling process in a 
ThermoHybaid PCR machine (Thermo Life Sciences Ltd) with a preheated lid 
element negating the need for any mineral oil overlay:
Cycle 1 -  95 °C for 30 seconds {PfuTurbo activation phase)
Cycle 2-18 - 95 °C for 30 seconds (melting phase)
- 55 °C for 1 minute (hybridisation phase)
- 68 °C for 14 minutes (extention phase)
Successful PCR mutagenesis was verified by the presence of a significant band of 
DNA (of approximately 7 Kb in size corresponding to amplified cDNA plasmid) 
when 10 pi of PCR product, mixed with 4 pi gel loading buffer, was run on a 1.5 % 
agarose gel (BDH) in TAE buffer (0.04 M Tris-acetate, 0.001 M EDTA) with 
1 pl/100 ml ethidium bromide at 100 mV for 1 hour alongside a 1 kB DNA ladder
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(Invitrogen). Unsuccessful mutagenesis reactions, as verified by the absence of a 
clear band, were repeated by varying either the hybridisation temperature, adding 
0.5 pi of 10 mg/ml bovine serum albumin (BSA; New England Biolabs), or adding 
1 pi 50 mM MgSC>4 . If mutagenesis was still unsuccessful then fresh 
oligonucleotides varying in sequence were ordered. All mutagenesis reactions were 
subsequently successful.
The PCR product was incubated with 1 pi of Dpn I (New England Biolabs) at 37 °C 
for 2 hours. This selectively digests methylated DNA, in this case the original parent 
cDNA strands, which are methylated by bacteria during cloning. The PCR amplified 
templates however are unmethylated as these were generated from individual 
unmethylated nucleotide bases with PfuTurbo during the PCR amplification stage. 
The digested PCR product is then transformed into chemically competent TOP 10 
E.coli bacteria (Invitrogen -  in exact accordance with the manual). Final 
transformed bacterial aliquots were plated onto ampicillin Lb agar plates (12.8 g Lb 
agar powder/ 400 ml molecular biology grade water +100 pg/ml ampicillin spread 
across twenty 10 cm Petri dishes under sterile conditions) as all the vectors used in 
this project contained an ampicillin resistance coding region.
Subsequent successful mutagenesis experiments typically yielded 10 - 200 colonies 
per plate of which 2 colonies were picked and pipetted into separate 5 ml aliquots of 
Lb broth (20 g Lb broth powder/ 1000 ml molecular biology grade water +100  
pg/ml ampicillin) to be grown overnight for 15 hours at 37 °C in an Orbital Shaker 
S I50, shaking at 250 rpm. DNA was purified using the Qiagen miniprep kit and then 
sequenced externally by Wolfson Institute of Biomedical Research where only the 
initial provision of a small DNA aliquot and some sequencing oligonucleotide were 
required. Receptors that yielded results deemed to be important, or which had 
unexpected propertiesjwere re-sequenced across the full length of the cDNA region. 
Correctly generated mutated receptor cDNA constructs were grown in bulk using the 
Qiagen maxiprep kit in accordance with the recommended protocol to concentrations 
of 500 -  1000 pg/ml ready for transfection into mammalian cells.
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Basic stocks of all wild-type receptor clones and point-mutated receptors were 
maintained by the subsequent transformation and cloning of remaining DNA into 
DH5a E.coli bacteria (Invitrogen) followed by the selection of a bacterial colony to 
bulk up and maxiprep into fresh DNA as and when required.
Cell culture and transfection
HEK cells (ATCC CRL1573) were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10 % foetal calf serum (FCS), 2 mM glutamine, 100 
units/ml penicillin G and 100 pg/ml streptomycin, incubated at 37 °C in 95 % air - 
5 % CO2 (Smart et al., 1991) and were passaged two to three times weekly. Cells 
(passage no. 10-25) transfected by one of two methods depending on requirements.
1) Electroporation technique: One 50% confluent, 10 cm sterile Petri dish of 
HEK cells was washed with and resuspended in Optimem (final 0.5 ml 
volume) taking care to wash away any trace FCS as this disrupts the 
electroporation process. The 0.5 ml cell aliquot, supplemented with DNA 
plasmid for transfection in a cuvette, was electroporated at 400 V, infinite 
resistance, 125 pF using a Biorad Gene Electropulser n. Cells were 
subsequently shaken over a 10-minute period and then plated to achieve 20 
% confluence on poly-L-lysine (100 pg ml'1) coated 35 mm coverslips 
(BDH) and used for electrophysiology the next day. This technique was 
used in Chapter 3 with plasmids containing GlyR a  cDNA clones co­
transfected 1:1 (3 pg:3 pg) with a reporter plasmid expressing the EGFP, 
final volume approximately 6 pi. Also this method was applied to situations 
where large quantities of DNA were required such as co-expression of GlyR 
ap heteromers, which need high concentrations of the GlyR p-subunit to 
ensure its efficient incorporation into an ap heteromeric complex. The 
GlyR p subunit expression construct was mixed with GlyR a  subunit 
plasmids at a 30:1 ratio (30 pg: 1 pg, plus 2 pg EGFP), final volume 
approximately 20 pi.
2) Calcium Phosphate technique; reaction mix:
1.5 to 3 pg cDNA plasmid plus 1 pg EGFP in final 4 pi aliquot 
20 pi CaCh (from 340 mM filtered stock)
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24 pi 2 x HBSS solution (280 mM NaCl, 2.8 mM Na2HPC>4 , 50 mM 
HEPES, pH 7.2 with NaOH and filtered)
This was incubated at 4 °C for 1 hour and then pipetted onto HEK cells plated 
4 hours previously at 20 % confluence on poly-L-lysine (100 pg ml’1) coated 35 mm 
coverslips. Cells were then used for electrophysiology the next day (more than 
18 hours later).
Neuronal spinal cord cell culture preparation
E l5 embryos were extracted immediately from terminally anaesthetised and 
cervically dislocated Sprague-Dawley rats by Caesarean section and placed in ice- 
cold phosphate-buffered saline (PBS). Up to four spinal columns (not more than 
four so that the speed of the culture preparation was maximised to give healthier 
cultures) were excised and separated from the meninges and dorsal root ganglia. 
Spinal cords were cut into four sections and treated with 0.25 % w/v trypsin in 
Earle’s balanced salt solution (EBSS) for 15 mins at 37 °C. The tissue was then 
washed three times in EBSS to remove residual trypsin and sequentially triturated 
three times using polished Pasteur pipettes of narrowing tip diameter. Spinal cord 
cell suspensions were then centrifuged at 500 g for 5 mins and resuspended in MEM 
plating media supplemented per 100 mis with 5 ml FCS, 5 ml horse serum (HS), 
0.6 % w/v L-Glucose (Sigma) and 0.04 % w/v NaHCC>3 . Cells were plated at a 
density of 5 x 105 (approximately one third of an E l5 spinal cord) per 35 mm 
coverslip coated either with poly-L-lysine or also with an astrocyte monolayer. High 
quality coverslips were used (Assistent) stored in 100 % ethanol and coated in poly- 
L-lysine that was suspended in a borate buffer (50 mM boric acid, 12.5 mM sodium 
tetraborate, pH 8.5 -  Banker and Goslin, 1998) in an attempt to reduce the toxicity of 
poly-L-lysine to spinal cord neurones. The coverslips were washed three times in 
sterile distilled water to remove excess poly-L-lysine. The next day the primary 
culture media was 50 % replaced with Neurobasal media supplemented with 1 % v/v 
B-27 nutrient additive, 0.25 % v/v of 200 mM L-glutamine, 1 ng/ml recombinant rat 
ciliary neurotrophic factor (CNTF, Peprotech, London) and 100 pg/ml recombinant 
glial cell-line derived neurotrophic factor (GDNF; Peprotech, London). This media 
was replaced again by 75 % with fresh Neurobasal at the end of the same day. 
Subsequently, this medium was then replenished twice weekly. Astrocytic cultures
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were prepared from rat cortex by Dr. P. Thomas or Miss H. Da Silva in accordance 
with an original protocol derived from Banker and Goslin, (1998). Astrocytes were 
maintained in astrocyte maintenance media (AMM) made up in 100 ml stocks 
consisting of 77.67 ml Earle’s MEM (without glutamine); 20 % FCS; 0.6 % (w/v) 
D-Glucose; 100 U/ml Pen/Strep. Astrocytic cultures were washed twice weekly to 
replenish the cells with fresh AMM and to wash away any contaminating 
lymphocytes. Astrocytes were passaged once every two weeks until the time they 
were required as monolayers for spinal cord cultures. A glass scrapper was used to 
resuspend astrocytes after pre-treatment for 1 hour with 5 ml trypsin/EDTA per 
10 cm dish (0.5 g trypsin, 0.2 g NaEDTA/L in HBSS without Ca2+ and Mg2+) at 
37 °C. Cells were then triturated and either plated in AMM to achieve 10 % 
confluence for passaging later, or plated onto 35 mm coverslips at 100 % confluence 
ready for the addition of spinal cord cultures in 7 days time. (* see end of methods)
Solutions
The internal patch pipette solution contained (mM): 140 KC1, 2 MgCh, 1 CaCh, 10 
HEPES, 11 EGTA, and 2 ATP. The pH was adjusted to 7.11 for HEK cells and 7.3 
for spinal cord primary cultures using 1M NaOH, (» 300 mOsm). The external 
saline solution consisted of (mM): 140 NaCl, 4.7 KC1, 1.2 MgCh, 2.5 CaC^, 10 
HEPES, and 11 D-Glucose. The pH was adjusted to 7.4 using 1M NaOH (« 300 
mOsm). Primary cultured neuronal cells were superfused in external saline that also 
contained 10 pM bicuculline, 0.5 pM tetrodotoxin (TTX), 20 pM 
5-aminophosphovalerate (AP5) and 10 pM 6-cyano-2,3-nitroquinoxalinedione 
(CNQX) to remove GABAa and glutamate receptor synaptic activity and all action 
potentials, during glycinergic whole-cell recordings.
Experiments requiring absolute control of low (1 nM -  10 pM) concentrations of free 
Zn2+ ions were carried out in the presence of a Zn2+ buffering agent. Tricine was
74-selected as the optimal buffering agent available due to its relatively low Kd for Zn , 
estimated at around 10'5 M (Paoletti et al., 1997). For those studies to elucidate the 
Zn2+ potentiation site of the GlyR family (Chapter 5) a concentration of 10 mM 
tricine was used, allowing: 0.26, 0.78, 2.6, 7.8, 26, 77.5, 254 and 775 pM total Zn2+ 
to provide effective free Zn2+ concentrations of: 1,3, 10, 30, 100, 1000 and 3000 nM
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Zn2+, respectively (Suwa et al., 2001). For those experiments investigating a 
potential Zn2+ transduction pathway from the inhibitory Zn2+ site (Chapter 4) the 
requirement for tricine based recordings was far more extensive, therefore a lower
2.5 mM concentration was used as this allowed for the health of the HEK cells to be 
maintained for longer recording sessions (unpublished observation). To calculate 
free Zn2+ concentrations in 2.5 mM tricine, WINMAXC 2.40 was used 
(http://www.stanford.edu/cpatton). The properties for tricine were entered manually 
into the program (K d = 10*5; Paoletti et al., 1997) and other parameters such as 
temperature (20 °C) and pH (7.4) could also be accounted for. WINMAXC 2.40 was 
also used to evaluate the final free Zn2+ concentrations in the presence of the high 
affinity Zn2+ chelator TPEN, 100 pM, (A,A,AT,/V,-tetrakis-(2-pyridylrnethyl)- 
ethylenediamine; KD = 10'15 6; Paoletti et al., 1997) at pH 6.4, 7.4, and 8.4. TPEN 
properties were already predefined in the WINMAXC 2.40 database. Both 2.5 and 
10 mM Tricine reduced the pH of the Krebs solution, which was therefore titrated 
back to pH 7.4 using 1M NaOH. TPEN had no observable effect on the pH of Krebs 
at the 100 pM concentrations used.
Cysteine accessibility experiments made use of 2-aminoethyl methane sulphonate 
(MTSEA) in the form of a hydrobromide salt (Insight Biotechnology Ltd). This 
agent covalently modified accessible Cys residues on the GlyR after incubation of 
transfected HEK cells for 1 minute in a 3 mM concentration of MTSEA. Frozen 
powdered MTSEA, dissolved in saline was applied directly to cells within 2 minutes.
Electrophysiology
An Axopatch 200B amplifier (Axon instruments) was used to record whole-cell 
currents from single HEK cells or spinal cord primary cultures using the patch-clamp 
technique. HEK cells exhibited resting potentials between -10 and -40 mV and 
were voltage clamped at a —40 mV holding potential. Recordings were only 
attempted from ideally single, or occasionally doublets/ of HEK cells to ensure 
effective space clamp of the cells as these cells maintain gap junction communication 
networks. Healthy spinal cord neurones were judged on the basis of robust dendritic 
networking (7 days in vitro (DIV) and above), resting potentials of —40 to -60 mV 
and steady holding currents. These cells were clamped at -70 mV. Cells were 
visualised with a differential interference contrast Nikon microscope with
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epifluorescence attachment to identify EGFP transfected cells. A Y-tube was used to 
rapidly apply drugs and Krebs solutions (exchange rate i.e. 10-90  %, rise time of a 
maximal saturating glycine concentration was approximately 7 - 2 0  ms) to patch- 
clamped cells. Patch electrodes were fabricated from borosilicate glass (GC150T-10 
from Harvard Apparatus Limited) using a Narashige PC-10 puller with resistances 
after polishing of 4 - 5 MQ. All recordings were performed in constantly perfusing 
Krebs at room temperature (20 - 22 °C).
Data acquisition and analysis
All recorded current signals were filtered using a low pass Bessel filter set to 3 kHz 
(-36dB per octave). Data were recorded in 20 s acquisition periods directly to a 
Pentium IV, 1.8 GHz computer running Clampex 8.0 via a Digidata 1322A (Axon 
instruments) interface sampling at 200 ps intervals. All digitised currents were 
analysed offline using Axoscope 8.2. Acquisition periods included an initial triplet 
of -10 mV steps to monitor the residual capacitance transients (after initial 
compensation) and also the cell access resistance between acquisition periods. Any 
change of greater than 10 % in the height of the capacitance transients between 
acquisition periods led to the data being discarded. Experimental run-up and run­
down was also monitored by the regular application of a submaximal concentration 
of glycine corresponding approximately to 50 % of the maximal Gly response i.e. 
application of an EC50 agonist dose. In the case of agonist dose response curves, the 
EC50 ‘monitor’ dose would be applied before and after application of 4 -  6 different 
doses of agonist. When modulators such as Zn, or inhibitors such as strychnine, 
were being tested, control EC50 monitor doses to check for wash out of the 
modulator/inhibitor and run-up/run-down were applied before and after every 2 - 4  
test doses. If response amplitude run-up or run-down was not observed, or was less 
than 15 %, then the test responses were normalised by linear interpolation between 
the two surrounding control agonist EC50 response amplitudes. The maxima of EC50 
dose response curves for taurine (Fluka biochemicals) and p-alanine, which were 
demonstrated to be partial agonists in some cases, were determined from 
concentration response curves normalised with respect to the current activated by a 
maximal concentration of glycine (usually 10 mM) measured in the same cell. 
Inhibition dose response experiments with picrotoxin (initially dissolved in dimethyl
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sulphoxide (DMSO) forming concentrated stock solutions), strychnine^ or Zn2+, 
involved pre-incubating the HEK cell with a dose of the inhibitor for 15 s to ensure 
full equilibration, and then co-applying the same inhibitor dose with an EC50 
concentration of agonist. For experiments using the GlyR inhibitor sodium 
cyanotriphenylborate (CTB -  Pfaltz & Bauer Inc), pre-incubation was not used as 
this molecule is an open channel blocker (Rundstrom et al., 1994).
The biphasic curves, describing the Zn2+ concentration response data, were generated 
using a non-linear least squares routine according to the following modified Hill 
equation which assumes Zn2+ binds to two distinct sites, one producing potentiation 
and the other inhibition of the glycine-activated membrane current (Harvey et al.,
1999). For simplicity this equation assumes only one of each site per receptor rather 
than the actual five predicted to be present in a homomeric pentamer:
I =  Inrin +  (Ux -  IMin) ( [ 1 / ( 1 +  ( E C 5(/ B D ]  - [ 1 / ( 1 +  ( I C 5(/ B D ] ) ,  ( 1 )
where I and 1 ^  represent the modulated peak glycine-activated currents by a 
concentration of Zn2+, B, and by a saturating concentration of Zn2+ respectively. Imjn 
represents the control glycine current in the absence of the modulator and was set to 
100 %. E C 50 and I C 50 define the Zn concentrations producing a half maximal 
potentiating effect and a 50% inhibition of the maximally potentiated current, 
respectively. Both nn and mH represent the respective Hill coefficients. Where this 
equation (1) was unable to provide good estimates of the E C 50 and I C 50 with
y_i
acceptable errors, due to limited resolution of parts of the Zn dose-response curves, 
the I C 50 values were evaluated from curve fits to the inhibitory components of the 
curve (equation 2). For these curve fits, the peak potentiation was taken as the 
maximum of the curve and the I C 50 measured as the point where 50 % inhibition 
relative to this peak was attained.
The agonist concentration response curves were fitted with the Hill equation:
I / I max =  [ ( l / 1 + ( E C 5 0 / A ) n) ] ,  ( 2 )
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The EC50 represents the concentration of agonist (A) inducing 50 % of the maximal 
current evoked by a saturating concentration of agonist and ‘n’ is the Hill coefficient. 
This curve was also used to fit IC50 plots for the inhibitors picrotoxin, strychnine and 
also for Zn2+ in cases where mutated GlyRs lacked the competing Zn2+ potentiation 
component, or where equation (1) provided inadequate fits. In some cases mutated 
GlyRs exhibiting clear biphasic inhibition by Zn2+ were observed, these inhibitory 
dose response curves were fitted with a biphasic inhibitory curve generated by the 
equation:
I/Imax = 1 - (a X An / (An + IC50n )) + (b X An / (An + IC50n )) (3)
All values are as previously stated but ‘a’ and ‘b’ represent proportionality constants 
reflecting the contribution to total inhibition provided by each of the two inhibitory 
components.
Where parallel agonist dose response profiles were evaluated in the presence of 
incrementing concentrations of inhibitory Zn , the potency of inhibition could be 
more thoroughly evaluated to obtain a pA2 value according to the method devised by 
Schild (Arunlakshana and Schild, 1959;Rocha E Silva and Schild, 1949). Full 
concentration response curves for glycine were obtained in each HEK cell and then 
at least one but usually more glycine curves were repeated in the presence of 
incrementing Zn2+ concentrations (50, 100, 200 and 500 pM). The curves were 
assessed for their parallel nature and the dose-ratios (r) for Zn2+ were measured at the
'y,
glycine E C 50 concentrations. The mean dose-ratios for each Zn concentration were 
then fitted with the Schild equation:
r-1 = B / Kb,
where Kb is the Zn2+ dissociation constant. The Schild equation was logarithmically 
transformed to:
log (r-1) = log B -  log Kb,
The Schild plot of log(r-l) versus log(B) was linear and if the slope of the line was 
judged to be not significantly different to unity, then the slope was constrained to one 
and the intercept on the abscissa used to determine, -logKB, which equates to the pA2* 
for Zn2+, a measure of Zn2+ affinity for the receptor. The best curve fits to the 
(* pA2 = Kd)
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experimental data were achieved by applying a non linear least squares fitting routine
2
running in Origin (version 6.0)*
Structural modelling
The mature N-terminal extracellular domain (ECD) of the human GlyR a l  subunit 
was modelled on the crystal structure of the acetylcholine binding protein (AChBP; 
(Brejc, 2001 89 /id)) using the freeware program SwissProt Deep View 3.7 available 
from http://ca.expasv.org/spdbv/. The AChBP crystal structure was downloaded as a 
PDB file labelled 1I9B from http://www.rcsb.org/pdb/ and loaded into SwissProt 
DeepView 3.7, under main header File -> Open PDB file. The GlyR protein 
sequence was uploaded in a simple text format into DeepView 3.7, under main 
header SwissModel —> Load Raw Sequence to Model (Fig 2.2^). The GlyR 
sequence was then aligned with AChBP in the alignment window (Fig 2.2A) under 
main header Window —> Alignment, in accordance with a ClustalW protein 
alignment (Fig 2.2B). This alignment was submitted for modelling via the program 
interface of Deepview, under main header SwissModel —> Submit Modelling 
Request. Upon submission a dialog box opened and the file was saved with an 
appropriate name in html format. Upon saving the file a SwissModel website 
window opens where the user e-mail details were entered and the location of the 
previously saved html file was provided so the website could access the modelling 
request. The results were requested in the Swiss-PDB Viewer mode and then the 
details were sent.
The GlyR transmembrane domains M l-3, and separately M4, were aligned using 
ClustalW and modelled on the atomic structure of the Torpedo nicotinic 
acetylcholine receptor (nAChR) chain A (PDB label, 10ED; Miyazawa et al., 2003) 
and imported into SwissProt DeepView in the same manner to that described above. 
The final GlyR ECD and M l-4 structures were then empirically docked to ensure 
that the C-terminus of the ECD linked with the N-terminus of TM1; the TM2-3 loop 
was closely apposed to the base of the N-terminal Cys loop; and that the N-terminal 
domains did not sterically hinder each other when assembled in a pentameric 
complex. The finalised models, required for presentation purposes, were processed
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using a 3D rendering freeware program called POV-ray 3.5 for improved image 
quality (available from http://www.povrav.org/).
Statistics
All statistical analysis was carried out using the Student’s t-test in Microsoft Excel. 
Comparisons of data sets recorded in the same cell were considered paired whilst 
those from separate cells were treated as unpaired. The analysis compared all data 
under a two-tail hypothesis and quantified significance to the 5 or 1 % levels, stated 
in the text.
* Animals were anaethetised in a chamber using halothane in accordance with the 
Scientific Procedures Act (1986). Animals were obtained from the University 
College London pharmacology animal house, where animals were kept in accordance 
with the government guidelines on animal housing.
*2 Exponential curves for decay components of desensitisation traces (Chapter 3) and 
for rates of action of glycine EC50 currents (Chapter 5) were fitted using Igor Pro 
version 4.01.
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hGlyR alL  MYSFNT- -LRLYLSGAIVFFSLAASKEAEAARSATKPMSPSDFLDKLMGRTSG--
hGlyR a2A MNRQLVNILTALFAFFLETNHFRTAFCKDHDSRSGKQPSQTLSPSDFLDKLMGRTSG---
hGlyR P MKFLLTTAFLILISLWVEEAYSKEKSSKKGKGKKKQYLCPSQQSAEDLARVPANSTSNIL
AChBP        LDRADILYNIRQT--
hGlyR aiL  ydarirpnfkgppvnvscnifinsfgsiaettmdyrvniflrqqInI prIayne
hGlyR a2A ------YDARIRPNFKGPPVNVTCNIFINSFGSVTETTMDYRVNIFLRQqInIsrIaYSE
hGlyR p n r l l v s y d p r i r p n f k g i p v d v w n i f i n s f g s i q e t t m d y r v n i f l r q kInI prIklps
AChBP  s r p d v i p t q r d r p v a v s v s l k f i n i l e v n e i t n e v d w f w q q t t|s|rt|awns
hGlyR alL YPDDSLDL - - DPSMLDS11FFANEKGAHFHEITTDNKLLRISRldfcjVLYSIRITLT
hGlyR a2A YPDDSLDL--DPSMLDSI|kH lFFANEKGANFHDVTTDNKLLRISKNjKVLYSIRLTLT
hGlyR P DFRGSDALTVDPTMYKCJkH lFFANEKSANFHDVTQENILLFIFRdIdVLVSMRLSIT
AChBP SH-SPDQV- -SVP- ISS L§vH lAAYN - AIS KP E VLT PQ - - LARWS d|e VL YM P SIRQR
hGlyR aiL laI pmdlknfpmdvqtJ i mq le s fg y tm ndlifewqeqgavqvadgltlpqf-ilkeekd
hGlyR a2A LS|PMDLKNFPMDVQtItMQLESFGYTMNDLIFEWLSDGPVQVAEGLTLPQF-ILKEEKE
hGlyR p lsIpldltlfpmdtqrIk mq le s fg y tt dd l rf iw q sg dp v ql e k-ialpqfdikkedie
AChBP FSJDVSGVDTESG-ATfRIKIGSWTHHSREISVDPTTENSDDSEYFSQYSRFEILDVTQK
hGlyR alL LRYCTKHYN-TGKFTCIEARFHLERQM
hGlyR a2A LGYCTKHYN-TGKFTCIEVKFHLERQM
hGlyR p YGNCTKYYKGTGYYTCVEVIFTLRRQV
AChBP KNSVTYSCC-PEAYEDVEVSLNFRKKG
Figure 2.2 SwissProt modelling program interface and amino acid homology 
alignment of hGlyR N-termini with the AChBP. The alignment was based on a 
ClustalW multiple sequence alignment and required mild manual optimisation. Grey 
boxed residues represent critically conserved residues present through the cys-loop 
receptor family.
Chapter 3 
Molecular determinants of glycine receptor ap subunit sensitivities 
to Zn2+ inhibition
Introduction
Zn2+ is a biphasic modulator of GlyRs, potentiating agonist responses at low 
concentrations (0.1 -  10 pM) and eliciting an inhibitory effect at higher 
concentrations (Bloomenthal et al., 1994;Laube et al., 1995). Whilst the specific site 
of Zn2+ potentiation has to date remained difficult to define (Laube et al., 1995;Laube 
et al., 2000;Lynch et al., 1998), three pivotal structure-function studies have all 
reported evidence supporting a clear role for GlyR a l  amino acids H I07 and H I09 
in Zn2+ mediated inhibition (Harvey et al., 1999;Nevin et al., 2003). These two
 ^i #
residues fit the criterion, chemically, of classical Zn binding moieties and are 
predicted to reside in close apposition on a GlyR structural model (Nevin et al.,
94-2003), ideal for the formation of a discrete Zn inhibitory site.
Despite this progress there have been no clearly defined studies investigating any
94-potential GlyR subtype dependence that may exist for Zn mediated inhibition. This 
is of interest as it may reveal novel insight into structure-function properties of the 
site and may identify Zn2+ as a useful pharmacological tool to distinguish between 
GlyR subtypes for which there are currently few selective antagonists (Laube et al., 
2002b). In the original study by Laube et al, (1995) GlyR a l  and a l  were both 
shown to retain a comparable sensitivity to Zn2+ mediated inhibition, whilst a recent 
study suggests the auxiliary GlyR p subunit is not important for the inhibitory effect 
(Nevin et al., 2003). Additionally, a comparison between the GlyR a2A and a2B 
splice variants, which differ by a dual amino acid substitution in the extracellular N- 
terminal domain, revealed similar sensitivities to Zn modulation, (Miller et al.,
2004). The comparable sensitivity of a l  and a2 to inhibitory Zn2+ suggested by 
Laube et al, (1995) is surprising as an amino acid alignment of GlyR a  1-4 plus GlyR
94-p encompassing the specified Zn binding site region of interest revealed that a l  
differs crucially from all other GlyR subtypes at the putative Zn2+ binding residue
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HI07 (Fig 3.1). This unique histidine is replaced by an Asn in GlyR al-3  and GlyR 
P, a residue not known for its chemical capacity to coordinate Zn2+ ions (Auld, 
2001). Previous studies to compare the subtype dependence in GABAa receptors for 
Zn2+ inhibition have already shown that potential Zn2+ binding residues, which vary 
between GABAa subunits, appear to impart on these subunits differing sensitivities 
to inhibitory Zn2+ (Smart et al., 1991;Draguhn et al., 1990;Hosie et al., 2003). 
Therefore, it follows that if GlyR a l  HI07 is a genuine Zn2" binding residue, it 
should alter the receptor’s sensitivity to inhibition by this divalent cation when 
compared to other GlyR subtypes where this histidine is absent.
This chapter aims to investigate what role,if any, GlyR a l  H I07 plays in subtype 
sensitivity to inhibitory Zn . This influence is investigated for potential 
physiological relevance by assessing the impact of co-expression of a-subunits with
^  i a  i
the GlyR p subunit on Zn inhibition and also by the measurement of Zn 
inhibitory potency in a spinal cord culture preparation. Furthermore, attempts were 
made to isolate additional variable elements that might be responsible for 
contributing to the differential sensitivity observed between GlyR subtypes. These 
studies were supplemented by an investigation using the P subunit, which can 
enforce a fixed stoichiometry of Zn2+ binding sites upon GlyR heteromers, to 
elucidate information about any asymmetry of function that may exist within the 
GlyR inhibitory Zn2+ site.
GlyR al PDLFFANEKGAH 
GlyR a2 PDLFFANEKGAN 
GlyR a3 PDLFFANEKGAN 
GlyR a4 PDLFFANEKGAN 
GlyR P PDLFFANEKSAN
Fig 3.1 Primary amino acid sequence alignment of the GlyR family 
highlighting the unique nature of H I07 (underlined), a candidate residue in the 
inhibitory Zn"" binding site, in the GlyR a l  subtype. Another important residue 
for Zn2" mediated inhibition, H I09 (blue background), is conserved throughout 
the family.
lEITTDNKLLRISR 122 
)VTTDNKLLRIS K 129 
SVTTDNKLLRIFK 122 
IEVTTDNKLLRIFK 115 
)VTQENILLFIFR 145
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Results
Differential Zn2+ sensitivity between GlyR a l and GlyR al subunits
A comparison of the sensitivities of GlyRs to Zn mediated inhibition was initiated 
since one of the key Zn binding residues, H I07, is present in the GlyR a l  but not 
the GlyR a2 subtype. Modulation by Zn was examined using two different 
protocols. The first involved co-application of varying concentrations of Zn2+ with a 
half-maximally effective (EC50) concentration of glycine. The degree of inhibition 
was measured for the peak glycine response (Ipeak) and 4s into the co-application ( I 4 )  
to reveal a delayed onset of inhibition (Fig 3.2A-C). The second protocol utilised a 
pre-incubation of Zn and only the peak glycine responses were measured as pre-
I
incubation allowed Zn to equilibrate with the GlyR (Fig 3.2D). Irrespective of the 
protocol, all Zn concentration response curves exhibited a biphasic shape due to the
' y,
potentiating and inhibitory effects of Zn on GlyRs. However, contrary to a 
previous report (Laube et al., 1995), a clear difference in the potency of inhibitory 
Zn2+ was observed between GlyR a l  and GlyR a2 subunits. This was most distinct 
using the pre-incubation protocol, with a 25-fold reduction in Zn2+ potency apparent 
from an I C 50 of 15 ± 2 pM, (n = 5) for GlyR a l  to an I C 50 of 360 ± 40 pM, (n = 11) 
for GlyR a2 (P < 0.05; Table 3.1). All subsequent experiments therefore utilised the 
pre-incubation protocol with Zn2+.
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Figure 3.2 Differential inhibition of glycine-activated currents by Zn2+ at GlyR a l  
and GlyR a2 using whole-cell patch-clamp recordings from HEK cells. A, Zn2+ 
modulation concentration response curves of 50 % maximal glycine-evoked currents 
measured at the peak (Ipeak) of a 4 s co-application of glycine and Zn2+. B, Zn2+ 
concentration response curves as in (A) but responses measured at the end of the co­
application (I4). C, Example membrane currents comparing glycine-activated Ipeak and 
I4 for GlyR a l  (top) and GlyR a2 (bottom) after applying 50 % maximal glycine 
concentrations in the absence and presence of co-applied 10, 100 and 1000 pM Zn2+. 
D, Glycine-activated current following co-application of 50 % maximal doses of 
glycine with Zn2+ after prior incubation for 15 s with an equivalent concentration of 
Zn2+ for GlyR a l  and GlyR a2. The inset shows a typical 50 % maximal glycine- 
activated current for GlyR a l  in the absence and presence of 1000 pM Zn2+ under the 
pre-incubation protocol. N = 6 -  13 for all experiments.
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Histidine 107 determines the differential Zn2+ sensitivity between GlyR a  
subunits
Comparing the N-terminal extracellular domains of the GlyRs reveals that GlyR a2, 
like all other a  variants except GlyR a l ,  retains an asparagine (N114) residue at the 
homologous position to the putative Zn2+ binding residue, H I07, in the GlyR a l  
subunit (Fig 3.1). If H I07 coordinates Zn2+, then the divergent N114 in GlyR a2
7 -4-could be responsible for the differential sensitivity to Zn as asparagines are poor
7 -4-coordinating partners for Zn (Auld, 2001). This was examined by exchanging 
residues between the GlyR a l  and a2 subunits at the equivalent positions of H I07 
(a l) and N114 (a2) to generate a l H107N and a2N114H. This exchange reversed the 
sensitivities of the GlyR a l  and a2 subunits with regard to Zn2+ inhibition, such that 
aihio7n 2 3 0  ± 40 pM, n = 5) was now approximately 8-fold less sensitive to 
Zn2+ compared to a2N114H (29 ± 2 pM, n = 4; P < 0.05, Fig 3.35, Table 3.1). Taken 
together this strongly suggests that H I07 not only forms part of the inhibitory Zn2+ 
binding site but also it is largely responsible for the different sensitivities of the GlyR
7  .
a l  and GlyR a l  subunits to Zn inhibition.
GlyR a3 exhibits low sensitivity to inhibition by Zn2+
To further establish the significance of H I07 in the subtype sensitivity to Zn2+ 
inhibition, the GlyR a3 subunit, which possesses an asparagine residue at the 
homologous 107 position, was also examined in this regard to its sensitivity to Zn2+ 
inhibition. This is of particular relevance as currently there are no selective 
pharmacological blockers to distinguish between the two adult GlyR subtypes, a l  
and a3. Consistent with the data for GlyR a2, the potency of Zn2+ was also 
substantially reduced on GlyR a3 ( I C 50 = 150 ± 10 pM, n = 4). In accord with GlyR 
a2 subunits, replacing N107 with histidine in GlyR a3 subunits (a3N107H) increased 
the potency of Zn2+ mediated inhibition ( I C 50 = 26 ± 7, n = 3; P < 0.05, Fig 3.35).
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Figure 3.3 Reversal of GlyR a  
subunit sensitivities to Zn2+ 
mediated inhibition. A, GlyR
H107N , ~N114Ha l  and GlyR a2
mutants and B, GlyR a3 and 
GlyR a3N107H Zn2+ concentration 
response curves for modulating 
50 % maximal glycine-activated 
currents. The current peaks were 
compared for 50 % maximal 
glycine responses in the absence 
and presence of varying 
concentrations of Zn2+ after 15 s 
pre-incubation with an equivalent 
Zn2+ concentration. Curves for
wild-type GlyR a l  and GlyR a2
2+Zn modulatory profiles are 
included for comparison in A 
(taken from Figure 3.2D). N  = 4 
-  5 for all experiments.
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Mechanism for Zn2+ inhibition on GlyR a l  and GlyR al subtypes
The proposed mechanism of Zn2+ inhibition has not been fully investigated, although 
glycine concentration response curves determined in the presence of a single
'7 -+- • • • • • •concentration of Zn show no depression in the maximum response which is in 
accord with an apparent competitive mechanism of inhibition (Laube et al., 
2000;Han and Wu, 1999). The mode of Zn2+ inhibition was characterised for both 
GlyR a l  and GlyR a2 subtypes by generating glycine concentration response curves 
in the presence of several inhibitory concentrations of Zn (Fig 3AA,B). For both 
GlyR a l  and a l  subunits the glycine curves were displaced by Zn2+ in a parallel 
manner without any significant reduction in the maximal current elicited by 
saturating concentrations of glycine, consistent with an apparent competitive mode of 
inhibition. Due to the relatively high sensitivity of GlyR a l  to Zn2+ inhibition it was
94-possible to pre-incubate at several different inhibitory Zn concentrations and 
achieve measurable separation between each of the glycine concentration response 
curves. This was not possible for the less sensitive GlyR a2 subunit without 
incurring solubility problems due to the high concentrations of Zn2+ required. This 
series of parallel glycine curves were transformed into a Schild plot for the 
evaluation of a pA2 value for Zn2+ as an antagonist at the GlyR a l  subtype 
(Fig 3 AC). The Schild plot slope was not significantly different from one, and the 
constrained slope, with a gradient of 1, provided a pA2 value that was 4.44 ± 0.14, 
yielding a dissociation constant for Zn2+ from the inhibitory site of 27.5 ± 0.87 pM, 
(n = l ).
Rate of onset of Zn2+ inhibition at GlyR a l and a2
From the data presented in Fig 3.2, a pre-incubation protocol using 1000 pM Zn2+ 
caused a substantial amount of inhibition at both GlyR a l  (90 ± 2.4 %, n = 6) and 
GlyR a2 (78 ± 4.4 %, n = 11). During co-application protocols however, the level of 
inhibition induced by 1000 pM Zn2+ was dramatically different between the two 
subtypes of receptor (compare raw data traces Fig 3.2C). To assess the rates of 
onsets of Zn2+ inhibition at GlyR a l  and a2, potency matched doses of Zn2+ (40 and 
1000 pM respectively) corresponding to approximately 70 % inhibition under pre­
incubation conditions, were instead co-applied with 50 % maximal Gly doses for a
94-prolonged 60 s penod to allow Zn inhibition to reach a steady-state. A prolonged
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60 s application of Gly alone revealed a directly comparable biphasic desensitisation 
profile for both GlyR a l  and a2, with initial fast desensitisation components of 
4.1 ± 0.2 s, (n = 6) and 5.6 ± 1.3 s, (« = 5), and secondary slow desensitisation 
components of 45.7 ± 7.8 s, (« = 6) and 49.5 ± 7.6 s, (n = 5) respectively (Fig 
3.5A,C). As observed previously for the co-application protocol, during the initial 
activation phase for Gly plus Zn2+ responses, the current was in fact enhanced for 
both a l  and a2 due to the rapid onset of Zn potentiation on GlyRs. In the case of 
the slow activating GlyR a2 subtype (Mangin et al., 2003) the initial Zn2+ 
enhancement caused a significant decrease in the 10 - 90 % rise time to reach steady- 
state from 1.4 ± 0.4 s, (n = 5) in the absence of Zn2+ to 0.5 ±0.1 s, (n = 5) in the 
presence of Zn2+ (P < 0.05; Fig 3.5A,B). The GlyR a l  subtype, however^ shows a
9 -4-faster activation time in the absence of Zn compared to a2 and this did not 
experience a significant increase in activation rate for the 40 pM dose of Zn tested 
(Fig 3.5A,B). The delayed inhibitory component of Zn2+ modulation observed during
9  ^co-application of equivalent doses of Gly with potency matched doses of Zn 
revealed that the rate of onset of inhibition is in fact indistinguishable between the 
two receptors. In both cases the slow desensitisation phase was completely ablated 
leaving only a fast decaying component. This fast phase exhibited a modest 1.5 to 
2-fold increase in the rate of decay to steady state compared to the previously
9 i
identified fast desensitisation in the absence of Zn , from 4.1 ± 0.2 s to 2.8 ± 0.4 s, 
(n = 6) for GlyR a l  and 5.6 ± 1.3 s, to 3.1 ± 0.3 s, (n = 5) for GlyR a2 (Fig 3.5,4,Q .
9 -4-The total amount of inhibition after 60 s in 40 and 1000 pM Zn compared to in the 
absence of Zn2+ was not significantly different between the two receptors. GlyR a l  
was inhibited by 63 ± 7 %, (n = 6) and a2 was inhibited by 57 ± 13 %, (n = 5) 
indicating that the potencies of inhibition were accurately matched. The data 
therefore suggest that the substitution of a l  H I07 with a2 N114 does not interfere
9 +  9 -4-with the rate at which Zn can access the inhibitory site,or the rate at which Zn can 
mediate its effect. (* Note that desensitisation time constants were measured by 
fitting decay components with single or double exponential curve fits as appropriate).
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Figure 3.4 Zn2+ exhibits a 
competitive mode of inhibition at 
GlyR a l  and GlyR a2. Glycine 
concentration response curves for 
both a l  {A) and a l  (.B) GlyRs 
exhibit clear parallel rightward
24 -
shifts in the presence of Zn
without any decrease in the
maximum response. In all cases 
2+ •Zn was co-applied with the
agonist glycine after a 15 s pre­
incubation with an equivalent
2+
concentration of Zn . Glycine 
curves for GlyR a l  were 
measured in the absence and 
presence of 50, 100, 200 and 
500 pM Zn2+; and for GlyR a2 in 
the absence and presence of 
500 pM Zn*. C, Schild plot 
generated from the GlyR a l  dose- 
ratios taken from the curves in 
(A). A  solid line indicates the 
constrained unity slope with 95 % 
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dashed lines. All experiments 
were from an n of 6 -  13.
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Figure 3.5 The effect of co-applied Zn2+ on the decay time constants of 50 % 
maximal Gly responses for GlyR a l  and a2. A, Typical raw data traces showing 
prolonged 60 s application of 50 % maximal doses of Gly in the absence (black) 
and presence (red) of potency matched doses of Zn2+, 40 and 1000 pM for GlyR 
a l and a l  respectively. R, 10 -  90 % rise-times in the absence and presence of the 
same Zn2+ concentrations, highlighted and enlarged in dashed green boxes in (A). 
The time for the slower activating macroscopic current of GlyR a2 to reach steady 
state is markedly reduced whilst the rate for a l  is unaffected by Zn2+. 
C, Barcharts revealing that GlyR a l and a l  have comparable desensitisation time 
constants in the absence and presence (red bars) of Zn2". In the absence of Zn2+ 
traces decay with two time constants, fast (4 - 5 s) and slow (40 -  50 s). In the 
presence of Zn2+ decay with only a fast time constant (approximately 3 s), dotted 
black lines denote the speed of the original fast decay time constant in the absence 
of Zn2+. N=2>-6.
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Differential sensitivity to Zn2+ inhibition is unaffected by the GlyR p subunit
The 30-fold increased sensitivity of GlyR a l  over GlyR a2 to Zn2+ inhibition makes 
this ion a potentially useful pharmacological tool. Whether this differential 
sensitivity could be maintained at native neuronal GlyR populations was assessed 
using recombinant GlyR ap heteromers, which are considered to be the major 
physiological subtype of the GlyR (Pfeiffer et al., 1982). Successful co-assembly of 
GlyR a  and P subunits was established by measuring a reduction in sensitivity to 
picrotoxin (by approximately 20-fold) compared to homomeric GlyR a  subunits as 
previously reported (data not shown; Pribilla et al., 1992;Handford et al., 1996). The 
GlyR a2p heteromers exhibited a subtle though consistent 2-fold increased 
sensitivity to Zn2+ inhibition ( I C 50 , 180 ± 30 pM, n = 13) compared to the GlyR a2 
homomers (360 ± 40 pM, n = 11; P < 0.05; Table 3.1). Consistent with the previous 
findings for GlyR homomers, the GlyR a2p sensitivity to Zn remained 
substantially lower when compared with GlyR a ip , which retained a comparable 
sensitivity to the GlyR a l  homomer (Fig 3.6A,B, Table 3.1).
GlyRs from cultured spinal cord neurones show a low non-al-like sensitivity to 
Zn2+ inhibition
To evaluate whether a differential sensitivity to Zn2+ inhibition was apparent in a
• 7-+- • •native environment, the Zn sensitivity profiles of neuronal GlyRs were assessed in 
embryonic spinal cord cultures and in adult rat acute spinal cord slices. During early 
embryonic development and in dissociated culture, the GlyR a2 appears to be a 
predominant a  subtype, with a limited up-regulation of GlyR a l  during the course of 
culture maturation (Hoch et al., 1989;Hoch et al., 1992). This becomes more evident 
in vivo during late embryonic to early postnatal development when neurons 
substantially up regulate the GlyR a l subtype (Becker et al., 1988;Takahashi et al., 
1992;Watanabe and Akagi, 1995). Whole-cell recordings from 90 % of rat spinal 
cord cultured neurones responded to exogenously applied glycine and multipolar 
neurones at 7 days in vitro (DIV) or older, displayed robust glycinergic synaptic 
activity (example recording Fig 3.7A). The three age groups that were selected for 
study at, 5, 7 and 10-14 DIV, showed an overall low sensitivity to Zn2+ with 5 DIV 
neuronal cultures especially exhibiting a pharmacological profile consistent with a
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low sensitivity GlyR subtype in accord with the GlyR a2 subtype (Fig 3.7B, Table
3.1).
Growing spinal cord cultures on an astrocyte monolayer has been shown to enhance 
the development of GABAergic and glutamatergic synaptic inputs during the first 
week of development (Li et al., 1999). We examined whether this co-culture may 
accelerate glycinergic maturation and perhaps drive the development of cultures into 
expressing a l  subunits as occurs in vivo (Becker et al., 1988;Takahashi et al., 
1992;Watanabe and Akagi, 1995). Astrocytic co-cultures did accelerate the 
formation of synaptic activity with 5 DIV co-cultures exhibiting both a substantially 
higher frequency of synaptic events and also larger amplitude events, compared to 
5 DIV monocultures. (5 DIV on astrocytes; mean synaptic amplitude, 450 ± 280 pA, 
frequency = 4.8 Hz: 5 DIV monoculture; mean synaptic amplitude, 250 ± 280 pA, 
frequency =1.8  Hz; Fig 3.8^4). However, development of spinal cord cultures on 
astrocyte monolayers failed to produce a noticeable increase in the sensitivity to Zn2+ 
mediated inhibition from 5 DIV to 7 DIV, or when compared to spinal cord cultures 
not grown on astrocytic monolayers (Fig 3.82?, Table 3.1).
This work was directly complemented by following the period during which GlyR 
expression switches in vivo. To do this, electrophysiological recordings were made 
from neurones in acute spinal cord slices at P0 and P I8 . Whole cell recordings using 
pre-incubation with 30 pM Zn2+ exhibited only a partial inhibition at P0, of 
36 ± 4 %, {n = 19) consistent with a possible mixed GlyR a l  and a l  population; 
however, a profound inhibition, 69 ± 4 %, (n = 13), was exhibited at P I8  in accord 
with a progressive developmental transition to the adult GlyR a l  subtype (Fig 
3.9A,B). These experiments were performed in collaboration with M.Beato.
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F igu re  3.6 Differential sensitivity to inhibitory Zn2+ is retained in 
physiologically relevant recombinant GlyR ap heteromers. A, Typical 50 % 
maximal currents evoked by application of an EC50 dose of glycine, on GlyR a2 
and GlyR a2p respectively, in the absence (solid line) and presence (dashed line) 
of 100 pM Zn2+. This shows there is a modest though not profound difference in 
the potency of inhibitory Zn2+ between the homomeric and heteromeric GlyR a2. 
B, Zn2+ concentration response curves for the modulation of 50 % maximal glycine 
responses on GlyR a lp  and GlyR a2p heteromers in the presence of varying 
concentrations of Zn2+ after 15s pre-incubation with the same concentration of 
Zn . For comparison, the Zn sensitivities of recombinant GlyR a l  and GlyR a2 
homomers are shown (taken from the curve fits in Figure 3.2D). N=  3 -7 .
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F igure  3.7 Native GlyRs from primary cultures of spinal cord neurones 
exhibit a low sensitivity to Zn2+ mediated inhibition. A, A selected epoch of 
synaptic activity from a 7 DIV neurone demonstrating that they receive robust 
glycinergic input. This was assessed by monitoring synaptic activity in the 
presence of 10 pM bicuculline, 20 pM AP5 and 10 pM CNQX to inhibit 
GABAA, NMDA and AMPA receptors respectively (left panel) and then 
ablating this activity in the presence of a GlyR selective inhibitor, 1 pM 
strychnine (right panel). B, Native receptors from rat spinal cord cultures at 5, 7 
and 10-14 DIV exhibit a low sensitivity to inhibitory Zn2+ consistent with the 
expected predominant presence of GlyR a2 in the embryonic spinal cord. 
Again, for comparison, the curve fits for the recombinant GlyR a l  and GlyR a2 
homomers are shown (from 3.2D). The inset raw data traces illustrate, on a 
5 DIV neuron, modulation by 100 and 1000 pM pre- and then co-applied Zn2+ 
with a 50 % maximal dose of glycine. N=  8.
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F igure  3.8 Spinal cord neurones plated on astrocytic monolayers exhibit a low 
sensitivity to Zn2+ mediated inhibition. A, Synaptogenesis occurred significantly 
earlier for astrocytic co-cultures (lower panels), which received robust synaptic 
input by 5 DIV (up to 2 nA currents; compare with 7 DIV neurones in Fig 2>.1A) 
whilst 5 DIV spinal cord monocultures (upper panels) had less frequent and 
smaller synaptic currents (< 200 pA). Whole-cell exogenous glycinergic 
responses were measured in the presence of 10 pM bicuculline, 20 pM AP5 and 
10 pM CNQX to inhibit GABAA, NMDA and AMP A receptors respectively plus 
TTX to effectively block all synaptic input including spontaneous glycinergic 
events (right panel). B, Despite accelerated synaptogenesis of rat spinal cord 
cultures on astrocytic monolayers these neurones retained a low sensitivity to 
inhibitory Zn2+ at 5 and 7 DIV. Comparison of inhibition curves for recombinant 
GlyR a l  and GlyR a2 homomers are included (from 3.2D). The inset raw data 
traces illustrate, on a 5 DIV neurone, modulation by 100 and 1000 pM pre- and 
then co-applied Zn2+ with a 50 % maximal dose of glycine. N=  8.
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Figure 3.9 A switch to the high GlyR al-like sensitivity to Zn2+ mediated
inhibition does occur in rat ventral horn spinal cord neurones in vivo. A, Bar 2+ . . 2+ chart of Zn inhibition following pre- and then co-applied 30 pM Zn . This
demonstrates the shift to high sensitivity Zn2+ inhibition in more mature acute
spinal cord slices consistent with an expected shift to the high Zn2+ affinity GlyR
a l  subtype (the bar for 5 DIV, representing embryonic stages, is taken from
Fig 3.7B). B, The sample currents demonstrate inhibition and subsequent
recovery (after 10 minutes) from modulation by 30 pM Zn2+ for a young PI and
juvenile PI 8 neurone. All experiments were from 8 - 1 9  cells. This work was
performed in collaboration with M.Beato.
Identification of the structural elements required for Zn2+ inhibition
Inspecting the aligned primary sequences of GlyR a  and p subunits reveals that the 
GlyR p subunit, like the a2 subunit, retains the low affinity asparagine residue at the 
homologous position to the Zn2+ binding GlyR a l  subunit HI07. This is curious 
since co-expression of the p subunit with the GlyR a2 subunit in this study caused a 
modest increase in the sensitivity of this homomer to Zn2+ inhibition. This suggested 
that perhaps contrary to previous reports, the p subunit may actually contribute to the 
Zn binding site. Such a p subunit dependent increase in sensitivity was not 
observed with the a lp  heteromer, presumably because the a l  subunit has the highest 
subtype sensitivity to Zn2+ realised through the presence of its unique residue, H I07. 
A directed comparative scan was therefore made of the a2 and p subunit primary
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amino acid sequences guided by modelling the GlyR N-terminal domains on the 
crystal structure of the homologous acetylcholine binding protein (AChBP; Brejc et 
al., 2001). This approach identified specific amino acid differences in the predicted 
vicinity of the GlyR a l  HI 07 and HI 09 based Zn2+ inhibitory binding site. Of these, 
only two residues differed that might impact on Zn2+ coordination at this site. In 
GlyR a2 subunits, G112 (a l G105) and T140 (a l T133) are replaced in the 
P subunit by SI28 and SI56, respectively (Fig 3.10,4,2?). In view of their proximity 
to the Zn2+ inhibitory site, the p subunit residues were switched for their a2 subunit 
counterparts using the mutations, GlyR psl28G and psl56T, in an attempt to remove 
and therefore elucidate, the cause of the p subunit induced increase in GlyR a2 
sensitivity to Zn2+ inhibition. However, neither GlyR p8128G nor pS156^  removed the 
ability of the p subunit to increase GlyR a l  sensitivity to Zn2+ inhibition (Fig 3.10C; 
Table 3.1). In the absence of other suitable p subunit residues capable of interacting 
with the Zn2+ inhibitory site, the effect of the p subunit on GlyR a2 may instead be 
an indirect structural effect. Such a role has been suggested for T i l2 in the GlyR
i
a  subunit (Nevin et al., 2003), which also affected GlyR sensitivity to Zn inhibition 
(Laube et al., 2000).
Further structural comparisons of the GlyR a l  subunits revealed that the T133 
residue is located on p strand 6 (according to the nomenclature of Brejc et al, 2001), 
which is predicted to reside directly below H I09 on p strand 5. Moreover, another 
threonine in GlyR a l ,  T135, is also located on p strand 6 directly below H I07 
(Fig 3.10,4,2?). Since GlyR a l  T133 and T135 residues are ideally located as 
potential coordinating ligands for Zn2+, lying just below the putative Zn2+ binding 
H I09 and H I07 respectively, these threonines were assessed for their role in Zn2+ 
inhibition by individual mutation to alanines. Although GlyR a l T135A exhibited a 
comparable Zn2+ I C 50 (29 ± 2 fiM, n = 3) to the wild-type GlyR a l  subunit, the GlyR 
a l T133A mutation ablated Zn2+ inhibition up to 1 mM (n = 5, Fig 3.10Z), Table 3.1).
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Figure 3.10 Evaluation of potential binding residues in the immediate vicinity of the 
inhibitory Zn2+ site. A, Two neighbouring GlyR a l subunits modelled on the AChBP, 
expanded in B, to highlight inhibitory Zn2+ binding site residues, HI07 and HI09 
(orange) and two newly-identified potential Zn2+ binding residues, T133 and T135 
(blue). An additional variant residue, in the P subunit SI28, is also shown (red). In (,4) 
p-strand 5 (green) containing HI07 and HI09 is presented directly above p-strand 6 
(pink) containing T133 and T135. B, Homologous residues are shown in parentheses. 
For reference, GlyR a l El 10 (green) and T112 (pink), previously shown (Laube et al., 
2000) to influence Zn2+ mediated inhibition, are included and are both predicted to 
face away from the site, suggesting the side chains of these residues could not directly 
coordinate Zn2+. C, Assessment of potential p-subunit variants that may induce the 
modest increase in sensitivity to Zn2+ mediated inhibition on the GlyR a2 subtype by 
measuring Zn2+ modulation of 50 % maximal glycine responses (using pre- and then 
co-applied Zn2+) on GlyR a2psl“8tj and GlyR a2psl56T heteromers. Comparison with 
recombinant GlyR a2 and GlyR a2p curves (originally from 3.2D and 3.65) show 
that these substitutions do not account for the p-subunit influence on a2. D, Zn2+ 
concentration response curves for modulation of 50 % maximal glycine responses at 
GlyR a l Tlj3A and GlyR a l T133A with wild-type GlyR a l  present for comparison (from 
3.2D). Inset shows raw data traces demonstrating the resistance of glycine responses 
on GlyR a l T133A to inhibition by 1000 pM Zn2+. N=  3 -6 .
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Using the GlyR p subunit to investigate functional asymmetry at the inhibitory 
Zn2+ binding site
Although a role for the p subunit in coordinating Zn has not been favoured 
previously (Bloomenthal et al., 1994;Laube et al., 2000;Nevin et al., 2003) the data 
presented here suggested that this subunit can influence the potency of Zn at GlyR 
a2p heteromers. We addressed the ability of the p subunit to contribute directly to 
the Zn binding site by examining whether it could, if appropriately mutated at 
homologous positions, compensate for mutated GlyR a l  subunits with reduced Zn2+ 
sensitivities. For example, to compensate for the mutation, GlyR a l H107N, with
94-regard to the sidedness of the Zn binding site, would require co-expression with the 
p subunit mutation, pN130H (Fig 3.1 IB). Similarly, the mutant GlyR a l H109F would 
require a pairing with wild-type P, since this subunit already possesses a homologous 
H I09 (p H I32). It should be noted that GlyR a l  H I09 was mutated to Phe rather 
than the typical Ala usually employed, as a previous report suggested GlyR a l H109A 
may exert a complicating side effect on Zn2+ potentiation of GlyRs (Harvey et al., 
1999). The Phe moiety also does not favour chemical coordination with Zn2+ but it 
is more similar in terms of its side chain size and shape to His compared with Ala. 
This a l H109F receptor still dramatically attenuated the potency of Zn2+ mediated 
inhibition but maintained wild-type levels of responsiveness to Zn2+ enhancement 
(Fig 3.11R). Finally, the novel GlyR a l T133A mutant could be compensated by the 
psl56T mutation (Fig 3.1 IB). GlyR a l  El 10 and T112, previously found to influence 
Zn2+ inhibition (Laube et al., 2000), were not investigated in this study as GlyR 
a l EU0A exerted only a modest 5-fold increase in Zn2+ I C 50 (67 ± 4 pM, n = 3, data 
not shown) and is predicted to face away from the H107/H109 based Zn2+ binding 
site, whilst T112 (also facing away from the site; Fig 3A0A,B) has properties 
consistent with an indirect effect on binding (Nevin et al., 2003).
For the GlyR a l  subunit mutations, H109F and T133A, both of which reside on the 
same face (nomenclature from Fu & Sine, 1996; Fig 3.1 IB) of the inhibitory Zn2+ 
binding site, no recovery of Zn2+ potency was observed when either of these subunits 
were co-expressed with the compensating GlyR P subunits including either H I32 or 
S156T, respectively ( I C 50S > 1 mM, n = 3; Fig 3.11R). Furthermore, we investigated
94-this face of the Zn binding site from the perspective of the GlyR a l  T133 residue
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and found that co-expression of the wild-type GlyR a l  subunit with a psl56A mutant 
also had no effect on the receptor sensitivity to Zn2+ inhibition (IC50 = 17 ± 7 pM, 
n = 3). These data, accrued from one face (-) of the Zn2+ binding site, concur with the 
previously reported lack of effect of co-expressing GlyR a l  with pH132A 0n 
Zn2+ mediated inhibition (Nevin et al., 2003).
By contrast, when the GlyR a l H107N mutant, which is present on the opposing 
‘+‘ face of the Zn2+ binding site to H109 and T133, was co-expressed with the GlyR 
pN130H subunit, a dramatic recovery in the sensitivity to Zn2+ was observed almost 
reaching wild-type GlyR a ip  sensitivity (IC50 = 24 ± 3 pM, n = 5, Fig 3.11R). To
2"bensure this mutation was not due to the de novo construction of an mtrasubumt Zn 
binding site in the p subunit, as this pN130H subunit now contained two juxtaposed 
histidine residues (HI30 and H I32), we co-expressed the pN130H subunit with a GlyR 
a l Hio7N> hio9f double mutant m d this exhibited no recovery to Zn2+ inhibition 
(IC50 > 1 mM, n = 4; data not shown). This strongly suggested the P subunit is 
indeed participating in an intersubunit site and that this contribution by the P subunit 
to the Zn2+ binding site can only be donated from the ‘+‘ face of the subunit.
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F igu re  3.11 Asymmetry at the GlyR a  subunit Zn2+ inhibitory site using p- 
subunit induced recovery of a  subunits with perturbed Zn2+ sites. A, Raw data 
traces illustrating the recovery of sensitivity to Zn2+ inhibition at the ‘+* face 
following co-assembly of a ‘corrected’ pN1 0H subunit with a defective a l HI07N 
subunit. B, Schematic cross sections of 3 of the 5 GlyR subunits in a pentamer 
showing the compensatory p subunits required for co-expression with GlyR a  
subunits lacking one component of the Zn2+ inhibitory site (HI07, HI09, or T133). 
Black or dark grey boxes represent the residues mutated for a l  and P subunits 
respectively. Red boxes occur at the ap subunit interfaces labelled, *+’ and to 
highlight Zn^ binding sites where all the binding components under examination 
have been restored. These sites would be restored regardless of whether the P 
subunits are portrayed as being separated by an a  subunit (shown here) or if the p 
subunits are neighbours. B, Graph presenting assessment of Zn2+ inhibition in HEK 
cells using 15 s pre- and then co-application of Zn2+ with 50 % maximal glycine 
doses. All co-expressed heteromeric a ip  receptors are predicted to reconstitute all 
components of the Zn2+ binding site at the ap subunit interface, however,only in the 
case of pN130H co-expressed with a l H107N is the sensitivity to Zn2+ inhibition 
recovered (as compared to an a  1 wild-type profile, dotted line, originally from Fig 
3.2D). The inhibition curves for GlyR a l H107N, a l H109F and a l T133A subunits are 
included for comparison (data for a l H107N and a l T133A are taken from Figs 3.3,4 and 
3.10£>, respectively). N=  3 - 6 .
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Discussion
a l HI 07 is responsible for high sensitivity GlyR mediated Zn2+ inhibition
• 2+This study has identified a distinct difference in the potency of Zn mediated
inhibition between the GlyR a l  and GlyR a l  subunits which is also manifest with
the corresponding ap subunit heteromers. Comparison of the primary amino acid
sequences around the previously deduced inhibitory Zn2+ binding site (Harvey et al.,
1999) revealed that a single residue, H I07 in the a l  subunit, was likely to be
responsible for the different Zn2+ potencies. The absence of this residue in the a l
subunit substantially accounts for its reduced Zn2+ sensitivity, further supporting the
2+assertion that this location on the GlyR is probably forming a binding site for Zn 
induced inhibition (Harvey et al., 1999;Nevin et al., 2003). Although a previous
7-4“study comparing Zn potency at GlyR a l  and GlyR a l  subunits did not report any 
differences in sensitivity between these subtypes (Laube et al., 1995), this could 
reflect the varying Zn2+ application protocols, or possibly the glycine concentration 
chosen for study since Zn2+ is acting as a competitive antagonist. The ability to 
switch the Zn2+ sensitivities of GlyR a l  and a2 subunits simply by point mutation 
( a lH107N and a2N114H) strongly suggested that this differential effect had a molecular 
basis.
Zn2+ inhibition affects the apparent affinity of the GlyR
Despite the differential sensitivity of GlyR a l  and a l  subunits to inhibitory Zn2+, 
both glycine concentration response curves were displaced in a parallel manner 
without any reduction in the maximal glycine-activated current. This is consistent 
with Zn2+ acting as a competitive inhibitor, however, this does not necessarily imply
94- • • 9+that Zn is directly competing for the glycine recognition site, since Zn could 
interact with the receptor allosteric fashion reducing the ability of glycine to bind to 
its entirely non-overlapping site and possibly vice-versa. Indeed, this explanation is 
consistent with the current views on the discrete locations of the inhibitory Zn2+ and 
agonist binding sites (Laube et al., 2002b). Prior evidence suggests that Zn2+ 
inhibition of GlyRs is largely caused by a reduction in the agonist efficacy (E; Laube 
et al., 2000). The values of E reported for glycine at GlyR a l  vary from, 10 - 2 0  
(Laube et al., 2000) and 16 (Lewis et al., 2003), to 40 (Beato et al., 2004) for the 
higher-liganded GlyR states. By assuming a sequential ligand binding site model is
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sufficient to explain GlyR activation and using this to simulate glycine dose response 
curves, a reduction in E alone will not produce parallel displacements in the glycine 
concentration response curves of the magnitude observed in our study without 
significant reductions in the maximum response. For example, for GlyR a l ,  E 
would need to be reduced from 40 to 0.19 to increase the glycine EC50 from 24 to 
214 /xM; however this would cause the P0 to be reduced from 0.97 to 0.15, a 
substantial reduction in maximum glycine current. Thus, it is highly likely that Zn2+ 
is also affecting the affinity of glycine for its recognition site. The Schild analysis 
here provides the first definitive measurement of Zn affinity for the GlyR a l
r
(pA2 of 4.44) and indicates that Zn has a much lower potency (329-fold) at the 
glycine receptor compared to the classical competitive GlyR antagonist, strychnine 
(pA2 of 7.08, Kb 83.2 nM; Saitoh et al., 1994).
^  I
To further support the mode of Zn inhibition being the same at GlyR a l  and a2, 
these receptors both exhibited comparable macroscopic kinetics for the rate of onset 
of Zn2+ inhibition at activated GlyRs. The fact that there was an indistinguishable
y ,
rate of onset for equipotent concentrations of inhibitory Zn when co-applied with a
y  I
50 % maximal dose of Gly suggests that the accessibility of the site to Zn and the 
rate at which Zn2+ mediates its effect is comparable between a l  and a2. Under these 
conditions the normal biphasic desensitisation of agonist currents was replaced in the 
presence of Zn2+ with a single fast decaying component. Unfortunately it is not 
possible to attribute this property to any effect of Zn2+ to alter the desensitising 
properties of the receptor as this may simply reflect an independent action of Zn2+ to 
inactivate the receptor via an alternative route. In addition it is not possible to 
accurately assess the purity of any desensitising effect mediated by inhibitory Zn 
due to the competing and rapid Zn2+ enhancement experienced at these co-applied 
Zn doses. This will increase the height of the initial response peaks and thus 
potentially increase the rate of desensitisation as if the receptor were effectively 
activated by a higher concentration of agonist.
The mechanism of Zn2+ inhibition
Measurements of Zn2+ inhibition using varying application protocols revealed that
y ,
pre-equilibration of Zn with the GlyR and subsequent co-application with agonist
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incurred the highest potency for inhibition. In agreement with this, prolonged co-
9+ 9+application of Gly and Zn revealed a delayed onset of Zn inhibition, which 
required a significant 5 - 1 0  second time period to reach steady-state. These
9+ • • . •observations support a hypothesis favouring Zn binding to either a closed agonist- 
bound GlyR or a closed agonist-unbound GlyR or both (or the two situations may be 
equivalent). This dictates that Zn2+ would exert its greatest level of inhibition under
9-j- • • •a pre-incubation protocol as is observed here where Zn can bind and stabilise the 
closed-bound/unbound receptor prior to the presence of agonist (see Smart, 1992 for 
a similar argument for GABAaRs). Under co-application conditions a delayed onset 
would be observed as some agonist will activate the receptor before Zn2+ can bind. 
Therefore as Zn2+ cannot bind, or binds less to the open receptor (or perhaps also to 
the closed receptor with agonist bound^it must wait for the receptor to close and
9 i
possibly for the agonist to unbind before Zn can coordinate and inhibit receptor 
reactivation during the course of the remaining agonist application. This also means
9 i
that the onset of Zn inhibition will be slower under a co-application protocol at 
lower Zn2+ concentrations because there is an increased likelihood that after the 
receptor has shut and/or agonist has unbound that another molecule of agonist will
9-4-bind and reactivate the receptor before the Zn can bind. This situation is 
represented in Fig 3.2C,D where despite the fact that under pre-equilibration 
conditions 100 and 1000 pM Zn2+ exert almost full inhibition at GlyR a l ,  under co­
application (C, example traces) the onset of 100 pM Zn2+ inhibition is substantially
9 I
slower than that of 1000 pM Zn . This hypothesis also supports the apparent
9+competitive mode of Zn inhibition inferred by parallel dose response curve shifts 
with unchanged maximal agonist responses. Under these conditions when a 
saturating concentration of agonist is applied the receptor will effectively always 
have agonist bound as whenever one agonist molecule dissociates another will 
immediately take its place. Therefore the equilibrium between open and closed 
channels will be biased towards the open state, reducing the prospect of Zn2+ binding 
and causing inhibition.
This observation also has implications for the activation mechanism of the GlyR as it 
suggests that when agonist is bound there is a section of the receptor, encompassing
2*F"as far as the Zn binding site, that is always conformationally shifted as long as
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agonist is bound. However this conformational change is not necessarily 
synonymous with opening of the receptor channel. The reason for this is that single 
channel studies clearly reveal that even in the presence of saturating agonist 
concentrations, i.e. effectively agonist is always bound (especially for GlyR 
homomers where 5 molecules of agonist can bind at any one time but only 2-3 are 
required to activate it; Beato et al, 2004) the receptor still flickers between open and 
closed states very rapidly, with occasional long closures presumably due to 
desensitisation. Yet Zn2+ does not appear to bind during these closed states as it does 
not reduce the Gly Imax suggesting part of the receptor is still in an activated 
conformation preventing Zn2+ binding to its inhibitory site.
Native GlyRs retain the sensitivity to Zn2+ inhibition of their recombinant 
counterparts
This study also revealed that a distinction between GlyR subtypes for Zn mediated 
inhibition extends to a native environment where the sensitivity of a GlyR 
population, that is expected to be predominantly composed of a2 subunits in early 
spinal cord culture, demonstrates an overall low sensitivity to Zn2+ inhibition. More 
mature neurons in acute spinal cord slices/ however, display a distinctly enhanced 
sensitivity consistent with the predicted shift to GlyR a l  receptor subtypes in adult 
tissues (Becker et al., 1988;Takahashi et al., 1992;Watanabe and Akagi, 1995). This 
suggests the physiological significance of Zn2+ inhibition is unlikely to be relevant at 
embryonic stages of development since native embryonic GlyRs require greater than
• j i  •
50 pM Zn before the glycine EC50 response is inhibited. This result is in keeping 
with a previous report (Laube, 2002a) where 50 pM Zn2+ induced marginal inhibition 
of glycinergic IPSCs in spinal cord cultures. Our data, in agreement with previous 
immunocytochemistry (Hoch et al., 1989;Hoch et al., 1992), suggests that in spinal 
cord cultures the embryonic GlyR a2 remains dominant during culture maturation, 
regardless of the presence or absence of astrocytes, as the sensitivity to inhibitory 
Zn2+ remains low up to 14 DIV.
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The properties of the P subunit support an asymmetric role for the inhibitory 
Zn2+ site
Previously, the GlyR p subunit has not been shown to exert any detectable influence 
on Zn2+ mediated inhibition at the GlyR (Bloomenthal et al., 1994;Laube et al., 
1995;Nevin et al., 2003). However, this report demonstrates that in the unique 
instance of the a2 subtype, co-expression with the p subunit revealed an increased 
sensitivity to Zn2+ mediated inhibition. Although we were unable to attribute this
■y,
effect to a specific moiety in the vicinity of the putative inhibitory Zn binding site, 
as a consequence, we identified GlyR a l  T133, as a pivotal residue for Zn 
inhibition. When considering the location of the intersubunit Zn2+ binding site, in 
accordance with the three-dimensional GlyR a l  model based on the AChBP, the 
T133 residue is predicted to lie beneath H I09. This would be an ideal location for 
participation in the putative inhibitory Zn2+ binding site.
Co-expression of GlyR a  subunits with complementary p subunits, designed to 
compensate for a  subunits lacking specific components of the inhibitory Zn2+ 
binding site revealed an asymmetry of function between the opposing faces of the 
intersubunit binding site. Effectively knocking out either GlyR a l  H109,or T133, 
both predicted to be on the same face of the subunit, could not be compensated by 
P subunits mutated to contain equivalent a  subunit residues. This demonstrates that 
the a  subunit H107 ‘+‘ face and the mutant p subunit H132/S156T *-* face cannot
^  I
form a functional Zn inhibitory site alone, when the a-subunit face has been 
disrupted by mutation. In contrast, following knock-out of the GlyR a l  HI 07 on the 
opposing ‘+‘ face, the attenuated sensitivity to Zn2+ inhibition was almost fully 
restored by co-expression with pN130H subunits. The restoration of Zn2+ inhibition for 
the GlyR a l  H107N mutant implies that such inhibition is probably mediated from 
either the GlyR a l  H109/T133 fac to r the p N130H ‘+‘ face, or both acting 
together. As the wild-type GlyR a l  subunit is able to mediate Zn2+ inhibition 
regardless of the removal of any inhibitory components in the p subunit this supports 
a hypothesis whereby the H109 and T133 face of the binding site is responsible 
for connecting Zn2+ binding to an effect on receptor function (transduction). 
Furthermore, this transduction must be driven through the GlyR a l  subunit. In
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comparison, H I07 can instead be regarded as a pure binding residue, as this can be 
donated from a neighbouring subunit that lacks its own Zn transduction apparatus
i.e., the p subunit.
A proposed molecular basis for the action of inhibitory Zn2+
The hypothesis of asymmetric transduction from the face of the GlyR a l  subunit
is in keeping with current perspectives of proposed structural rearrangements that
occur upon receptor activation of cys-loop receptors. Intermediate resolution
micrographs of the torpedo nAChR demonstrate that the conformation of each
monomer within the pentamer is equivalent in the agonist-bound conformation of the
receptor (Unwin, 1995). However, in the absence of agonist the conformation of the
extracellular N-terminus for the principal nAChR agonist-binding a  subunits is not
equivalent to the more structural p, y and 8 subunits. In fact the p, y and 8 subunits
appear to undergo only minor movements from the conformation adopted in the
agonist-bound pentameric state whilst the a  subunits undergo a significant
conformational change to adopt a new position. Though direct structural data is
lacking for the GlyR, the evidence suggests that the roles of the a  and p GlyR
subunits are probably equivalent to those of the nAChRs, i.e. the a  subunit is the
primary contributor to agonist binding whilst the p subunit acts as structural support.
This is in contrast to GABAa receptors where evidence supports the converse (Amin
and Weiss, 1993). Structural rearrangements in GlyRs may therefore occur in a
similar manner with the agonist binding a  subunit undertaking the majority of the
dynamic conformational shifts, at least as far as the extracellular N-terminus is
concerned. Apparent differences in the resting conformations of the a  and
P subunits has been recently supported (Shan et al., 2003). In this study the
reactivity of cys-modifying reagents at the M2-3 linker region, a region critical for
receptor activation, revealed an asymmetric contribution of a  and P GlyR subunits to
aP heteromeric activation. Furthermore, mapping the AChBP onto the nAChR
a-subunit in its closed and agonist-bound, presumed open, conformation, revealed
that the a  subunit rotated around a diagonal axis resulting in the greatest movement
across the side of the subunit (Unwin et al., 2002). This suggests that the
GlyR H109/T133 face undertakes a greater conformational shift in location
compared to residues on the *+’ receptor face. Here the ability of Zn2+ to stabilise
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the closed receptor state is determined by whether or not a conformational change in 
response to agonist binding occurs, which would be transmitted as a conformational 
shift primarily across to the face of the monomer i.e. a transduction route to this 
side of the Zn2+ site. The ‘+’ HI 07 face by contrast is expected to undergo a smaller 
structural perturbation in response to activation and therefore this residue may still 
remain in a position where it can coordinate Zn2+, thus explaining how the p subunit 
can donate its equivalent N130H, but not its perturbed H132/S147 face, to a Zn2+ 
binding site.
Comparisons with the GABAaR family of inhibitory Zn2+ binding sites
• 9 iOur current understanding of the molecular components required for Zn mediated 
inhibition in other cys-loop ligand-gated receptors is derived from the GABAa 
receptor family. A recent in depth study of GABAa receptors pinpointed the 
sensitivity for Zn2+ inhibition to two separate inhibitory sites, a high potency site 
between two neighbouring p subunits and a lower affinity site between an a  and a 
p subunit, rather than the single location elucidated for GlyRs (Hosie et al., 2003). 
This also revealed that GABAa receptors confer on the pentameric receptor varying
• • • • • 94-levels of sensitivity to inhibitory Zn by replacing one of the two neighbouring 
p subunits, which form a high potency intersubunit Zn2+ binding site, with a reduced 
sensitivity 8, s or y subunit. This means that rather than simply varying the potency 
of the site whilst maintaining the same mechanism of action as appears to be the case 
for the GlyR, GABAa receptors featuring 8, s or y subunits instead form a new 
reliance on the secondary low potency site between the a  and p subunits. However, 
despite these initial differences, the GABAa inhibitory Zn2+ sites do still retain 
notable similarities to that predicted for the GlyR. Both the high and low potency 
GABAa receptor Zn2+ sites are proposed to be present as intersubunit sites forming a 
bridge between two neighbouring subunits. Furthermore both sites contain histidine 
residues, the most commonly occurring coordinating partner for Zn2+ (Vallee and 
Auld, 1990). In the case of the high potency site, two histidines from adjacent 
p subunits are proposed to form part of an intersubunit site, similar to the case for the 
GlyR a  subunits. Only the polar hydroxyl GlyR a l  T133 identified here differs 
from the remaining components of the two GABAa sites, all of which are acidic 
residues (Hosie et al., 2003).
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In view of the apparent conservation of intersubunit Zn sites across these receptors 
it is tempting to postulate that the GlyR may share a similar potential mechanism of 
Zn inhibition to its closest relative, the GABAa receptor. Unfortunately, 
alignments of the Zn2+ sites in GABAa and GlyRs suggest that though they may 
share certain chemical and structural similarities, the sites are expected to reside in 
different areas of the proteins, with the high potency GABAa site predicted to 
occupy a space at the mouth of the ion channel. In addition to this several studies 
investigating the properties of Zn inhibition at GABAa receptors suggest that the 
high potency inhibitory component exhibits a non-competitive mode of inhibition 
(Smart and Constanti, 1990;Legendre and Westbrook, 1991;Gingrich and Burkat, 
1998), whilst the low potency y-subunit dependent component displays properties 
consistent with an apparent mixed antagonism, and also does not show the same 
dependence as the GlyR for pre-equilibration to ensure a high degree of inhibition 
(Gingrich and Burkat, 1998).
Identification of residues required for Zn2+ mediated inhibition in other cys-loop 
receptors currently extend to a histidine residue reported to be important for the 
GAB Ac receptor subtypes a  1-3 (Wang et al., 1995). Evidence to support 
mechanisms of actions at other cys-loop receptors varies with Zn2+ inhibition of 
GABAa p subtypes 1 -3  proposed to be via an apparent mixed antagonism (Chang et 
al., 1995). Though there has been no molecular basis of Zn2+ inhibition elucidated 
yet for nAChRs this process does bear similarities to that of the GlyR as the 
sensitivity is dependent on subunit composition (Hsiao et al., 2001). In addition,the 
inhibition requires pre-incubation and due to its voltage independence and an 
apparent effect on the agonist affinity it has also been suggested to act via an 
apparent competitive mode either directly or through an allosteric process (Palma et 
al., 1998).
Conclusion
Taken overall, this study identifies Zn2+ as a useful pharmacological tool to 
distinguish between GlyR a l  and a2 or a3 subunits and identifies a new critical 
component in Zn2+ mediated inhibition, GlyR a l  T133. It also provides a rationale
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by which Zn2+ binding initiates the transduction of Zn2+ mediated inhibition resulting 
in an effect on glycine binding to the receptor. This appears to be propagated 
asymmetrically from the Zn2+ binding site being driven from the face. This 
phenomenon of asymmetric propagation of transduction is quite likely to be a 
common feature characterising the binding of ligands to many different sites on 
ligand-gated ion channels.
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GlyR subtype
CHyECsoOiM) W(nA) n Zn2+ IC50 (pM) n
a l 24 ±5 4.5 ± 0.5 10 15 ± 2 5
a 2 6 6  ± 6 3.7 ±0.5 13 360 ± 40 11
al & 18 ± 3 4.5 ± 0.9 6 13 ± 2 3
a 2 & 51 ±4 5.6 ±0.5 3 180 ±30 13
a l“ 24 ±2 5.9 ±0.3 4 230 ± 30 5
a l ta * 56 ±5 5.1 ±0.2 3 > 1 mM 3
a jTUJA. 64± 10 4.8 ±0.7 2 * > 1 mM 5
a- p t i s - - ......  - 17 ±2 3.3 ±0.6 3 26 ± 6 3
28 ± 8 4.8 ±0.8 3 24 ±3 5
a jto«>gSis«I 39 ± 4 5.2 ± 1.2 3 > 1 mM 3
a jTin*gilsil 90 ± 16 3.2 ±0.9 3 > 1 mM 3
a l 0 ^ 40 5.7 ±0.8 1 17 ± 7 3
...... ■ 58 ±3 4.2 ± 0.7 3 29 ±2 4
a 2 ftsa* 52 ±5 5.0 ± 1.6 3 170 ±20 4
ca ff3** 52 ±2 5.2 ± 1.2 2 * 2 1 0  ± 2 0 5
a3 48 ±3 5.3 ± 1.3 4 150 ± 10 4
a3mOTS 53 ± 12 5.3 ± 0.8 5 26 ±7 3
scDIVS *40 3.1 ±0.3 1 2 320 ± 50 8
scDIVT *30 4.9 ± 0.7 1 2 1 1 0  ± 10 8
sc IHV10-14 *30 4.3 ± 0.4 8 8 8  ± 2 1 8
sc astro DIV5 *30 4.3 ± 0.4 8 170 ±50 8
sc astro DIV7 *30 4.3 ± 0.4 8 170 ±50 8
Table 3.1 GlyR sensitivities to glycine and Zn2+.
The values indicate the glycine EC50S for activating recombinant and native 
GlyRs and also the Zn2+ IC50S for inhibiting the 50 % maximal glycine-activated 
responses where Zn2+ is first pre-equilibrated with the receptor for 15 s before an
9-4- •equivalent dose of Zn is co-applied with glycine. All numbers are means ± s.e. 
from n cells. For the native GlyR in spinal cord (sc) neurons, the EC50S were 
estimated from linear segments of the dose-response curves. Imax represents the 
maximal glycine-activated current.(* Due to an n of 2, these errors represent 
standard deviations).
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Chapter 4
Evidence for an allosteric transduction pathway across the 
extracellular domain of the glycine receptor
Introduction
Evidence so far accrued from three independent studies provides strong support and 
agreement that Zn2+ inhibition appears to be mediated via a discrete site featuring at 
the very least two histidine residues GlyR a l  H I07 and H I09, which are presented at 
an intersubunit site (Harvey et al., 1999;Nevin et al., 2003;Chapter 3). Furthermore 
this site appears to be distinct from the agonist-binding site as substituting these 
residues with alternative moieties does not exert a substantial effect on agonist 
potencies or their maximal responses (Harvey et al., 1999;Nevin et al., 2003;Table
3.1). These residues also differ from those previously shown to have a substantial 
impact on the agonist potency in a manner consistent with an effect on agonist 
binding. Residues implicated in agonist binding include GlyR a l  D96 to G105 (loop 
A;Han et al., 2001;Vafa et al., 1999), Y159 to F161 (loop B;Kuhse et al., 
1990b;Schmieden et al., 1993), and C l98 to C209 (loop C;Vandenberg et al., 
1992a;Vandenberg et al., 1992b; Rajendra et al., 1995b). The structural homology 
model (Fig 4AA,B) predicts the agonist-binding site and the inhibitory Zn2+ site
74- • • • •occupy distinct non-overlapping locations suggesting Zn is unable to elicit its 
apparent competitive inhibitory effect (Chapter 3) by direct competition to block 
access of the agonist to its recognition site. In addition the predicted location of the 
inhibitory site in relation to the ion channel suggests that Zn2+ is not operating as an
open channel blocker on GlyRs (Fig This is also supported by the
• 2+ observation that pre-incubation of the GlyR with inhibitory concentrations of Zn
enhances the steady-state inhibition, suggesting that Zn2+ can access its site even
when the channel is closed (Fig 3.1,4 -  D). This is in contrast to an open channel
blocker such as cyanotriphenylborate (CTB), which requires channel activation
before it can inhibit the GlyR (Handford et al., 1996). Substantial parallel agonist
dose-response curve displacements in the presence of inhibitory Zn , without a
reduction in the maximal agonist response, are consistent with this site exerting at
least some part of its inhibition in an apparent competitive mode to reduce the
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affinity of the agonist-binding site. Given the physical separation of the two sites 
this would therefore require allosteric communication between the two sites. From 
the studies in chapter 3 (Fig 3.11) the effect of Zn2+ binding is transduced from the 
H109/T133 face of the Zn2+ binding site. Therefore, to exert an effect at the 
agonist-binding site would presumably require transmission through, or around, the 
hydrophobic core of the extracellular domain, as these two sites are on opposing 
sides of the extracellular domain of the protein (Fig 4.1 A,B).
This chapter aims to investigate the consequences of disrupting potential residues 
that may reside on a route for signal transduction across the protein from the 
H109/T133 Zn2+ inhibitory site face to the agonist-binding site. This study is of 
particular interest as to date there are no studies that clearly elucidate transduction 
pathways through cys-loop ligand-gated receptors either in terms of agonist 
transduction to activate the receptor or in terms of the numerous modulator sites that 
are present in this receptor family (Laube, 2002; Lester et al., 2004). Most likely this 
is a result of the complications that arise from attempting to dissect between whether 
particular amino acids are important for binding, or transducing, or causing an 
indirect structural effect on either of these properties. However, this study has 
several factors in its favour, firstly, through appreciation of chemistry and numerous
74-crystal structures of Zn binding sites (Auld, 2001), some limitation can be placed 
on the number and the type of residues directly contributing to Zn2+ binding. 
Secondly, several studies have already provided consistent support for the 
identification of a significant portion of the inhibitory Zn2+ binding site in the form 
of two histidine residues, GlyR a l  H107 and H109 (Harvey et al., 1999;Nevin et al., 
2003;Chapter 3). Furthermore, evidence in Chapter 3 suggests that transduction is 
most likely from one side only of this site, the H109/T133 face, giving a starting 
point for investigating any transduction routes through the protein to the agonist- 
binding site. Finally the model of the GlyR based on the AChBP (Brejc et al., 2001) 
gives a structural guide to probing any route through the protein using mutagenesis. 
This can also be used to then mutate residues on either side of any transduction 
pathway to establish the specificity of an effect, thus increasing the level of 
confidence in whether it is a genuine effect on receptor function rather than an 
indirect structural perturbation.
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Figure 4.1 GlyR model, 
based on the AChBP, 
displaying the location of the 
inhibitory Zn2+ site viewed 
from the inside face of the 
receptor (A) and from above 
(B), highlighted by the small 
inset pictorials (red). Two 
neighbouring subunits from 
the pentameric GlyR are 
presented with the 
extracellular domains in green 
or yellow. Transmembrane 
domains are included (blue) 
with the pore lining M2 helix 
in pale yellow. The agonist 
binding motifs (red) and 
residues (bubble chains) are 
labelled as are the inhibitory 
Zn2+ binding site residues 
(thin chain). A black and 
white arrow marks a possible 
route by which the allosteric 
inhibitory Zn2+ site face 
may transduce its effect 
downstream to the agonist 
binding site.
T133
Y161 N102 
F159
K200
N102
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Other clues as to the genuine contribution of a residue to a transduction pathway can 
also be gleaned from what actually happens to the inhibitory process. For example in 
the case of neurosteroid modulation of GABAa p receptors, substitution of an M2 
1307 residue can reverse the polarity of a neurosteroid effect, from inhibition to 
potentiation (Morris and Amin, 2004: A similar but reverse effect is also seen for the 
Zn2+ potentiation of GlyRs, see Chapter 5). The study presented here initially 
compared substitutions of residues at each of the inhibitory Zn binding site faces to 
ascertain whether these affected receptor properties besides a simple reduction in the 
potency of Zn2+ mediated inhibition. This in turn elucidated a novel receptor 
phenotype whereby Zn2+ itself could directly activate the GlyR from the face of 
the inhibitory site and subsequently a hydrophobic transduction pathway from the 
inhibitory Zn site to the agonist-binding site was tentatively identified.
Results
Disruption of the GlyR a l face of the Zn2+ inhibition site generates a family 
of low potency Zn2+-activated GlyRs (ZAGs)
During whole cell recordings from HEK cells transiently transfected with GlyR 
a l Ti33A, a mutation that impaired Zn2+ inhibition (Chapter 3) the appearance of a 
persistent but small (less than 10 % of the Gly Imax) inward current was observed 
upon pre-incubation with a high 1 mM dose of Zn2+. This unexpected effect was not 
observed during recordings made from cells expressing either a l  wild-type, a l H107N, 
a l Hi°9F Qr untransfected cells and therefore appeared to depend on the location of 
disruption at the inhibitory Zn2+ binding site. To establish and characterise this 
property further for any possible new information this may reveal about the function 
of the inhibitory Zn2+ site, two sets of mutated a l  receptors were made representing 
residues lining the vicinity on either side of the intersubunit site, i.e. on the 
previously labelled *+’ and faces. The face, previously shown to contain 
important contributions from GlyR a l  H I09 and T133, was mutated with Ala 
substitutions individually at 5 selected locations. These included H I09 and T133, 
also E110 and T112 previously implicated to influence Zn2+ mediated inhibition 
(Laube et al., 2000) and finally an N61 residue that resides on the next ‘rung’ down 
on P-strand 2, laying directly beneath T133 (Fig 4.2A). These a l N61A, a l H109A, 
a l E110A, a l T112A and a l T133A GlyRs were first characterised for their sensitivity to
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Zn2+ mediated inhibition of glycine 50 % maximal responses. The sensitivities to 
inhibitory Zn2+ were measured by comparing the current after 4 seconds (I4) of co­
applied 50 % maximal doses of Gly plus 1000 pM Zn2+, to the current of 50 %
^ I
maximal Gly doses applied alone. A Zn pre-incubation protocol was not used as 
GlyR a l N61A, a l TU2A and a l T133A all exhibited significant inward currents during 
pre-application of Zn2+, and this may partially desensitise the GlyR causing
v y  / 1 1 q n i 1 ^  A T 1  “2 ^  A   ^  1
erroneous results. In the case of a l  , a l  and a l  , inhibition by Zn was 
completely absent even at the high 1000 pM dose tested leaving only the residual 
potentiating component of Zn2+ modulation on Gly responses apparent (Fig 4.2C). 
GlyR a l H109A and GlyR a l E110A by contrast were still significantly inhibited by 
33 ± 6 %, (n = 4) and 97 ± 1 %, (n = 3) respectively in response to a high 1000 pM 
Zn2+ dose. Furthermore, these two receptors did not display a noticeable inward 
current during pre-incubation with 1000 pM Zn and were therefore fully assessed
'ji
for their sensitivity to Zn mediated inhibition using the pre-mcubation protocol. 
This surprisingly revealed that a l H109A exhibits only a modest 2-fold increase in the 
Zn2+ IC 5 0  to 32 ± 16 pM, (n = 5, P < 0.05) compared to the wild-type a l  (15 ± 2 pM, 
n = 5) and intriguingly reduces the maximal amount by which Zn2+ can inhibit Gly 
responses to 47 ± 7 %, (n = 5) compared to 91 ± 7  %, (n = 6) for the wild-type 
receptor (Fig 4.2B). GlyR a l E110A, by contrast, harboured a slightly more significant
94-4-fold reduced sensitivity to Zn mediated inhibition (IC50 = 67 ± 4 pM, n = 3, 
P < 0.05) and did not affect the maximal amount of Zn2+ inhibition (Fig 4.25).
The persistent inward current observed during pre-incubation of GlyR a l N61A, 
a l T112A and a l T133A with 1000 pM Zn2+ was possibly due to Zn2+ acting alone as a 
GlyR agonist. In agreement with the persistent inward current observed during pre­
incubation, dose response curves for Zn2+ activation on the GlyR a l N61A, a l H109A 
and a l T133A mutants, representing the residues on the aligned rungs of the ladder at 
the interface, revealed in each case, a significant but low, millimolar potency for 
Zn2+ activation. This resulted in EC50 values of > 10 mM, for GlyR a l N61A and 
aihio9a 2 respectively) and 5.4 ± 2.5 mM, (n = 5) for a l T133A
(Fig 4.3A, C). Though it was not possible to obtain maximal currents for these dose 
response curves due to the requirement for higher doses of Zn2+, the curves were
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sufficient to estimate that the Imax for Zn2+ as a percentage of Gly Imax (i.e. relative 
efficacy) was greater than 30 % for GlyR a l N61A and a l H109A and greater than 40 % 
for a l T133A (Fig 4.3A,C). This apparent action of Zn2+ as an agonist was termed 
‘Zn2+-Activated Glycine receptor’ (ZAG) activity in accordance with a cys-loop
• "74- • •ligand-gated receptor previously identified as Zn -activated channel (ZAC) activity, 
though this receptor lacked activation by a battery of agonists tested including Gly 
(Davies et al., 2003). In comparison, Ala substitution of the nearby El 10 residue, 
which faces away from the site of Zn2+ coordination, yielded a GlyR a l E110A with no 
discemable ZAG activity up to 30 mM Zn2+ (n = 3). However, GlyR a l T112A 
produced a high sensitivity ZAG with EC50 = 3.5 ± 1.5 pM and a relative efficacy of 
42 ± 5 % (n = 4; Fig 4.3A,C). As a control, a wild-type GlyR revealed no noticeable 
ZAG activity at Zn2+ concentrations up to 30 mM, (n = 3). The Zn2+ current traces 
for all four of the ZAG mutants identified revealed that the Zn2+ activated current 
was relatively slow, whether applied at maximal or submaximal doses, reaching a 
steady-state between 3 and 15 seconds compared to onset times of less than 2 s for a 
submaximal EC50 dose of Gly (Fig 4.3C). Current-voltage (IV) data accrued for each 
mutant using 50 % maximal responses to Zn2+ revealed a typical linear relationship 
with membrane voltage in keeping with that for Gly currents recorded from wild- 
type a l  GlyR (Fig 4.3B). Due to the small currents and extremely high 
concentrations of Zn2+ required for activation of a l H109A an IV plot was not obtained. 
In addition the reversal potentials for Zn2+ activated currents from a l N61A, a l T112A 
and a l T133A GlyRs was close to zero (range -4  mV to 7 mV, n = 3), comparable to 
the predicted reversal potential for Cf of around 0 mV. The data was in accordance 
with the Zn activated current eliciting its effect via the GlyR Cl' channel. 
Furthermore, though the receptors were clearly perturbed in a manner consistent with 
a disruption to the transduction apparatus of the Zn2+ inhibitory site, the agonist 
activities of the receptor, via the glycine binding site, did not appear to be overtly 
influenced with Gly EC50S remaining within 4-fold of wild-type values and maximal 
Gly currents not differing significantly (Table 4.1).
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Figure 4.2 Alanine substitutions at the Zn2+ binding site face disrupt GlyR 
a l Zn2+ mediated inhibition. A , Structural homology model of GlyR a l  
highlighting potential residues of interest in the face of the inhibitory Zn2+ 
site, boxed orange. The orange P-strands represent the three ‘ladder rungs’ upon 
which residues were selected. B, Zn2^  dose response curves constructed using a 
pre-incubation protocol to measure modulation of 50 % maximal Gly-evoked 
responses. This was carried out for GlyR a l H109A and a l E110A both of which 
were significantly inhibited by 1000 pM Zn2+. Both receptors revealed a reduced 
sensitivity to Zn2+ mediated inhibition compared to wild-type GlyR a l (dashed 
line) but while a l E110A suffered a 5-fold reduced sensitivity to Zn2+, a l H109A 
instead exhibited a reduced maximal level of inhibition. C, Current amplitude 
measurements at the 4-second time point (I4) during co-application of 1000 pM 
Zn2+ with a Gly concentration corresponding to 50 % of the maximal Gly 
response (as a percentage of a Gly concentration causing a 50 % maximal 
response in the absence of Zn2+). This demonstrates that Zn2+ mediated 
inhibition is completely abolished at this high concentration of Zn2+ for a l N61A, 
a l  ~ and a l  . Due to the discrete Zn2+ potentiation site these receptors 
retain potentiation at this concentration. Asterisks represent a significant 
difference from the wild-type receptor (P < 0.05). N=  3-6.
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Figure  4.3 Disruption of the Zn2+ inhibitory site *-* face produces receptors that 
are sensitive to activation by Zn2+ acting as an agonist. A, Zn2+ dose response
r  /-m t> 1 N 6 IA 1 H I09A .  T112A , .  T133A . „  , . rcurves for GlyR a l , a l  , a l  and a l  plotted as the percentage of 
a maximal response to glycine applied to the same cells. B, IV plots and the 
reversal potentials of EC50 Zn2+ activated currents for a l N6lA, a l Tll2A, a l Tl33A and 
EC50 Gly activated currents for a wild-type a l  GlyR. Due to the small currents 
and extremely high concentrations of Zn2+ required for activation of a l Hl09A an IV 
plot was not obtained. C, Typical currents recorded upon Zn2+ activation (black 
traces) of GlyR a l N6lA, a l Hl 9A, a l Tll2A and a l Tl33A. The time-scale matched 
doses are applied in pM (red bars). Comparative 50 % maximal glycine induced 
responses are displayed in blue revealing a faster activation profile than the Zn2+ 
activated currents. The doses applied are in mM (red). Scale bars represent 1 s 
and 1 nA respectively. N  = 3 -  6.
'.30000
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Disruption of the GlyR a l ‘+‘ face of the Zn2+ inhibition site does not induce 
ZAG activity
9_i
To further assess this unusual Zn sensitive property from the perspective of the 
residues surrounding the proposed inhibitory Zn2+ binding site, the three residues 
residing on the opposing ‘+* face of the site were examined. These were again 
selected from each p-sheet ‘rung of the ladder’ and evaluated for ZAG activity upon 
Ala substitution to generate GlyR a l R59A, a l H107A and a l T135A (Fig AAA). Initial 
assessment of each mutation for any influence on the potency of Zn2+ mediated 
inhibition at the receptor using a pre-incubation protocol revealed, in agreement with 
previous studies (Harvey et al., 1999;Nevin et al., 2003), that a l H107A induces an 
approximate 15-fold increase in the IC50 of Zn2+ inhibition from a wild-type value of 
15 ± 2 pM, (n = 5) to 330 ± 30 pM, (n = 3; Fig AAB). In contrast a l 115^  failed to 
reduce the potency of inhibitory Zn2+ with an IC50 value of 5.2 ± 0.7 pM, (n = 3) and 
a l T135A was previously shown (Chapter 3) not to significantly affect Zn2+ inhibition, 
(IC50 = 26 ± 6 pM, n = 3). In addition to this, attempts to elicit ZAG activity from 
these three receptors and also from an a l H107N receptor, all failed to elicit a 
noticeable current at up to 30 mM Zn2+ (n = 3; Fig A AC). Thus H107A seems to 
represent the sole contribution from the *+* face of the inhibitory site and influences 
Zn2+ inhibition in a manner consistent with a role in Zn2+ binding, in support of the 
original asymmetry of function for the two faces proposed for this site (see Chapter
3).
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F igure  4.4 Alanine substitutions at the *+’ Zn + binding site face disrupt GlyR 
a l Zn2+ mediated inhibition only at a l  HI07. A, Structural homology model of 
GlyR a l highlighting potential residues of interest in the ‘+* face of the inhibitory
^ I ^
Zn site, boxed orange. The orange p-strands represent the three ‘ladder rungs’ 
upon which residues were selected. B, Zn2+ dose response curves using a pre­
incubation protocol to measure the modulation of 50 % maximal Gly-evoked 
responses. Of the three residues, R59, H107 and T135, tested, only GlyR a l H107A 
exhibited a reduced sensitivity to Zn2^  mediated inhibition with no shift in the 
maximal level of inhibition. GlyR a l RM)A revealed a modest 2-fold increase in the 
potency of Zn2+ mediated inhibition. C, Typical currents recorded upon maximal 
activation (blue - 500pM) demonstrating that there is no Zn2+ activated response 
for *+' face Ala substitutions when 30 mM Zn2+ was applied (red traces). N  = 3. 
Note that GlyR a l wild-type (dashed line) and a l T133A (small squares) traces were 
taken from Fig 3.2D and 3.107). Scale bars represent time of 0.5 s and current 
amplitude of 1 nA.
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A putative hydrophobic transduction pathway between the Zn2+ inhibition and 
agonist-binding sites
• • 94* • •So far, these data support the supposition that the face of the inhibitory Zn site is 
responsible for mediating the downstream effect of Zn2+ inhibition and sufficient 
disruption of this face causes Zn2+ binding to stabilise the open state of the receptor
94-creating a ZAG. In the wild-type receptor, Zn seems to act allostencally to reduce 
agonist potency suggesting there must be a mechanism by which the agonist binding 
and the inhibitory Zn2+ sites interact. Closer inspection of the GlyR structural model 
does not suggest any obvious route by which this communication could occur as the 
agonist binding site and the inhibitory face are almost diametrically apposed 
(Fig 4AAJ$). This communication may perhaps derive from an electrostatic 
displacement passed around the polar amino acids on the outskirts of the receptor 
protein, or via a conformational reorganisation directly through the hydrophobic core 
of the protein. Previously Unwin et al, (1995) have suggested the ligand-binding 
a  subunit of the homologous nAChR does undergo a conformational rearrangement 
upon agonist binding, which is communicated throughout the extracellular domain 
and so a hydrophobic communication between the two sides of the receptor may 
represent the most likely routing.
To address this issue, residues representing the most direct route (by eye) across the 
hydrophobic core were mutated to alanine residues. The rationale for this was that if 
large hydrophobic groups are required to push against each other and induce 
conformational change along a pathway through the centre of the protein, then at the 
point of Ala insertion, which is much smaller, there will be no side moiety to induce 
steric pressure and the communication may break down. This presumably would 
lead to a reduction in the efficacy of the transduction pathway, which would be 
manifest by a reduction in Zn2+ inhibition, assuming there were no indirect 
perturbations to the inhibitory site to affect its affinity. Initially eight hydrophobic 
residues were selected reflecting their prime locations to drive signal transduction 
from the agonist binding site to the Zn2+ inhibitory face; L98, F99, F I00, F I08, 
1132, L134, L156 and F207 (Fig 4.5A,B). Amino acids L98, F99 and F100 on strand 
p4, LI 56 on p7 and F207 on piO, are spread across P-strands on the agonist-binding 
side of the transduction pathway (nomenclature of Brejc et al., 2001). F I08 on P5
121
and the P6’ LI34 and 1136 are present on P-strands alongside the Zn2+ inhibitory site 
face (Fig 4.5A,B). These residues can be tentatively ascribed to three domains 
with 1132 present directly on the back of the inhibitory site face. FI 00, FI 08 and 
LI 34 are present in the hypothetical linker region in the pathway between the two 
protein domains, as are L98 and LI 56, though these residues are slightly to the side 
(Fig A.5A,B). All these residues from each side of the meeting point between the two 
domains have their hydrophobic faces opposing each other. Finally, F99 and F207 
face directly into the agonist binding site and may reflect the initiation point of any 
allosteric communication that is to be transmitted across the protein to or from the 
inhibitory site face.
Disruption of the hydrophobic pathway generates spontaneously open GlyRs 
that are dependent on background Zn2+ and protons
The initial proviso was to investigate these residues with the intention of determining 
potential changes in the maximal inhibition by Zn , used as an indicator of the 
efficacy of the inhibitory process. However initial attempts to record from some of 
these mutant receptors expressed in HEK cells revealed the presence of significant 
background leak currents in the absence of any agonist, which in the most extreme 
cases, declined rapidly over a 5 -  10 minute recording period making it very difficult 
to measure dose response curves for modulators. These persistent background 
inward currents could be blocked by the application of the GlyR open channel 
blocker cyanotriphenylborate (CTB; 20 pM) and were therefore initially proposed to 
be spontaneous openings of the mutant receptors. The extent of spontaneous opening 
was 0.5 ± 0.1 nA (7.4 %) for odL98A, 1.4 nA ± 0.2 nA (51 %) for a l F99\  
0.3 ± 0.1 nA (7.2 %) for a l F108A and 0.7 ± 0.1 nA (12.4 %) for a l LI34A where values 
represent the CTB blockable current (Ic t b) as a percentage of Ictb plus the maximal 
Gly response (lay), (« = 4 -  10; Fig 4.6A). Thus^,percentages reflect the size of the 
leak current as a percentage of the maximal activatable GlyR current. All other 
mutated receptors exhibited a leak current of less than 2 % in the presence of CTB 
(data not shown; n = 4 - 5). Also a wild-type GlyR a l  exhibited only a 0.4 ± 0.1 % 
(n = 4) reduction in leak current following CTB application, suggesting a negligible 
level of spontaneous opening, in accord with single glycine channel studies (Beato et 
al., 2002;Beato et al., 2004). Although these mutant receptors appeared to have
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spontaneously open phenotypes, in view of the ZAG channels observed earlier, these 
receptors were also tested for activation by contaminating background Zn2+ in the 
Krebs, which may be responsible for the observed receptor opening. Incubation of 
transfected HEK cells with 2.5 mM of the low affinity Zn2+ chelator tricine caused a 
significant reduction in the basal leak current of all four mutants a l L98A, a l F99A, 
a l F108A and a l L134A (Fig 4.6/1) accounting for between 60 and 80 % of the total leak 
as measured by using CTB. Studies on a l L98A and a l F99A, where the leak current 
was now small enough (< 0.5 nA) in the presence of tricine such that it did not 
rundown, showed that the remaining leak could be further attenuated by applying a 
more potent Zn2+ chelator, TPEN, presumably by chelating any remaining free Zn2+ 
(Fig 4.6A). This TPEN solution was applied on the tricine background but did not 
actually contain tricine. Using previously published Kd values of 10'5 for tricine and 
10'15 6 for TPEN (Paoletti et al., 1997) and assuming the initial contaminating Zn2+ 
concentration in the saline solution was 0.2 pM (Wilkins and Smart, 2002) produced
 ^ I
final predicted free contaminating Zn concentrations of 5.42 nM in 2.5 mM tricine, 
reduced to 0.1 atomolar in 100 pM TPEN. Given the extremely low concentration of 
free Zn in TPEN it is unlikely that the remaining leak current can be attributed to 
Zn2+. This residual leak in TPEN was therefore most likely due to activation of these 
receptors by protons. This assumed that the Zn2+ activation was being mediated by 
the original Zn2+ inhibitory site, H I09, which is also an important residue for the 
proton mediated inhibition of GlyRs (Chen et al., 2004) and so protons may now also 
be activating this new set of receptors. This was supported by the fact that applying 
TPEN at pH 8.4, an increase of 1 pH unit and a 10-fold decrease in the basal 
concentration of protons, from 39.8 nM to 3.98 nM, further reduced the residual leak 
current compared to that with TPEN at pH 7.4. TPEN at pH 8.4 induced an outward 
current (reduction in leak current) of 2.0 ± 0.8 % of the total GlyR current (measured 
as the Gly Imax + the leak current inhibited by CTB, Ic t b) for a l L98A and 3.7 ± 0.6 % 
for a l F99A (n = 4 - 5; Fig 4.6B). Furthermore, application of TPEN at pH 6.4 on a 
background of TPEN at the normal pH 7.4 evoked a proton-induced current of
5.3 ± 0.7 %, (n = 5) and 7.0 ± 0.6 %, (n = 4) for a l L98A and a l F99A respectively (Fig 
4.6B). This increased to 10.3 ± 1.7 %, (n -  4), for a l F99A at pH 6.0 whereas Gly a l  
wild-type receptors evoked an inward current of just 0.2 ±0.1 %, (n = 4). These 
measurements were from proton induced currents at steady-state 4 s time points as
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HEK cells are known to possess an endogenous rapidly inactivating proton induced
sle
current, which dropped to 0.2 ±0.1 %, (n = 4) for wild-type GlyR transfected HEK 
cells in this time (Fig 4.6B). As 100 pM TPEN was predicted to reduce the Zn2+ 
concentration to at least 10 atomolar across the pH range 6 -  8.4 it is unlikely that the 
induced currents responses at variable pH values were due to changes in the 
efficiency with which TPEN chelates Zn2+.(* Gunthorpe et al., 2001)
F igure  4.5 Mapping a 
hydrophobic pathway 
through the GlyR N- 
terminus. Close-up GlyR 
structural models showing 
a potential hydrophobic 
transduction pathway from 
the *-* face of the 
inhibitory Zn2+ site to the 
agonist binding site. A , 
View from the inside face 
and B, view from the 
outside face (see grey 
pictorials; Zn2+ site -  
orange triangle, agonist 
site -  red square, white 
arrow shows the direction 
from which the subunit is 
being viewed, black arrow 
shows the predicted 
communication pathway). 
The *-* inhibition site is 
represented by orange (3- 
strands and an orange box 
where the candidate 
binding residues are 
presented (not shown here 
for clarity but see Fig 
4.2/1). The agonist 
binding motifs are 
presented in red. 
Seven hydrophobic
residues are shown as a 
route between the two 
domains with residues
regarded to be at the end of the path in green and residues that are in the centre of 
the path shown in blue and grey. Note that some extraneous structure on the outside 
face is cut away from B, for ease of viewing.
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Figure 4.6 Zn2+ and H+ basal leak currents in mutated GlyRs. Experiments to 
remove leak currents from hydrophobic mutated a l L98A, a l F99A, a l F108A and
LI 34A • • 2+a l receptors were carried out using Zn chelators and external pH 
modulation. A, Leak currents were measured in terms of the background current 
ablated by cyanotriphenylborate (CTB) a GlyR open channel blocker (white bars). 
This was measured as a percentage of the total current, which is equal to the 
amount of CTB leak (Ictb) plus the maximal glycine response (Ioiy)- 2.5 mM 
tricine (black bars), a Zn2+ chelator, significantly (*; P < 0.05) reduced the leak by 
50 -  80 % (Itricin</IcTB+Iieak as a percentage) and 100 pM of a higher affinity Zn2+ 
chelator TPEN (shaded bars) caused a further reduction. B, Lowering external pH 
(pH 6.0 (black) and 6.4 (white)) in the presence of TPEN elicited stable currents in
L98A F99Aa l  and a l  GlyRs but not in wild-type a l. Removal of protons (pH 8.4 -  
shaded) decreased the leak on a TPEN background. C, Typical currents induced 
by increasing and reducing pH, measurements were made after 4 s (I4) to 
inactivate the endogenous H+ receptors of HEK cells (see a l  trace). Scale bars 
represent time of 1 s and current amplitude of 100 pA. N=  3 -8 .
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Disruption of the hydrophobic pathway ablates Zn2+ mediated inhibition
In the cases where there was a significant leak current, subsequent recordings to 
investigate the sensitivity of these receptors to Zn2+ mediated inhibition were carried 
out in a 2.5 mM tricine background to avoid rundown. Additionally, due to the 
apparent ZAG activity, 1000 pM Zn2+ was co-applied with Gly and the I4 value was 
measured instead of using a pre-incubation protocol. Of the eight hydrophobic 
residues tested six of them, a l L98A, a l F99A, a l F100A, a l F108A, a l I132A and a l L134A 
ablated sensitivity to Zn mediated inhibition up to 1 mM Zn co-applied with 
glycine concentrations causing a 50 % maximal response. This supports the 
supposition that the inhibitory site has been converted to a high sensitivity ZAG 
mediating site responsible for background leak currents (Fig 4.7A). Of the remaining 
two residues, a l F207A was non-functional {n = 5) and a l L156A did not exhibit a 
significantly shifted IC 50  for Zn2+, 23 ± 6  pM, (n = 3; Fig 4.1 B). Furthermore 
a l L156A did not demonstrate any obvious Zn2+ mediated leak current, nor any ZAG 
activity in response to high 30 mM concentrations of Zn2+ suggesting this residue 
and strand p7 are not involved in the Zn transduction pathway (data not shown, 
n = 3).
Disruption of the hydrophobic pathway generates a family of high sensitivity 
ZAG receptors
1
To assess and correlate the sensitivities of these residues to Zn the side chain 
moieties were split into two groups. One group comprised residues closest to each of 
the binding sites, F99 for the agonist binding site and 1132 for the inhibitory Zn2+ 
binding site. The second group included residues that are present at the critical 
bridging region between the two sites, L98 and FI00 from the agonist-binding side, 
and F108, L134 from the inhibitory Zn2+ binding face (Fig 4.5A,B). Due to the 
high sensitivities of these receptors to Zn2+ these GlyRs were characterised for the
2“F • •potency of Zn acting as an agonist alone on a 2.5 mM tricine background to reduce 
the amount of free Zn2+ and control exactly the level of free Zn2+. Though TPEN 
could remove background Zn2+ more effectively, its high affinity for Zn2+ meant that 
it was unsuitable for regulating the Zn2+ concentration across the range required for a 
dose response curve. Furthermore, although there will be some small contamination 
from background proton activation, it was deemed more appropriate to carry out
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these experiments out at physiological pH, and with the exception of a l F99A, the 
contribution from background protons was small, < 3 %. Dose response curves for 
glycine revealed that these receptors retained a sensitivity within 4-fold of the wild- 
type glycine E C 5 0  and did not exhibit significantly different Gly Imax values with the 
exception of a l F99A, which exhibited an 8-fold increase in E C 5 0  from 35 ± 3 pM, 
(n = 6) to 250 ± 40, (« = 4) and a two-fold reduction in Imax from 6.8 ± 0.5 nA, 
(n = 6) to 3.8 ± 0.4 nA, (n = 10; Table 4.1). This is not unexpected as the F99 moiety 
faces directly onto the predicted agonist-binding site (Fig 4.5AJB) and in addition this 
mutant had the largest leak currents suggesting that a portion of the a l F99A 
population may already be in a desensitised state which could account for a reduction 
in the maximal currents attainable. By comparison to the original face binding 
site mutations, the mutated a l F99A GlyR exhibited a far higher sensitivity to Zn2+ 
activation with an E C 5 0  of 0.13 ± 0.03 pM, (n = 5) and a higher relative efficacy of 
91 ± 6 %, (n = 5) (Fig 4.8A,C). GlyR a l I132A exhibited a lower potency for Zn2+ 
perhaps because it is backed onto the inhibitory face and could indirectly distort 
the site, however, the relative efficacy was still high at 72 ± 5 %, (n = 5; Fig 4.8A,C). 
In a similar manner to the face inhibitory ZAG receptors, the 50 % maximal Zn2+ 
activated currents of a l F99A and a l I132A also had slower onsets than that elicited by 
an E C 5 0  dose of Gly (Fig 4.8C). Current-voltage (IV) relationships again revealed a 
comparable linear voltage dependence to that previously shown for Gly on wild-type 
a l  receptors and the reversal potential was close to zero consistent with the ZAG 
current being mediated by chloride flux through the GlyR (Fig 4.8B). Analysis of 
the residues representing the bridging region between the two sites revealed that 
these mutated receptors also all exhibited high sensitivities to Zn2+ as an agonist with 
EC50s of 0.26 ± 0.078 pM, (n = 4) for a l L98A, 9.19 ± 0.63 pM, (n = 4) for a l F100A,
2.3 ± 0.6 uM, (n = 6) for a l F108 and 0.1 ± 0.03 pM, (n = 4) for a l L134A (Fig 4.9A). In 
contrast though, the relative efficacy values compared to Gly for these receptors were 
generally lower at 49 ± 5 %, (n -  4) for GlyR a l L98A, 7.4 ± 3.8 %, (n = 4) for
a l F100A, 25 ± 6 %, (n = 6) for a l F108A and 18 ± 3 %, (n = 4) for a l L134A (Fig 4.9,4).
* 2+  • •Again the rates of Zn activation for the steady-state macroscopic currents were
slower compared to Gly activation, and the Zn2+ IV plots were comparable to those
for Gly obtained for wild-type GlyR a l  (Fig 4.9B,C).
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Figure 4.7 Ablation of Zn2+ inhibition by substitution of hydrophobic residues 
in the GlyR. Alanine substitutions of hydrophobic residues lining the transduction 
pathway between the Zn2+ inhibitory site face and the agonist binding domain
74*ablate GlyR a l  Zn mediated inhibition. A , Measurements at the 4-second time
2+point (I4) during co-application of 1000 pM Zn with a Gly concentration 
corresponding to 50 % of the maximal Gly response (as a percentage of a Gly 
concentration causing a 50 % maximal response in the absence of Zn2+). 
Inhibition is completely abolished at this high concentration of Zn2+ for six
I . J  u  j  - J  L98A . F99A ^ lO O A  . F108A ,1 1 3 2 a  ,hydrophobic mutated residues tested: a l  , a l  , a l  , a l  , a l  and
L134A 2+a l  . Due to the absence of Zn mediated inhibition these receptors invoke 
currents in the presence of 1000 pM Zn2+ greater than 100 % possibly due to the 
remaining presence of Zn2+ potentiation. * Asterisks represent a significant 
difference from the wild-type receptor (P < 0.05). B, Zn2+ dose response curve 
using a pre-incubation protocol to measure modulation of 50 % maximal Gly 
evoked responses for the single GlyR a l L156A, which did not exhibit ablated Zn2+ 
mediated inhibition. N = 4 - 6 .  The GlyR a l  wild-type (dashed line) trace was 
taken from Fig 3.2D. Bar chart values represent mean ± s.e.
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Figure 4.8 High relative efficacy ZAGs. Alanine substitutions for 
hydrophobic residues marking each end of the transduction pathway between the 
Zn2+ inhibitory site face and the agonist binding domain produces receptors 
with high relative efficacies that are sensitive to direct activation by Zn2+. A, 
Zn2+ dose response curves for GlyR a l F99A and a l I132A plotted as the percentage 
of the maximal response to glycine applied to the same cells. B, Current-voltage 
(IV) relationships and the reversal potential of EC50 Zn2+ activated currents for
F99A I132Aa l  and a l  . These IVs are comparable with the Gly IV plot from a wild- 
type GlyR a l  (dashed blue line). C, Typical currents recorded upon Zn2+ 
activation (black) of GlyR a l F99A and a  l 11 2A. The time-scale matched doses 
applied are in pM (red bars -  this represents the longest application required as 
the low doses took longer to reach steady-state). 50 % maximal Gly evoked 
responses are also included (blue) as a comparison and reveal a faster onset rate 
than the response matched Zn2+ currents. Scale bars represent 1 s and 1 nA. 
N=  4 - 5 .
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Figure 4.9 High sensitivity, low relative efficacy ZAGs. Alanine 
substitutions for hydrophobic residues in the bridging region between the Zn2+ 
inhibitory site face and the agonist binding domain produce receptors 
sensitive to activation by Zn2+ with low relative efficacies. A, Zn2+ dose
r  / - M r *  1 L98A , F100A ^ lO S A  , .L 1 3 4 A  , „  ,response curves for GlyR a l  , a l  , a l  and a l  plotted as the
percentage of the maximal response to Glycine applied to the same cells. B , 
Current-voltage (IV) relationships and the reversal potential of EC50 Zn2+
/> F99A H32Aactivated currents for a l  and a l  . These IVs are comparable with the
EC50 Gly IV plot from a wild-type GlyR a l  (dashed blue line). C, Typical 
currents recorded upon Zn2+ activation (black) of GlyR a l L98A, a l Fl00A, a l  l08A 
and a l Il32A. The time-scale matched doses applied are in pM (red bars -  this 
represents the longest application required as the some doses took longer to 
reach steady-state). 50 % maximal Gly evoked responses are also included 
(blue) as a comparison and reveal a faster onset rate than the Zn2+ activated 
currents. Scale bars represent 1 s and 1 nA. N=  3 - 6 .
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ZAG receptors require binding components of the Zn2+ inhibitory site
The concomitant observations that a l L98A, a l F99A, a l F100A, a l F108A, a l I132A and 
a i  li34a receptors aj-g activated by protons and that the inhibitory Zn2+ site no longer 
functions, suggests that this ZAG activity is derived from the original inhibitory Zn2+ 
binding site. However, it also appears that there are at least two different types of 
ZAG site present; a high affinity site that appears in response to the hydrophobic 
core disruptions and a low potency site that occurs upon disruption of the 
inhibitory binding face. The low potency ZAG site formed from the inhibitory 
face disruptions can be explained by the fact that these receptor mutants 
potentially suffer disruption to the Zn2+ coordinating partners in the ZAG reducing 
the affinity of the site. In the case of the high affinity sites though the potencies for 
Zn2+ are as low as 0.1 pM compared to the potency for Zn2+ inhibition at wild-type 
receptors of approximately 20 pM, suggesting this site may have changed chemically 
to produce a higher affinity for Zn2+. To test this hypothesis two mutated receptors, 
a  1 Ti33A to represent the low potency ZAGs and a l F99A to represent the high potency 
ZAGs, were compared for their dependence on residues forming the original 
inhibitory Zn2+ binding site, namely HI07, H I09 and T133.
GlyR a l T133A, which had a low sensitivity to Zn2+, possibly due to the loss of T133 
as a coordinating partner, lost almost all ZAG activity when an extra H107A, or 
H109F (which unlike HI 09A had no ZAG activity of its own; data not shown, n = 3) 
were incorporated, with 30 mM Zn evoking currents, as a percentage of the Gly 
W , of only 1.8 ± 2.2 %, (n = 3) for a l T133A’ H107A and 1.4 ± 0.2 %, (« = 3) for 
a jTi33A, H109F ^ 0 A ) .  gy contrast, introduction of substitutions at HI 07 or H I09
on the a l T133A receptor only slightly affected Gly potency (Fig 4.1 OR, Table 4.1). As
 ^ I
a further test of the criticality of H I07 for Zn coordination and induction of ZAG 
activity this residue was also mutated to an alternative Zn2+ binding moiety, Asp. 
The a l T133A’ H107D receptor retained a similar Gly potency to a l T133A, but the Zn2+ 
potency was still significantly reduced almost to the extent of a l T133A,H107A 
suggesting that the exact nature of the residue at position 107 is critical, though 
whether this requirement is structural, chemical,or both,is unclear (Fig 4.10A,B).
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Figure 4.10 Shared Zn2+ 
binding components between 
Zn2+ inhibition and low 
potency ZAGs. The low 
potency Ala substituted ZAG 
receptors formed by 
disruption at the face of the 
inhibitory site still require the 
Zn binding residues of the 
inhibitory site for direct Zn2+ 
activation. A , Zn2+ dose 
response curves plotted as the 
percentage of a maximal 
response to Glycine applied to 
the same cell. For GlyR 
a l T133A based mutants, the 
introduction of extra 
disruptions to the putative 
Zn2+ binding residues, H I07 
and HI 09, introduces 
substantial reductions in the 
potency of Zn2+. (The a l Tl33A 
Zn2+ dose response curve is 
taken from Figure 4.3 A). 
B, Gly dose response curves 
for GlyR a l T133A based 
mutants showing 
introduction of
that 
extra
disruptions to the putative 
Zn2+ binding residues, H I07 
and H I09, introduces only 
modest shifts in Gly potency. 
N= 3 -5 .
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For a l  , mutation of the inhibitory Zn site residue, H I09 caused a significant 
10-fold reduction in the Gly potency but more substantially, virtual ablation of ZAG 
activity, such that a 1 mM Zn induced a current of only 2.4 ± 2.8 %, (n = 5) for 
a l F99A, H109F Qf the Qly (Fig 4 ^  Intriguingly, a l F99A’ H107A and a l F99A’
T133A, induced similar 10-fold reductions in Gly potency, but they only exerted 
modest 3 to 5-fold decreases in the sensitivity to Zn2+ activation with Zn2+ EC50 
values increasing from 0.13 ± 0.3 pM, (n = 5) for a l F99A to 0.4 ± 0.1, (n = 5) for
a l F99A, H107K ^  t( )  Q J $  ±  Q  ^  ^  =  ^  f o r  a l F99A, T133A 4  U B y  ^  k e e p i n g  w i t h
the consistent reductions in ZAG sensitivity of these mutated receptors the level of
*y I
spontaneous Zn dependent leak was also reduced, evident from the block induced 
by both CTB and tricine (Fig 4.11C). This suggests these two residues do not have 
the same degree of importance as H I09 for the high potency ZAG site. Further 
studies to attempt to elucidate alternative Zn coordinating partners for the high 
potency ZAG site did not reveal any obvious candidates. The nearby residues 
selected were a l F99A’ D97A, a l F99A’ E103A, a l F99A’ D114A and a l F99A’ E157A from the 
‘+* face and a l F99A’ E110A and a l F99A’ T112A from the face, all of which failed to 
reduce the potency of Zn2+ at an a l F99A based ZAG (Fig 4.124^5). An a l F99A,D57A 
receptor was also tested but this proved non-functional (n = 5).
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Figure 4.11 Dependence of 
high nM sensitivity ZAG 
receptors on Zn2+ binding
residues of the original
2+inhibitory site for direct Zn 
activation. A , Gly dose response
FQQAcurves for GlyR a l  based 
mutants showing that 
introduction of extra disruptions 
to the putative Zn2+ binding 
residues, H107, H109 and T133, 
introduces a consistent ten-fold 
reduction in the sensitivity to 
glycine. B, Zn2+ dose response 
curves plotted as the percentage 
of a maximal response to 
glycine applied to the same cell.
FQQAFor GlyR a l  based mutants, 
the introduction of extra 
mutations to the Zn2+ binding
residues, HI 07 and T133,
introduces a comparable
reduction in sensitivity to the 
agonist Zn2+. However, 
introduction of an H109F
mutation introduces a near 
complete ablation of ZAG 
activity. (The a l F99A Zn2+ dose 
response curve is taken from 
Figure 4.&4). C, In keeping with 
the lower Zn2+ sensitivity of 
these a l F99A receptors the leak 
current measured as a 
percentage of the total current, 
(Ictb plus the maximal Gly 
response (Iciy)) is significantly 
reduced (*; P < 0.05, white 
bars) and could be further 
reduced by 2.5 mM tricine 
(black bars). N = 4 -  5.
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Figure 4.12 Acidic residues residing in the vicinity of the inhibitory Zn2+ site 
do not mediate Zn2+ binding for the high Zn2+ potency ZAG receptors. The ZAG 
sensitivity was analysed on the high sensitivity ZAG a l F)9A background in terms 
of the size of the leak currents (A) and the % maximal current evoked by a 
submaximal 0.3 pM dose of Zn2+ (B). A, Leak currents measured as a percentage 
of the total current, Iqjq plus the maximal Gly response (Ioiy) were not 
significantly reduced in any of the six potential Zn2+ coordinators tested when 
measured as the CTB blockable current (white bars) or the 2.5 mM tricine reduced 
current (black bars). B, In keeping with this, the percentage current induced by 
0.3 pM Zn2+ (shaded red bars) was also not significantly reduced compared to theF99Aa l background when recorded as a percentage of the maximal Gly evoked 
response or, in cases where Gly was not the most efficacious agonist (black bars),
2“Fas a percentage of the Zn 1 ^  (red bars) in the same cell. N = 3 - 4 .
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The formation of high sensitivity ZAG receptors is specific to residues of the 
hydrophobic transduction apparatus
• 94-From the group of residues tested for their ability to compromise Zn mediated 
inhibition all but one, a l L156A, resulted in formation of a ZAG. Therefore to 
demonstrate that this ZAG transduction pathway was in fact specific to these 
residues, several other hydrophobic amino acids in the surrounding region were also
94-mutated to Ala and tested for an influence on Zn mediated inhibition. GlyR 
aim 154A g.om ^  p7  strand as well as GlyR a l I130A and GlyR a l L136A were selected 
as the closest hydrophobic residues surrounding the hydrophobic bridging section. 
Also, and a l A101L and a l N102A, immediately adjacent to the DLFF motif, were also 
tested. These mutations failed to induce any ZAG activity with 30 mM Zn2+ (n = 3). 
Furthermore these mutated GlyRs all exhibited biphasic dose response curves for
  7 1 VII A   *> I
Zn modulation (a l not tested) when Zn was pre-applied and then co-applied 
with a 50 % maximal dose of Gly and the IC50 values were all within 2-fold of that 
for the GlyR a l  wild-type (Fig 4.13^4,5).
Both low and high sensitivity ZAG receptors exhibit a slower rate of 
macroscopic current activation
The evidence so far provides strong support for the presence of a hydrophobic 
transduction pathway stretching across the extracellular domain from the inhibitory
94-Zn binding site to the glycine recognition site. In the wild-type receptor this 
pathway presumably mediates the effect of Zn2+inhibition on the agonist-binding 
site. Howevei^ from the data presented so far it is not obvious what function this 
pathway performs upon the actual binding of agonist and subsequent activation of 
the receptor. The Gly EC50S, and Imax values for both the low and high potency 
ZAGs do not show any obvious patterns of disruption relative to the wild-type 
receptor (Table 4.1). It could be that this pathway exists simply to mediate a 
modulatory effect from Zn2+ during physiological processes. However it is also 
possible that this conformational transition from one side of the extracellular domain 
to the other also fulfils some other purpose in terms of receptor function. To address 
this issue the shapes of the macroscopic traces were analysed to measure any effects 
on the extent of glycine induced desensitisation, which inhibitory Zn2+ has been 
shown to influence in the NMD A receptor (Zheng et al., 2001), and also to measure
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the activation rates of the receptors. In a comparable manner to the effects on 
glycine potencies, the desensitisation studies did not reveal any obvious disruption to 
this process in the ZAG receptor mutants with the wild-type receptor desensitising by 
45 ± 2 %, (n = 7) during a 10 s supramaximal 10 mM glycine application 
(Fig 4.14,4,5). Only GlyR a l L98A, a l T133A and a l L134A displayed modest increments 
in the extent of desensitisation with Igiy reducing to 36 ± 3 %, (n = 3), 44 ± 3 %, 
(n = 7) and 41 ± 2 %, (n = 3) of the peak current, respectively under the same 
conditions (P < 0.05; Fig 4.144,5).
In contrast to the extent of desensitisation, when a single exponential was fit to the 
upper phase of 50 % maximal Gly currents, a significant increase in the time constant 
to reach steady-state was measured for all high and low potency ZAGs with the 
exception of GlyR a l F99A (P < 0.05; Fig 4.15A,B). This increase in the time constant 
to reach steady-state peaked for the hydrophobic residues located in the bridging 
region with a l F100A, a l F108A and a l L134A having time constants of 250 ± 30 ms, 
(n = 8), 220 ± 30 ms, (n = 11) and 210 ± 60 ms, (n = 5) respectively, compared to 
GlyR a l  wild-type of 100 ± 10 ms, (n = 7). For the low potency ZAGs, the time 
constants were even slower with a l T133A exhibiting the slowest time constant of 
450 ± 80 ms, (n = 6). To demonstrate that this effect on receptor macroscopic rates 
of activation was specific to the ZAG mutants, four other nearby non-ZAG 
mutations, the hydrophobic a l I130A, a l L136A and a l L156A mutants and the ‘+* face 
mutation a l 115^  were tested. All failed to induce any change in the rate of activation 
values (Fig 4.15,4,5). It should be noted that these estimations of activation rates 
were carried out using doses of Gly giving 50 % maximal responses in 0.25 mM 
tricine to remove contaminating background Zn2+, which is sufficient to activate 
many of these receptors to a certain degree with a slower onset rate, potentially 
interfering with the rates of onset presented here. However a l F99A the most sensitive 
and efficacious ZAG did not exhibit slower onset rates suggesting this possibility of 
Zn interference was unlikely.
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Figure 4.13 Demonstration of the specificity of the hydrophobic transduction 
path from the inhibitory Zn2^  site face to the Gly binding site. A , View from 
the outside face (see grey pictorial; Zn2+ site -  orange triangle, agonist site -  red 
square, black arrow shows the viewing angle, white arrow - predicted transduction 
pathway) showing the green and blue hydrophobic residues previously 
demonstrated to mark a pathway between the inhibition site (orange p-strands 
and orange box) and the agonist binding motifs (red). Residues labelled in pink 
are hydrophobic residues that lie just outside the predicted path of the transduction 
domain. Some extraneous structure is cut away for ease of viewing. B, Zn dose 
response curves using a pre-incubation protocol for the modulation of 50 % 
maximal Gly evoked responses demonstrates that Ala substitution of these 
residues failed to reduce the sensitivity to Zn2+ mediated inhibition when 
compared to the wild-type a l  GlyR. N=  3.
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Figure 4.14 Variations in the extent of macroscopic desensitisation do not show 
any obvious correlation with mutations that induce the formation of ZAGs. 
A, Mean values for the extent of desensitisation of macroscopic currents measured 
in terms of the current amplitude after 10 seconds of supramaximal 10 mM Gly 
application (Iio) as a percentage of the peak amplitude of the same current (Ipeak)* 
Mutated GlyRs were compared to the wild-type a l receptor (black bar) and were 
separated into categories as follows; mutated receptors that did not form ZAGs - 
white bars; low potency ZAGs formed through disruption of the inhibitory Zn2+ 
binding site face -  orange shaded bars; high relative efficacy ZAGs -  green shaded 
bars; and high potency, low relative efficacy ZAGs -  blue shaded bars. Asterisks 
depict mutated receptors, which reached a significantly different extent of 
desensitisation compared to the wild-type a l  receptor (P < 0.05). B, Typical 
currents showing the extent of desensitisation during 10 s applications of a 
supramaximal 10 mM dose of Gly. Scale bars represent 1 s and 1 nA. N  = 3 - 7 .
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Figure 4.15 Rate of glycine current activation measured in terms of the time 
taken to reach steady-state, is correlated with mutations that generate ZAGs.
A, Mean values for the rate of onset measured by fitting a monoexponential curve fit 
from the current onset to the time taken to reach steady-state of 50 % maximal Gly 
evoked responses. The wild-type a l  receptor (black bar) was compared to non- 
ZAG mutated receptors (white bars) and ZAG receptors with; low Zn2+ potency 
formed by disruption of the inhibitory Zn2+ binding site face (orange bars); high 
relative efficacy (green bars); and high potency, low relative efficacy (blue bars). 
Asterisks depict a significant increase in the time constant (a decrease in the 
activation rate) compared to that for the wild-type a l  receptor (P < 0.05).
B, Typical 50 % maximal Gly evoked currents highlighting (dashed box) the region 
over which the monoexponential curve fit was determined (faint blue overlay over 
the black trace). Scale bars represent 1 s and 1 nA. The currents presented here are 
timescale matched for ease of comparison. N  = 3 -1 1 .
140
Discussion
The data presented here describe the identification of a hydrophobic pathway, 
predicted from a structural model, to travel through the hydrophobic core of the 
protein from the inhibitory Zn2+ site face across to the agonist binding domain. In 
addition these data also support the previous hypothesis from Chapter 3 that 
transduction from the inhibitory Zn2+ site occurs initially through the H109/T133 
face of the Zn2+ binding site.
Evidence favouring an asymmetric function of the Zn2+ inhibition site
Mutagenesis studies introducing Ala substitutions to amino acids predicted to reside 
on the three rungs of the (3-sheet ladder at the *+* face of the inhibitory site revealed 
that a l H107A attenuated the sensitivity to inhibitory Zn2+. In keeping with a pure 
binding role for this residue, Zn2+ potency at the Ala mutated receptor was reduced 
without any evidence for the generation of a ZAG. Two other mutated receptors 
a l 115^  and a l T135A that reside on the *+’ face failed to induce any effect on Zn2+ 
mediated inhibition demonstrating that the *+’ face donates only H I07 to the 
inhibitory Zn2+ site, and this occurs in a manner consistent with an involvement in 
Zn2+ binding. By contrast, Ala substitution of residues predicted to reside at the
9 -1-face yielded receptors with unexpected phenotypes in response to Zn , 
suggestive of an important transduction role for this side of the site. Of these amino 
acids, only disruption to an El 10 residue produced an a l E110A receptor phenotype in 
keeping with a possible pure binding role for this amino acid as the mutant exhibited 
a modest 5-fold decreased sensitivity to inhibitory Zn2+ without affecting the
9 -4-maximal limit of Zn mediated inhibition. According to the model this residue is 
predicted to face away from the Zn2+ binding site precluding a direct role in Zn2+ 
binding, however this model is not capable of predicting the exact side chain position 
based on such a low primary sequence homology (approximately 20 %) and 
therefore in the real protein structure it may be that binding at El 10 can be 
accommodated, or that an El 10A substitution simply introduces an indirect structural 
perturbation. The other four mutated receptors, a l N61A, a l H109A, a l T112A and a l T133A 
all yielded either an attenuated maximal level of inhibition by Zn2+, as was the case 
for a l H109A, or ablated Zn2+ mediated inhibition. Furthermore, these receptors were 
now susceptible to direct activation by Zn2+ acting as an agonist, with relative
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efficacies, compared to glycine, of between 20 and 50 %. Consistent with Zn2+ 
acting as an agonist, receptor activation was concentration dependent, in a voltage- 
independent manner relying on transmembrane chlonde flux, indicating Zn was 
eliciting anionic flow via the GlyR chloride channel.
A simple hypothesis to explain ZAG formation
If Zn2+, by binding to the inhibitory site, is causing channel activation in the mutated 
receptors, it suggests that ZAG activity involves a reorganisation of the ‘-‘ face of the 
inhibitory site, altering the transduction machinery of the receptor such that Zn now 
activates rather than inhibits the receptor. Though it is not possible from these 
studies to understand exactly how such an apparently substantial phenotypic 
conversion could have occurred, the most likely explanation is potentially quite 
simple. Previous evidence (Nevin et al., 2003, Chapter 3) supports the supposition 
that Zn exerts its inhibitory effect by forming a ‘bridge’ between two adjacent 
a  subunits, stabilising a closed conformation of the receptor. Therefore, in order to 
switch this site to elicit activation, all that is needed is a disruption to the face 
such that the bridging residues, primarily H109/T133 of the face and HI 07 of the
'j,
*+’ face, are now better aligned for Zn coordination when the receptor is activated,
rather than when it is closed. This will have the resultant effect that application of
2+
Zn to the receptor can induce activation by drawing the two faces together through 
coordination and subsequently, in principle, the receptor may activate. This 
reorganisation might not necessarily even require a substantial disruption of the
face as it is dependent on the size of the movement that would normally occur at 
this location during activation. As was previously discussed (Chapter 3) under the 
hypothesis that the nAChR a  subunit (and therefore quite probably the GlyR 
a  subunit also) undergoes a twist during activation (Unwin, 1995), we would expect 
the H109/T133 region to move relative to the *+’ H107 residue on the 
neighbouring subunit (Unwin et al., 2002) such that Zn2+ can no longer bind. So 
then, disruption to move the ‘-‘face out of alignment could be sufficient to induce the 
ZAG phenotype. Though it is speculative, based on the relatively non-specific 
structural data currently available for GlyRs and their movements during activation, 
a schematic model displaying the basic tenets of such a process and the relative
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simplicity by which it might arise in the context of what is expected for cys-loop 
receptors is presented in Fig 4.16A,B.
A. Wild-type B. ZAG
Fig 4.16 Schematic model presenting a simple mechanism for ZAG 
formation. A, Wild-type GlyR a l  can bind inhibitory Zn2+ (blue circle) to 
stabilise the closed state but not when the receptor activates (bottom). 
B, Disruption of the *-* face of the inhibitory Zn2+ site prevents Zn2+ binding in 
the closed state (top) but enables Zn2+ binding in the activated conformation 
(bottom) creating a ZAG receptor.
The data discussed here do, of course, assume that the Zn2+ site eliciting activation is 
in fact derived from the original Zn2+ inhibition site. This does seem to be the case 
as for all the ZAG receptors generated, Zn2+ mediated inhibition is ablated 
suggesting this functionality has been replaced by the ZAG property. Furthermore, 
mutation of either of the principal histidine Zn2+ binding residues, HI 07 or H I09, to 
non-Zn2+ binding groups on a ZAG a l T133A background, removed the ZAG activity 
suggesting this novel phenotype is still derived from the original H107/H109 based 
inhibitory site. Given these observations the Zn2+ potencies measured for the face 
disrupted ZAGs reveals information about the nature of the residues in terms of their 
function at the inhibitory Zn2+ site. Both a l N61A, a l H109A and a l T133A all formed
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very low potency ZAGs, suggesting the site had been disrupted such that the affinity
T1 1 O A   'Siwas also reduced. However, at a l  , Zn had a much higher potency for causing 
activation with an EC50 of similar magnitude to the original IC50 for Zn mediated 
inhibition, yet its relative efficacy was similar to that for Zn2+ on a l T133A. Though 
this means T112 can clearly affect the transduction from the site it may not be 
affecting the potency and therefore is unlikely to have a role in binding, which 
concurs with its predicted location facing away from the inhibitory site (Nevin et al., 
2003;Chapter 3). One potentially confusing issue remaining is the fact that a l H109A 
which forms a very low potency ZAG also retains sensitivity to Zn2+ mediated 
inhibition although with a decreased maximal inhibition. This most likely reflects a 
situation where disruption to the face of the site is more subtle and this allows 
Zn2+ to compete for two conformations of the site, one which stabilises the closed 
state and one which stabilises the open state.
Evidence supporting the hydrophobic pathway as a transduction pathway
n 1
The evidence so far supports an asymmetric role for the inhibitory Zn site with the 
face mediating the initial downstream transduction process. This hypothesis is 
further strengthened here by the identification of an apparent hydrophobic 
transduction pathway leading selectively from this face of the inhibitory site 
across to the agonist binding site. Though it is not always possible from mutagenesis 
studies alone to ascribe the exact function of amino acids within the context of a 
binding-transduction role there are several factors elucidated here that support the 
assertion that this hydrophobic pathway could be a genuine transduction pathway. 
First and foremost is the availability of a structural model for the GlyR, which shows 
strong agreement with the hydrophobic residues identified here lining up to form a 
path between the agonist binding site and the inhibitory Zn2+ face. This structural 
evidence is also supported by a previous study investigating the putative p4-strand in 
the homologous GABAa receptor P-subunit. The use of a cysteine accessibility 
reagent revealed access to residues in this domain were consistent with them 
adopting a p-strand structure and also showed that the GABAa receptor p subunit 
residue equivalent to GlyR F99 was predicted to face into the agonist binding site. 
This means that GlyR L98 and FI00 are predicted to face into the receptor 
hydrophobic core (Boileau et al., 2002). Secondly, the consistent phenotypic
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exchange upon distortion of the transduction pathway to create ZAGs is supportive 
of a transduction role since if these residues are part of a chain, as is predicted here, 
then disruption to any one residue within the linear chain should elicit the same 
phenotype. In addition to this, the substitutions introduced do not simply ablate site 
function, which would then preclude the dissection of whether the corresponding 
residues are important for transduction, binding or are causing an indirect structural 
perturbation. Instead, these phenotypic disruptions still retained a high potency for 
inhibitory Zn2+ suggesting that though the residues clearly influence the potency of 
the site they also clearly influence signal transduction from the site. As these 
residues are predicted to reside in the hydrophobic core of the receptor and are not 
considered likely Zn binding residues, it seems reasonable to ascribe to them a pure 
transduction role. The only ZAG to have a low Zn2+ potency was I132A, which was 
located directly on the back of the face inhibitory site. It is the best located of 
those hydrophobic residues to elicit a secondary indirect effect on the structure of the 
Zn2+ binding site to reduce the Zn2+ affinity and therefore the potency. In further 
support of the hydrophobic chain hypothesis was the demonstration that generation 
of these ZAGs was not a general side effect of disrupting the GlyR global structure. 
It was instead selective to the hydrophobic residues in question, as was verified by 
the absence of any ZAG phenotype when nearby hydrophobic residues, lying just off 
the hypothetical pathway, were similarly substituted with an Ala moiety.
Reliance of Zn2+ binding residues at the high and low potency ZAGs and the 
original Zn2+ inhibition site
As mentioned previously this transduction pathway also relies on the tenet that ZAG 
activity is still derived at least in part from the original Zn2+ inhibitory site and again 
this does appear to be the case. Each of the hydrophobic Ala substitutions ablated 
the previous Zn2+ mediated inhibition and replaced it with ZAG activity rather than 
creating a receptor with both properties as has been observed previously for a 
mutated nAChR (Palma et al., 1998). Secondly, and most critically, the 
incorporation of an H109F mutation into GlyR a l F99A ablated the ZAG activity 
demonstrating that this activity still has a critical reliance on the face HI 09 
inhibitory site residue. Interestingly the potency of Zn2+ activating the channel is 
high, reaching nanomolar sensitivity compared to the original micromolar sensitivity
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for Zn2+ inhibition. The incorporation of H107K and T133A mutations into the
a l F99A background introduced a far more modest reduction in Zn2+ potency for ZAG
• • 2+activation compared to the substantially reduced sensitivity to Zn mediated 
inhibition that is induced by removing these residues. However it cannot be ruled 
out that these residues do have critical requirements for the high potency ZAG
7 • • • •receptors but upon substitution another Zn coordinating residue can step in to take
their place, a point that has been raised previously (Traynelis et al., 1998) and which
2+could not be discounted here. Though a scan of additional capable Zn binding 
moieties within range of the putative ZAG site did not reveal any obvious candidates 
for the high sensitivity a l F99A based ZAG. This relatively modest influence from 
substitutions at H I07 and T133 on an a l F99A background was perhaps not surprising 
as reorganisation of the inhibitory site face, so that it now favours activation, 
would be expected to at least induce a partial shift in the emphasis placed on each of 
the binding residues. This, however, does not appear to be the case for the low 
potency ZAGs generated upon disruption to the inhibitory site face as a l T133A
74-retained a heavy reliance on both H I07 and H I09. Thus the Zn binding residues of 
the high and low potency ZAGs appear to differ in nature, though they do both 
require H I09.
Consequences for the hydrophobic transduction pathway in determining 
macroscopic rates of receptor activation
Under the assumption that reorganisation of the hydrophobic pathway, elucidated 
here, does indeed represent a valid transduction pathway between the agonist-binding 
site and the face of the GlyR, then this process may represent more than just a 
mechanism for allosteric modulation in response to Zn2+ mediated inhibition. 
Though this study investigated this pathway in the context of Zn2+ induced allostery, 
basic characterisation of mutated receptor properties suggested that this transduction 
process may be able to exert an effect over the rate of activation for the GlyR. In 
contrast there was no obvious correlations with the varying agonist potencies and 
modest effects on desensitisation measured from these Ala substituted receptors. 
This important influence over the rate of receptor activation could have important 
physiological consequences as it has been suggested that the slower macroscopic 
activation of the GlyR a2 subunit may reduce its efficiency as a rapid inhibitory
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mediator at synapses (Mangin et al., 2003). Though the molecular basis of this 
slower rate of activation at the GlyR a2 subunit has not yet been dissected the 
pathway identified here could represent one way in which this GlyR subtype may 
alter its activation rate. This may also extend more generally to the variable 
activation rates observed throughout the cys-loop family of receptors.
The significance of related studies on ZAC formation
Unfortunately the data depicted here and the hypotheses put forward do not have 
much previous evidence, or prior studies to draw on. Investigations tend to steer clear 
of perturbations to the hydrophobic core due to problems with interpreting the 
specificity of any downstream consequences, something that could be addressed here 
due to the fortuitous ZAG effect. A low potency Zn2+ activated channel (ZAC) has 
previously been reported (Davies et al., 2003) and further structure-function studies 
of this receptor may reveal a resemblance to the low potency ZAGs identified here, 
as this ZAC has a comparable low sensitivity and also retained a slow onset profile 
for Zn2+ induced currents. Though the site itself will not bear direct chemical 
comparison to that of the mutated GlyRs in this study, the ZAC does possess acidic 
residues at equivalent predicted locations to GlyR HI07, El 10 and T133 suggesting 
the site may be analogous (alignment not shown). Also of interest is a previous 
report identifying an M2 nAChR a l U47T mutant that exhibited a very high 
nanomolar sensitivity for Zn2+ activation (Palma et al., 1998). However subsequent 
structure-function studies to elucidate the nature of this phenomenon have not been 
forthcoming. Furthermore such studies may be of limited relevance to the ZAG 
receptors discussed here as this mutation appeared to create a novel Zn2+ binding site 
rather than changing the function of a pre-existing site, as Zn2+ mediated inhibition 
was also retained in this receptor.
The rate of progress: As measured by the NMD A receptor
The data presented in this study represent a significant contribution to understanding 
Zn2+ modulation of GlyRs. As a comparison, the most intensely studied Zn2+ 
mediated process at a ligand-gated ion channel is that of Zn2+ inhibition of the 
NMDA receptor. This receptor exists as heteromers of NR1 and NR2 subunits, with 
inclusion of the NR2B subunit introducing a low affinity site, with sensitivity around
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10 - 100 pM, and inclusion of the NR2A subunit providing a high affinity Zn2+ 
inhibitory site, with sensitivity in the range 10 -  100 nM (Paoletti et al., 1997). 
Though the low affinity inhibitory site remains unreported the location of the high 
potency site has been the subject of several studies (Choi and Lipton, 
1999;Fayyazuddin et al., 2000;Paoletti et al., 2000). Candidate residues, as well as 
their positions, have been identified using site directed mutagenesis and a structural 
homology model in a similar manner to that reported here for the GlyR. Though 
these studies have not yet proposed any molecular basis for the transduction
 ^ I
apparatus responsible for mediating the effects of the inhibitory Zn binding site. 
Also, this unrelated receptor (to the GlyR) has not been reported to exhibit any ZAC 
properties despite extensive mutagenesis of potential Zn2+ binding site residues (Choi 
and Lipton, 1999;Fayyazuddin et al., 2000;Paoletti et al., 2000). This could perhaps 
be a consequence of the fact that the identified voltage-independent high affinity
94-Zn binding site of the NMDA-R is believed to act by reducing the ability of the 
receptor to gate rather than by reducing agonist binding (Christine and Choi, 
1990;Legendre and Westbrook, 1990). In the case of the Zn2+ inhibitory process 
reported here for the GlyR, it appears the communication is an intrinsic process 
specific to a single globular domain of the receptor and this reduces the affinity of 
the protein for the agonist glycine. However in the case of the NMDA-R each 
subunit is split into several separate modular domains, of which the so called 
leucine/isoleucine/valine-binding protein (LIVBP) domain, that carries the identified 
high affinity voltage-independent site, is predicted to feed its transduction effect 
across to the gating and agonist binding modules to disrupt the communication 
between these two, a process which, if true, is vastly different to the unrelated GlyR 
(Paoletti et al., 2000). Previous studies have not attempted to discern whether Zn2+ 
inhibition elicits an effect on desensitisation in the GlyR and the studies in chapter 3, 
though demonstrating that Zn2+ can accelerate the rate of decay during co­
application, which might be construed as an effect on desensitisation, are insufficient 
to support such a proposition. Most evidence supports an interaction of 
desensitisation with the GlyR ion channel domain (Breitinger et al., 2002;Breitinger 
et al., 2001) while Zn2+ inhibition appears to interact with the agonist-binding site 
(Chapters 3 and 4). By contrast, recent studies on the NMDA receptor suggest the 
main mechanism by which the high affinity Zn2+ inhibition site acts is by introducing
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a very rapid desensitisation component into glutamate activation of NMD A receptors 
(Zheng et al., 2001). The two receptors are clearly separate in terms of how Zn 
exerts inhibition, both in molecular and mechanistic terms, but the ability to now 
draw such comparisons demonstrates the progress that has now been made in these 
two fields of research.
Conclusion
The data here present a strong case for the presence of a hydrophobic transduction 
pathway across the N-terminus of the GlyR from the face of the Zn inhibition 
site to the p4 strand of the agonist-binding domain. Though the extent of the 
relevance of this communication route cannot be exactly pinpointed in the context of 
this work, the evidence strongly suggests that this path at the very least marks the
94-route of allosteric communication between the inhibitory Zn site and the agonist- 
binding site. Under this hypothesis agonist binding transmits a reorganisation to the
94-face of the GlyR at the location equivalent to the Zn inhibitory site via the
94*hydrophobic pathway such that Zn can no longer bind and stabilise the closed state 
of the GlyR. From the reverse perspective, Zn2+ binding presumably stabilises the 
interface between the and *+’ faces of the GlyR preventing the agonist from 
binding and inducing reorganisation of the hydrophobic pathway to allow the 
receptor to open. Furthermore, due to a consistent reduction in the activation rates of 
the resultant ZAG receptors, this pathway may represent an important regulatory 
process by which cys-loop receptors can determine their intrinsic activation rates.
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EC50 (pM)
Glycine
W n A ) ft
" z ? *
EC50 (pM)
Agonist
Imax
(% Gly Imax)
n IC5o(hM)
Inhibition
U (% ) n
Zn2+ face 
al 35 ±3 6.7 ± 0.5 6 No Activation 4 15 ± 2 9 ± 7 5
a lN61A 95 ± 18 6.2 ± 0.8 4 > 10 mM > 25 % 5 None — 4
a lH109A 21 ± 2 5.9 ±0.7 4 > 10 mM > 20 % 3 33 ± 16 53 ± 7 5
a lEll0A 24 ± 4 6.0 ± 1.5 3 — No Activation 3 67 ± 4 4 ±  1 3
a lT112A 19 ± 6 5.0 ±0.6 4 3.5 ±  1.5 42 ±5 4 None ___ 4
a lT133A 133 ±32 5.4 ±  0.7 5 5400 ±  2500 >  45 % 5 None ___ 4
a jT133A,H107A 100 ±28 4.9 ±0.3 3 >  10 mM > 2 % 3 n.e n.e n.e
a jT133A,H107D 53 ± 15 4.4 ± 0.7 3 > 10 mM > 12  % 3 n.e n.e n.e
a jT133A,H109F 180 ±28 5.7 ±0.8 3 > 10 mM > 2 % 3 n.e n.e n.e
Zn2+ ‘+‘ face 
a lM9A 52 ±5 7.3 ±0.7 3 No Activation 3 5.2 ±0.7 3 ± 3 3
a lH107A 56 ± 9 7.2 ± 0.3 3 ___ No Activation 3 330 ± 30 12 ± 3 3
a lT135A 17 ± 2 3.3 ± 0.6 3 --- No Activation 3 26 ± 6 5.8 ± 0 3
Hydrophobic pathway
a lL98A 35 ± 6 6.4 ± 0.5 6 0.26 ± 0.08 49 ± 5 4 None 4
a lF99A 250 ± 8 3.9 ± 0.4 4 0.13 ±0.03 90 ± 6 5 None — 4
a jF99A,H107K 4200 ± 1700 3.5 ±0.6 5 0.4 ±0.1 53 ± 12 5 n.e n.e n.e
a |F99A,H109F 3400 ± 330 0.5 ± 0.2 5 n.e > 2 5 n.e n.e n.e
a jF99A,Tl33A 3300 ± 700 4.9 ± 0.9 4 0.75 ± 0.22 65 ± 4 4 n.e n.e n.e
a l F100A 117 ±21 4.5 ±0.7 6 9.19 ±0.63 7 ± 4 4 None — 4
a l FI08A 14 ±3 4.5 ±0.5 5 2.3 ± 0.6 25 ± 6 6 None — 5
a lI132A 96 ± 15 6.1 ±0.7 6 140 ± 60 72 ±5 5 None — 4
a l L,34A 83 ± 17 6.0 ± 0.3 7 0.1 ±0.03 18 ± 3 4 None — 4
Table 4.1 Summary table presenting sensitivities for the agonist Gly and where appropriate for Zn2+ acting as 
an agonist or antagonist of glycinergic currents. Values presented as means ± s.e. Definitions: n.e -  not evaluated,
‘—’ could not be evaluated as property is not present, none -  property not present.
ECso(pM)
Glycine
Imax (nA) n
Zn
ICso(pM)
Inhibition
Imin ( % ) n
Non ZAG receptors 
al 35 ± 3 6.7 ± 0.5 6 15 ± 2 9 ± 7 5
alA,01L 43 0 ± 113 6.5 ±0.8 3 18 ± 5 0.3 ± 0.3 3
alI,30A 3.4 ± 0.9 6.4 ± 0.7 4 38 ± 6 3 ±0.9 3
alL136A 16 ±0.6 6.8 ± 0.8 3 22 ± 4 4 ± 0 3
a jM I54A 99 ± 14 4.4 ± 1.4 3 27 ± 6 1.8 ±0.8 3
alL156A 105 ± 2 6.7 ± 0.7 3 23 ± 6 0.1 ±0.1 3
Table 4.2 Summary table presenting sensitivities for the agonist Gly and the 
antagonist Zn acting on GlyRs without the ZAG phenotype. Values presented as 
means ± s.e.
Chapter 5
Identification of a Zn2+ potentiation site in GlyRs and a mechanism 
of action involving the cys-loop gating domain
Introduction
The cys-loop family of receptors, most notably comprising nAChRs, GABAaRs,
GlyRs and 5 -HT3RS are all susceptible to Zn2+ mediated inhibition with varying
*
degrees of sensitivity and selectivity (Hsiao et al., 2001;Hubbard and Lummis,
2000;Chang et al., 1995;Smart et al., 2004). In some instances these receptors have
• 2+  •also been shown to exhibit a more complicated biphasic modulation by Zn , with 
enhancement of agonist responses occurring at low Zn2+ concentrations and a 
secondary inhibitory phase initiating at higher doses, as is the case for GlyRs, 
5 -HT3RS and certain nAChR subtypes (Bloomenthal et al., 1994;Hubbard and 
Lummis, 2000;Hsiao et al., 2001). Current research regarding inhibitory Zn2+ sites 
has identified discrete locations on both GABAa (Hosie et al., 2003) and GlyRs 
(Harvey et al., 1999;Chapter 3), but there have been no clear candidate sites 
elucidated for Zn potentiation. An understanding of the molecular components and 
the dynamic interactions that occur during potentiation by Zn2+ is of importance for 
two reasons. Firstly, understanding the mechanism of Zn2+ potentiation at cys-loop 
receptors provides insight into how drugs can exert a positive influence on receptor 
function and this may be relevant to a number of other pharmacologically relevant 
potentiators including anaesthetics, barbiturates, benzodiazepines, ethanol and 
neurosteroids. Secondly, in cases where Zn2+ potentiation has been reported, this 
process occurs with higher potency than Zn2+ mediated inhibition and therefore may 
be of more relevance physiologically, where the concentrations of Zn2+ at a synapse 
are currently considered to reside in the range, 0.01 -  5 pM (Frederickson et al., 
2000). (* Gill et al., 1995).
A previous study by Laube et al, (1995) identified a GlyR a l  D80 residue, which as 
well as being capable of binding Zn2+ also produced a receptor insensitive to Zn2+ 
enhancement of glycine-evoked responses when substituted with an Ala residue. 
However, a subsequent study by Lynch et al, (1998) demonstrated that GlyR a l D80A
ablated potentiation only of glycine mediated currents and not those elicited by 
taurine, another agonist of the GlyR that is also thought to bind to the glycine 
recognition site (Schmieden et al., 1993). This suggests either there is more than one 
Zn2+ enhancement site for each agonist, a seemingly unlikely proposition given that
94 -both agonists bind to the same receptor region and Zn has the same potency for 
causing potentiation of both agonist-activated currents, or that D80A is having a 
complicated action on the Zn2+ potentiation site in a manner unrelated to the direct 
coordination of the cation. The study by Lynch et al, (1998) also identified a number 
of other residues all within the extracellular TM2-3 loop that attenuate Zn2+ induced 
enhancement when substituted with alanine; however the chemical nature of these
94-residues is not consistent with Zn coordination. Studies of other positive 
modulators of cys-loop receptors locate the GABAa potentiating benzodiazepines in 
the N-terminal extracellular domain (Sigel and Buhr, 1997), whilst anaesthetics and 
ethanol have been suggested to interact with the cys-loop receptor transmembrane 
domains (Mihic et al., 1997). Thus from current studies there are no definitive 
candidate regions to begin a search for a discrete Zn2+ potentiating site in the GlyR.
This study took advantage of an observation in chapter three that GlyR a l  and a2 
appear to have subtly different sensitivities to Zn2+ potentiation of glycine-evoked 
responses (Fig 3.1 A-C). An initial comparative scan of the GlyR a l  and a2 
N-terminal domains was therefore made and substitutions to swap potential Zn2+ 
binding residues between the two receptor subtypes identified a candidate Zn2+ 
binding residue responsible for this differential sensitivity. This study used this 
information in combination with the AChBP structural model to characterise a 
discrete site for Zn2+ potentiation. Furthermore, it also identified an important 
regulatory element, which appeared to control the ability of this site to influence 
receptor function and attempt to explain how the site may exert a modulatory role on 
receptor efficacy via the cys-loop gating domain.
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Results
GlyR a l and a2 exhibit distinct sensitivities to Zn2+ mediated potentiation
The sensitivity of the GlyR a l  and a2 subtypes to Zn2+ mediated potentiation of 
50 % maximal Gly responses was compared using whole-cell recordings from HEK 
cells. To accurately maintain low concentrations of Zn the buffering agent tricine
9 -4-was used to remove interference from Zn contamination in the external saline 
solution (Suwa et al., 2001). Consequently, in the presence of 10 mM tricine a 
significant 15-fold increase in the potentiating Zn EC50 was observed from 
13.9 ± 3.4 nM, (n = 4) for GlyR a l  to 203 ± 68 nM, (n = 5) for GlyR a2 (P < 0.05; 
Fig 5.1 A,C). This distinct difference was not affected by co-expression with the 
GlyR ancillary P-subunit (Fig 5.15), whose faithful incorporation to form ap 
heteromers was ratified as before, by an approximate 20-fold shift in picrotoxin
9 1
sensitivity (data not shown; Pribilla et al., 1992). The Hill slopes for Zn mediated 
potentiation varied between 1.2 and 1.5 suggesting more than one Zn2+ ion 
coordinates to each receptor oligomer. To identify the determinant(s) responsible for
• 2“P • • •differential Zn sensitivity the extracellular domain was scanned for residues that 
differed between GlyR a l  and a2 by concentrating on classical Zn2+ binding 
substituents; Cys, Asp, Glu, and His (Auld, 2001). Three locations were identified 
(Fig 5.15)) and upon individual reconstitution of the GlyR a l  variations into a2, an 
a2E2°iD substitution was found to be solely sufficient to recover a l  levels of 
sensitivity to potentiating Zn2+ (Fig 5.1A,C) with no influence observed for a2L178Q’ 
si79E , di8oq Qr a 2E187D mutated receptors (data not shown).
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Figure 5.1 Zn2+ potentiation of 50 % maximal Gly responses for GlyR a l  and a2 
in 10 mM tricine from whole-cell recordings in HEK cells. A, GlyR a2 recovers a l  
levels of sensitivity to potentiating Zn2+ when reconstituted with the homologous 
residue to a l  D194, to generate a2E201D. B, GlyR al(3 and a2p heteromers retain 
differential Zn2+ potencies for potentiation. C, Raw data traces of 50 % maximal 
glycine responses in the presence and absence of 30 nM Zn2+ for GlyR a l ,  GlyR a2 
and GlyR a2E201D. D, Amino acid sequence alignment of GlyR a l  and GlyR a2 
displaying the region of the N-terminal extracellular domain that harbours 
differences in potential Zn2+ binding residues (bold, underlined). A grey box 
highlights the residue responsible for the differential sensitivity to Zn2+ mediated 
potentiation between a l  and a2. N=  4-6.  Maximal potentiation was normalised to 
140 % at the 1 - 3 pM Zn2+ measurement for ease of comparison, though the 
maximal potentiation did not differ significantly between any individual receptor 
subtype (data not shown).
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GlyR a l E l92, D194 and H215 are all essential for high sensitivity to 
potentiating Zn2+
The discovery that a residue equivalent to GlyR a l  D194, a potential Zn2+ binding 
residue, is capable of influencing the potency of Zn2+ potentiation suggests this 
moiety may be an a direct contributor to Zn2+ binding at the potentiation site. To test 
this hypothesis it is necessary to remove the Zn2+ binding power of the Glu side 
chain by mutation to, for example, an inert alanine. Unfortunately due to the 
biphasic nature of Zn2+ action at the GlyR, where Zn2+ potentiates at low doses 
(0.1-10 pM) and inhibits at doses greater then 10 pM (Bloomenthal et al., 1994; 
Chapter 3), any attempts to measure substantial reductions in the sensitivity to Zn 
enhancement will be masked by the onset of the contaminating Zn2+ mediated 
inhibition. To partially alleviate this effect, all experiments to identify the Zn 
potentiation binding site were performed using an H107N background (defined as 
Reduced Inhibition - RI) GlyR, which exhibits a dramatically attenuated sensitivity 
to inhibitory Zn2+ without overtly affecting other receptor macroscopic properties
i
(Table 5.1). However, it was not possible to completely remove the interfering Zn 
mediated inhibition component as all other candidate residues for the inhibitory site 
have significant side effects on general receptor properties (as discussed in chapters 
3 & 4). To further reduce the sensitivity to Zn2+ mediated inhibition all recordings 
were made using a co-application protocol for Gly plus Zn2+ as this favours the rapid 
onset of Zn2+ potentiation over the delayed onset of Zn2+ inhibition (Chapter 3). This 
resulted in an IC 50  for Zn2+ inhibition at RIGlyR a l  of >3000 pM. In addition, 
potentiation was measured for two agonists, glycine and taurine, as residues that are 
not part of the presumed sole potentiating Zn2+ site have been identified that knock 
out enhancement of currents activated by one agonist but not the other, presumably 
due to an indirect affect on some downstream transduction mechanism (Lynch et al.,
 ^1
1998). However, Zn potentiation of both glycine and taurine EC50 responses can 
be ablated, as demonstrated for the RI a l D194A (Fig 5.2A,B). As an apparent 
consequence of removing Zn2+ enhancement the sensitivity to competing Zn2+ 
inhibition increased from > 3000 pM to 270 ± 50 pM (n = 3; Table 5.1).
To elucidate further residues capable of interacting with the putative a l  D194 based 
binding site, alanine point mutagenesis was carried out on classical Zn2+ binding
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residues selected from motifs predicted to be structurally close to D194 in 
accordance with a GlyR structure modelled on the AChBP (See methods and Fig 
5.2C; Brejc et al., 2001). This strategy identified two further residues, E192 and 
H215 that may contribute to Zn2+ potentiation for both Gly and taurine currents. The 
mutant RIGlyR a l E192A entirely ablated Zn2+ potentiation, whilst R Ia lH215A 
dramatically reduced the potency of Zn2+ enhancement such that the Zn2+ EC50 for 
potentiation of 50 % maximal glycine responses was increased from 0.8 ± 0.2 pM, 
(n = 4) for RIGlyR a l  to 22 ± 4 pM, (n = 4) for the mutant (P < 0.05; Fig 5.2A,B). 
The results for other Ala substituted acidic residues had no effect on the potency of 
Zn2+ enhancement (Table 5.1). By removing, or reducing, Zn2+ enhancement the 
sensitivity to competing Zn2+ inhibition increased for both R IalE192A and R Ia lH215A 
(Fig 5.2A, B\ Table 5.1). All three of these RI mutants, a l E192A, a l D194A and a l H215A 
did not shift the maximal responses evoked by the agonist and only RIaD194A exerted 
a modest 3-fold shift upon the agonist EC50 (Table 5.1) suggesting these mutations 
selectively affected the Zn2+ potentiation binding site and do not exert a general 
perturbation on receptor function. Importantly, with regards to the potential of these 
residues to form the core of a Zn2+ binding site, the GlyR homology model 
(Fig 5.2C) predicts each of these residues, E l92, D194 and H215 to reside in close 
proximity to one another and to all face the same direction pointing out into solution 
from the outside face of the N-terminal extracellular domain. This is in accord with 
the site being accessible to Zn2+. To highlight the localised nature of this small 
domain to Zn potentiation, alanine mutagenesis was carried out on other residues 
facing out into solution, selecting those residues immediately to either side of the 
putative Zn2+ binding site. These RI a l K190A, a l R196A, a l R213A and a l E217A mutated 
receptors did not have any significant shifts in Gly, taurine or Zn2+ EC50S or in the 
size of maximal Zn2+ potentiation or maximal Gly currents (Table 5.1). In addition, 
co-expression of a GlyR R IalE192A with the p-subunit did not recover Zn2+ mediated 
potentiation suggesting the p-subunit is not an important contributor to Zn2+ 
enhancement (data not shown; n = 3).
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F igu re  5.2 Zn2+ dose response curves for the modulation of 50 % maximal 
responses of Gly or taurine to screen for residues important in Zn2+ potentiation. 
All experiments were performed on a reduced sensitivity to Zn2+ inhibition 
background (reduced inhibition -  RI) GlyR a l H107N. A, Gly and B, taurine both 
exhibit equally attenuated sensitivity to Zn2+ enhancement for all three candidate 
residues identified, RlGlyRalD194A, R IalE192A and R IalH215A compared to Rial. 
Insets represent typical raw data traces for the Rial background and mutants in 
the absence and presence of 10 pM Zn2+, scale bars represent 1 nA by 1 s. 
C, Amino acid motifs in the extracellular GlyR a l  domain and homologous GlyR 
a  counterparts that reside in close proximity to the identified a l D194A; based on the 
AChBP. Potential Zn2+ binding residues are in bold and underlined, whilst 
identified, important residues are highlighted in grey boxes. N = 4-8.
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Asymmetry of function at the putative Zn2+ potentiation site
To further strengthen the evidence in support of these residues as direct Zn2+ 
coordinators at a localised site it is necessary to demonstrate that this domain is
i
accessible to water, a vital requirement of any dynamic Zn binding site. To test 
this, individual Cys substitutions of a l  El 92, D194 and H215 were created to assess 
the site for accessibility to the covalent Cys modifying reagent, MTSEA. If this 
agent modifies the potentiation site, it will introduce a positive charge to the binding 
site that should attenuate Zn2+ mediated enhancement of Gly EC50 drug applications. 
Pre-application of 3 mM MTSEA for 1 minute to non-Cys mutated R ial did not 
have any observed effect on Zn2+ potentiation or Gly sensitivity (Fig 5.3A). Upon 
individual replacement of E l92, D194 or H215 with Cys, another capable Zn2+ 
coordinator, receptors were generated which exhibited similar sensitivities to Zn2+ 
potentiation (Table 5.1). Significantly though, when these receptors were pre­
incubated with 3 mM MTSEA for 1 min, Zn2+ potentiation (assessed before and after 
in the same cell) was ablated in the cases of R Ia lD194C and R Ia lH215C as would be
'y,
expected if a Cys binding Zn was occupied with a positively charged MTSEA 
substituent (Fig 5.3B,C). In the unique case of R Ia lE192C no significant effect was 
observed after chemical treatment, perhaps suggesting that this part of the site is not 
directly accessible to MTSEA (Fig 5AA). However, in contrast to the results 
obtained with the R ial background, a consistent reproducible increase in Gly 
potency was observed after MTSEA treatment on R Ia lE192c even in the total absence 
of Zn2+, with the 50 % maximal glycine response being potentiated by 45 ± 12 %, 
(n -  4; Fig 5.4R). This suggests the E l92 location is accessible to MTSEA, as it 
affects the sensitivity of the receptor to Gly, but that the glutamate side chain moiety, 
unlike D194 and H215, is probably not necessarily a direct or major contributor to 
Zn2+ coordination.
The data so far clearly demonstrate that a l  E l92, when perturbed by substitution 
with an Ala residue, exerts a strong influence on Zn mediated potentiation but 
unlike D194 and H215 it does not exhibit properties that are entirely consistent with 
direct binding to Zn via its side chain moiety. This raises the possibility that the 
effect elicited by E l92 may be in response to a perturbation of the P-strand 9
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F ig u re  5.3 Covalent
modification experiments using 
MTSEA to measure the 
accessibility of the candidate Zn2+ 
potentiation site. A-C, Zn2+ dose 
response curves for modulation of 
50 % maximal Gly responses 
were measured for the sensitivity 
to Zn2+ enhancement on R ial and 
receptors mutated to incorporate 
Cys mutations at putative Zn2+ 
binding residues. This was 
assessed before and after 
incubation of HEK cells with 
3 mM MTSEA for 1 min. 
A, RIGlyR a l  background does 
not exhibit any perturbed 
sensitivity to Zn2+ mediated 
potentiation in response to 
MTSEA treatment, whilst 
complete ablation of Zn2+ 
enhancement is observed after 
R Ia lD194C (.B) and R Ia lH215C (C) 
have been exposed to the Cys 
covalent modifying reagent. The 
insets present example raw data 
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showing EC50 Gly responses 
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160
A RIalE192S
0
■ Before MTSEA 
g  After 3 mM MTSEA (1 min)
1 f ' ’"mrp . r r t . rrr^ .............. ............................•
0.1 1 10 100 1000 
Zn2-" concentration (pM)
B R i a l R I a l E192CMTSEA 
Gly ■■ Gly
0
COCD
9>oc
-O
CDOD
<
LU
CO
1 nA
0coc
oQ.
CO
s>
s?o
LU
>>
O
V*—o
190
170
150
130
110
90
1 s
Rial RIalE192C
160 ' C
= 120
5  1  801
■ RI a1 
0 RI a 1 E192P
0.1 1 10 100 1000
F ig u re  5.4 GlyR a l  E l92 is 
unlikely to directly coordinate Zn2+ 
via the glutamate side chain. 
A, 50 % maximal Gly responses 
recorded from HEK cells reveal that
E192CR ial shows only minor
attenuation of sensitivity to Zn2+ 
enhancement in response to 
MTSEA treatment. B, Bar chart 
and raw data traces demonstrating 
that R Ia lE192c does appear to be 
modified by MTSEA treatment as 
an increase in sensitivity of the 
receptor to the agonist Gly is 
observed. C, Further evidence that-y_L
E l92 may influence Zn mediated 
inhibition in a manner independent
of its side chain moiety.
Replacement with a Pro residue, 
typically considered to introduce 
rigidity to the protein backbone is 
incapable of supporting Zn2+
coordination via its side chain. 
Zn2+ dose response curves on 50 % 
maximal Gly responses for
El 92PR ial produced a receptor that 
retained a high sensitivity to Zn2+ 
enhancement only 5-fold less 
sensitive than the R ial background 
(Table 5.1). N=  3-4.
Zn2-" concentration (pM)
161
backbone (nomenclature of Brejc et al., 2001) in this region, either because the 
backbone indirectly disrupts the nearby Zn2+ potentiation site, or because the polar 
peptide backbone is directly contributing to Zn2+ coordination at this position. To 
address this issue an R Ia lE192P GlyR was generated to replace glutamate with 
proline, an amino acid associated with introducing an increased level of rigidity to 
the peptide backbone (Chou and Fasman, 1974;Yohannan et al., 2004). This might 
therefore prevent the same apparent disruption of the peptide backbone that is 
observed for R Ia lE192A. In this unique circumstance, potentiation was not ablated 
and the receptor merely experienced a subtle, reduced potency for Zn2+ potentiation 
from 0.8 ± 0.2 pM, (n = 4) for R ial to 4.2 ± 0.8 pM, (n = 3) for R Ia lE192P (P < 0.05; 
Fig 5.4C; Table 5.2). As the proline side chain is considered to be a poor donor for 
Zn coordination this suggests that this region must retain a specific conformation at
'y,
the backbone of E l92 in order to retain Zn mediated potentiation. As a control, the
I
mutation of D194 to a Pro was found to still ablate Zn mediated potentiation, the 
expected outcome if it is indeed the side chain moiety that is contributing to Zn2+ 
coordination at this position (Table 5.2; n = 3).
Comparative influence of GlyR a l  E l92 and D194 on (3-strand 9 with H215 of 
p-strand 10
9-+-In all three point mutations where Zn potentiation is attenuated or ablated there was 
always an increased sensitivity to the competing Zn2+ inhibition. This could simply 
reflect an enhanced ability of Zn2+ to exert inhibition from the inhibitory site as 
competition, when the Zn2+ potentiating component has been removed. In this 
simple case, removal of a further residue at the Zn2+ inhibitory site should cause a 
direct rightward shift to reduce the sensitivity profile for inhibition of the R Ia lE192A, 
R Ia lD194A and R Ia lH215A mutants. In turn this may allow for more accurate 
assessment of the extent by which Zn2+ enhancement was ablated for R Ia lE192A and 
R Ia lD194A where any low sensitivity enhancement remaining is masked by the onset 
of inhibition. Introduction of an R Ia lH109F mutation, originally identified by Harvey 
et al, (1999), further reduced the sensitivity of Zn2+ mediated inhibition without
* 2 iaffecting Zn potentiation or overt disruption of other receptor properties (Fig 5.5A, 
Table 5.2). Evaluation of R Ia lH109F’ H215A did indeed generate, as predicted, a 
modest rightward shift to reduce the sensitivity profile of the inhibitory component
162
of this mutant (Fig 5.55). However for both RIctlH109F> E192A and R Ia lH109F’ D194A 
there was not the expected reduction in potency of inhibitory Zn2+, with R Ia lH109F’ 
D194A actually exhibiting evidence for a novel biphasic inhibition, suggestive of two 
separate inhibitory sites each with differing potencies (Fig 5.5C,D).
This could reflect a situation whereby the R Ia lE192A and R Ia lD194A are exerting a 
more complicated effect on the potentiation site, which has resulted in a reversal of 
the sites polarity to switch a high potency potentiation site into a novel low potency 
inhibitory site. Thus further ablating the original low potency inhibitory site based 
on H I07 and H I09 would not affect the receptors inhibitory profile as the inhibition 
now arises largely from the reversed potentiation site. To elucidate the nature of the 
actions of E l92 and D194 on Zn mediated potentiation more thoroughly, each of 
these residues was instead mutated to a non-Zn2+ binding residue with an extra 
carbon atom in the side chain, as is present on the Glu and Asp side chains, to ensure
7+this complicating side effect of apparently converting the Zn potentiation site to 
one that mediates inhibition was not specific to alanine substitution. In the case of 
R Ia lE192K, potentiation was still ablated, but consistent with the previous evidence 
suggesting this residue exerts a more complicated effect on the potentiation site not 
directly correlated with the properties of the side chain moiety, an even clearer 
biphasic inhibitory profile was now observed (Fig 5.6A, Table 5.2). This supports 
the supposition that disruption of E l92 to an Ala residue was indeed reversing the 
polarity of the potentiation site to generate two separate inhibitory Zn2+ sites, the 
novel E192K based inhibitory site and the original H107/H109 based low potency
inhibitory site. Conversely, the R Ia lD194K receptor, which also exhibited ablated
2+ 2+  Zn potentiation, revealed less of an increased sensitivity to inhibitory Zn
compared to its R Ia lD194A counterpart and did not result in a biphasic inhibitory
profile, raising the possibility that introduction of a Lys at D194 had perhaps not
reversed the polarity of the potentiation site (Fig 5.65). The modest increase in
sensitivity to Zn2+ mediated inhibition for R ia lD194K may simply reflect the removal
7 -4-of Zn enhancement therefore allowing the H107/H109 based inhibitory site to 
manifest its effect with a monophasic profile. This was validated by evaluation of an 
R Ia lH109F’ D194K receptor, which demonstrated a monophasic rightward shift to
7 -4-reduced sensitivity for inhibitory Zn (Fig 5.65) comparable to that seen for
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R Ia lH109F’ H215A (Fig 5.5B). Therefore in agreement with the MTSEA studies 
suggesting that D194 is a genuine Zn2+ coordinator at the binding site, there was no 
detectable functional side effect for an R Ia lD194K disruption on the transduction 
process, such as a polarity reversal of the potentiation site.
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E192A and a l D194A do not exhibit pure effects on Zn2+ binding 
Introduction of an H109F mutation to attenuate the
Figure 5.5 GlyR a l  
at the potentiation site.
sensitivity of the H107/H109 based Zn2+ inhibitory site results in a clear rightward 
shift of the inhibitory curves for A, R Ia lH109F and B, R Ia lH109F’H215A compared with 
R ial, demonstrating that Zn2+ inhibition at R ial and R Ia lH215A is derived from the 
H107/H109 site. C, Introduction of an H109F mutation to create R Ia lH109F’ E192A 
does not produce any further shift of the inhibitory profile suggesting Zn inhibition
E1Q2A .at R ial is no longer derived from the H107/H109 inhibitory site and that a 
novel inhibitory site is probably responsible for inhibition. D, In the case of 
R ial ’ a rightward shift of the lower phase of the inhibitory profile is 
evident creating a biphasic inhibition curve (arrow), supporting the presence of two 
inhibitory sites each with differing potencies, one derived from the H107/H109 
based site and another novel inhibitory site. Most likely, E l92A and D194A have 
reversed the ‘polarity’ of the potentiation site. The data for the non H109F based 
mutants, represented by dashed lines, are taken from Fig 5.2A. N=  4 -  8.
164
A B
<P 40
20  ^ a RI a 1 E192K 
Q -  ~ -  RI a 1 E192A
*
v ------  \
T RI a 1 H109F’D194K \
D194A ^
0.1 1 10 100 1000 0.1 1 10 100 1000 10000 
Zn2+ concentration (pM) Zn2* concentration (pM)
Figure 5.6 GlyR a l D194K exhibits properties consistent with a pure effect on 
Zn binding at the potentiation site. Zn dose response curves were evaluated for
E192Kthe modulation of 50 % maximal glycine responses. A, GlyR R ial exhibits a 
clear biphasic inhibitory profile consistent with this receptor ablating potentiation 
and generating an additional inhibitory site, most likely by reversing the polarity of
D194Kthe original potentiating site. B, GlyR R ial shows a reduced increase in 
sensitivity to Zn2+ mediated inhibition compared to its D194A counterpart (dashed 
line, from Fig 5.2A) but still ablates the Zn2+ potentiation of glycine responses. 
Furthermore, introduction of H109F to disrupt the original H107/H109 inhibitory 
site decreases the sensitivity of this receptor to inhibitory Zn2+. This suggests Zn2+
D194Kmediated inhibition in the R ial receptor is derived from the H107/H109 site, 
thus D194K has not reversed the polarity of the potentiation site and may not be 
interfering with transduction from the Zn2+ site but rather is having an effect on 
binding at the potentiation site. N=  3 - 6 .
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GlyR a l T151 is a critical control element for Zn2+ potentiation
A previously generated chimera, (Laube et al., 1995) where part of the GlyR a l  
subunit was replaced by the ancillary p receptor, including a section of the cys-loop 
region investigated here, was reported to ablate Zn2+ potentiation. The two Asp 
residues, D141 and D148 of the Cys loop, mutated in this report, did not exert a 
selective effect on Zn potentiation with D141A having no discemable affect and 
D148A ablating receptor function, consistent with a previous report (Schofield et al., 
2003;Table 5.1). One potential unexplored candidate residue is T151, which is 
chemically capable of interacting with Zn through its hydroxyl group, and is also 
replaced by an Arg in the p-subunit. An alanine substitution was therefore 
introduced at a l  T151 to generate an R ia l1151A GlyR. Subsequent examination of
-ji
the Zn enhancement of 50 % maximal Gly and taurine evoked responses revealed 
no detectable potentiation by Zn2+ (Fig 5.1 A J$). Intriguingly, although the lack of 
potentiation was clear, there was also an unusual additional effect revealed in the 
form of a novel biphasic sensitivity to Zn2+ inhibition, with high (IC50 1.6 ± 0.6 pM, 
n = 5) and low potency components (IC50 1040 ± 290 pM, n = 5; Table 5.3). This 
biphasic profile was directly comparable for taurine (IC50 = 3.2 ± 0.8 pM, n = 5 and 
2840 ± 820 pM, n = 3; Fig 5.IB). The potency for the high sensitivity inhibitory 
component is comparable to the original Zn2+ IC50 (0.8 ± 0.2 pM, n = 4) for 
potentiation of R ial (Table 5.1) raising the possibility that the a l T151A substitution 
converted the Zn2+ potentiation site to a high sensitivity Zn2+ inhibitory site. In
t i  c i * r i  a
support of this hypothesis the R ial ’ mutant, designed to disrupt the original 
potentiating site, reduced the sensitivity of the high potency component of the 
biphasic curve (Fig 5.7.4; Table 5.3). Whilst removal of the H107N background 
mutation to recover the original inhibitory Zn2+ site gave an a  11151A receptor with an 
increased sensitivity for the lower potency component (Fig 5.1 A,B\ Table 5.3).
To further characterise the role of T151, this residue was mutated to its P-subunit
counterpart, R Ia lT151R, which ablated Zn2+ mediated potentiation at GlyR a l  and
also generated a biphasic sensitivity to inhibitory Zn2+ (Fig 5.1C). In this case,
whilst the sensitivity of the high potency component was still comparable to the Zn2+
potentiation EC50 of R ial (R IalT151R IC50 = 3.6 ± 0.4 pM, n = 4) the maximal
contribution of the high sensitivity inhibitory component on glycine evoked
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responses was reduced to 39 ± 3 %, (n = 4), from 73 ± 8 %, (n = 4), for R Ia lT151A 
(Fig 5.7C, Table 5.3). Threonine 151 was further mutated to the 5-HT3AR 
counterpart, Asn, as this homologous receptor is also potentiated by Zn2+; however, 
Zn2+ mediated potentiation was still abolished for this mutated R IalT151N receptor. 
Again, though the potency of the high sensitivity inhibitory component remained 
similar to the original Zn2+ potentiation EC50 of R ial (R IalT151N 
IC50 = 1.6 ± 0.7 pM, n = 4) but the maximal contribution of this high potency 
inhibitory site was now even less at just 6.5 ± 0.3 %, (n = 4; Fig 5.7C, Table 5.3).
The 5-HT3AR Zn2+ potentiation site does not operate through its GlyR T151 
homologue
The data for GlyR a l T151N demonstrated that this receptor was not amenable to 
potentiation by Zn2+ suggesting that this residue may not form part of the apparatus 
required for Zn enhancement of the homologous cys-loop 5-HT3AR. To validate 
this assertion a wild-type 5-HT3AR and a 5-HT3ARN170A were each assessed for 
sensitivity to Zn mediated potentiation of 50 % maximal serotonin induced 
currents. Serotonin in the presence or absence of Zn was co-applied to receptors 
without Ca2+ or Mg2+ present as these cations compete with Zn2+ for potentiation of 
5-HT3ARs, (Hubbard and Lummis, 2000; though Ca2+ and Mg2+ were still present in 
the background saline solution to maintain the health of the cells). Serotonin dose 
response curve analysis showed that the sensitivity of each receptor to serotonin was 
directly comparable (wild-type EC50 = 0.86 ± 0.11 pM, n = 3 and 5-HT3AN170A EC50 
= 1.05 ± 0.25 pM, n = 3; Fig 5.85). Furthermore, in agreement with the supposition 
that N170 does not play an equivalent role in the 5-HT3AR to the GlyR T151 as
^ 1
regards Zn potentiation, both serotonin receptors exhibited biphasic profiles in 
response to Zn2+ modulation with the sensitivity to potentiating Zn2+ and the 
maximal enhancement remaining indistinguishable (Fig 5.8C, n = 3).
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Figure 5.7 Zn2+ potentiation of 50 % maximal Gly or taurine responses is 
abolished in a l  T151 mutated receptors and replaced with a novel biphasic 
inhibition. R IalTl5lA exhibits biphasic inhibition for^f, Gly and B, taurine. The 
lower potency component can be shifted to the left when the low sensitivity site 
residue N107 (RI) is reconstructed (N107H) to create a l n51A. Introduction of 
E l92A to perturb the original Zn2+ potentiation site, by contrast, induces a 
reduction in the sensitivity of the high potency inhibition component of the curve 
on RIalT151A. C, RIalTl5IN or R ia lII5lR also ablate Zn2+ potentiation of 50 % 
maximal Gly responses and introduced biphasic inhibition curves. Notably the 
potency of the two phases remains comparable, but the maximum inhibition 
(dashed red lines) for the high potency component is reduced in the order 
R ia lTL>lA > R ia lTl51R > Rja ] 1 l5lN £> GlyR a l extracellular domain based on 
AChBP, highlighting T151 (yellow) within the putative cys-loop gating domain 
(grey) and its proximity to another important determinant in gating, the TM2-3 
linker region (pink; Lynch et al, 1997). N = 4-6.
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GlyR a l T151 influences apparent agonist gating
As T151 resides in the cys-loop, recently implicated as important for agonist gating 
in the cys-loop based ligand-gated ion channel superfamily (Kash et al., 2003), each 
of the T151 mutations was assessed for altered agonist potencies. All three 
mutations, either a l T151A or R Ia lT151A, R Ia lT151R and R IalT151N, resulted in a 
progressive reduction in sensitivity to both Gly and taurine with R ia l1151N 
demonstrating an 11-fold and 23-fold increase in EC50 for Gly and taurine 
respectively (n = 4 - 5 ;  Fig 5 . 9 Table 5.3). Consistent with a gating effect, the 
percentage Imax for taurine (compared to maximal glycine responses in the same cell, 
termed ‘relative efficacy’), which has a lower absolute efficacy than Gly at GlyR a l  
(Lewis et al., 2003) decreased from 100 %, (n = 4) and 97 ± 4 %, (n = 4) of Gly 
maximal currents in R ial and R ia l7151A respectively to 93 ± 3 % for R ia l7151R and 
to 46 ± 6 % for R Ia l7151N. Additionally in the case of R Ia lT151N the Gly maximal 
current also dropped significantly (P < 0.05) from wild type responses of 
4.5 ± 0.4 nA to 2.9 ± 0.5 nA (Fig 5.9A-D, Table 5.3). Though this reduction in 
maximal Gly current amplitude is consistent with a reduction in the efficacy of the 
receptor it cannot be ruled out that the receptor may instead be less efficiently 
expressed at the cell surface i.e. the receptor may carry an assembly or trafficking 
defect. However, such an explanation does not explain the taurine data. In further 
support of an effect by these mutations on gating there was no appreciable shift in 
sensitivity to the competitive antagonist strychnine (Fig 5.10,4,5) suggesting the 
ligand-binding region was not substantially distorted (Vandenberg et al., 
1992a;Vandenberg et al., 1992b).
To investigate further the chemical properties required by the residue at position 151 
e.g. polarity and side chain volume, five other T151 mutants were generated 
including: GlyRal7151c, a l 7151D, a l 7151E, a l 7151F and a l 7151s. Glycine and taurine 
dose response curves for the a l 715ic, a l 7151E, and a l 715is receptors all showed a 
significant (P < 0.05) but small 2 - 4  fold increase in E C 5 0  for both agonists 
(Fig 5.10C,A Table 5.3) compared to the wild-type receptor. This was comparable 
to the a l 7151A receptor despite the fact that these new mutations retained polar 
electronegative moieties at this position. Furthermore introduction of a large 
hydrophobic side chain at this position in the form of a l 71517 did not cause a
170
significantly greater (P > 0.05) perturbation to agonist potencies than any of the 
previously inserted polar substitutions (Fig 5.10C,A Table 5.3). Even more 
intriguing was that a l T151D, which introduced another polar electronegative side 
chain, produced a receptor with maximal currents less than 20 pA (n = 10).
GlyR a l T151 and residues in the proposed Zn2+ potentiation site region can 
interact in mutated receptors
The mutation of GlyR a l  T151 to an Ala followed by an Arg and then an Asn
9 -4-resulted in a progressive reduction in the ability of Zn to interact with the receptor 
via the Zn potentiation site. As the function of the potentiation site was reversed to 
instead elicit inhibition this progressive reduction was measured as a decreasing 
contribution of the high sensitivity inhibitory component to the total amount of 
inhibition in the biphasic inhibition profile (Fig 5.7Q. This same series of mutations 
also resulted in an apparent progressive deterioration in receptor gating, in the same
order ofT151A < T151R < T151N, suggesting that there may be a direct link
2+between the Zn potentiation site and domains involved in receptor gating. To 
further demonstrate a potential influence of the Zn2+ potentiation site on receptor 
gating via T151 the agonist EC50S of Gly and taurine along with their maximal
/. r> T -T 1 5 1 A , E l 92 A T151A, D194A i T151A, H215A .responses were compared tor R i a l  , a l  , a l  to the
R ia l7151A receptor. Whilst the presence or absence of H107N does not affect agonist 
potency at a l T151A mutant receptors (Fig 5.9CJ), Table 5.3) and E192A, D194A and 
H215A mutations alone introduce minimal disruption to receptor function 
(Table 5.1), addition of these mutations to an R ia l7151A background did cause a 
synergistic disruption to receptor gating. Introduction of E l92A to R Ia l7151A 
reduced agonist potencies in a manner consistent with a change in channel gating. 
Gly and taurine E C 5 0 S  were both 10-fold higher and the taurine maximum was
reduced from 100 % (n = 4) to 65 ± 4.3 %, (n = 7) of the Gly maximal response.
Again the maximal Gly responses were also reduced from 4.0 ± 0.4 nA, (n = 5) for 
R Ia l7151A to 1.9 ± 0.5 nA, (n = 7) for R Ia l7151A’ E192A? consistent with a decrease in 
the efficiency of channel gating, assembly or trafficking. The strychnine sensitivity 
remained at wild-type levels suggesting the agonist-binding site retained the 
characteristics required for agonist binding (Fig 5.10,4,5). In comparison to the dual 
mutation of T151 and E l92, the strongest candidates for direct Zn2+ coordination,
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R IalT151A’ D194A and R IalT151A’ H215A showed a more dramatic phenotype with Gly 
currents significantly reduced to 150 ± 70 pA, (n = 8 from 27) for R Ia lT151A’ D194A 
and 40 ± 10 pA, (n = 7 from 23) for R Ia lT151A’H215A (Fig 5.1 IA-Q. Once more the
  'T1 c 1 a r  i q*) *
Gly EC50 increased significantly in a comparable fashion to R ial ’ with a 
14- and 24-fold increase to 220 ± 20 pM, (n = 4 from 24) and 370 ± 30 pM, 
(n = 2 from 23) for R IalT151A’ D194A and a l T151A’ H215A respectively. The relative 
efficacy of taurine was also substantially reduced to 33 ± 6 %, (n = 3 from 24) for 
R Ia lTI5IA’D194A and 40 ± 10 %, (n = 7 from 23) for R Ia lT151A' H215A (Fig 5.11A-Q.
”74-Thus D194 and H215, the strongest candidates for Zn potentiation binding site 
residues, also have the strongest influence on receptor function when mutated in 
combination with T151A.
Further studies, mutating residues immediately surrounding the proposed Zn2+ 
binding site and which are presented on the same side of the p-strands, revealed that
a l T151A, K190A, a l T151A, R196A, ^ TISIA, R213A ^  al T151A, E217A ^  exacerbated ^
properties of the RI a l T151A mutation in a comparable way to the R Ia lT151A’ E192A 
mutation. This is despite the fact that individually these K190A, R196A, R213A and 
E217A mutations do not influence GlyR agonist properties (Table 5.1). The Gly and 
taurine EC50S were increased in each case, whilst the maximal glycinergic response 
was reduced and taurine was reduced to a partial agonist with maximal taurine 
currents varying between 30 and 85 % of the maximal glycine response 
(Fig 5.11A-C, Table 5.3). This synergistic disruption to receptor function, especially 
at the core of the proposed Zn2+ potentiating binding site (D194 and H215), suggests 
this region is capable of interacting with T151.
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Figure 5.9 T151 mutated GlyR a l  receptors exhibit altered agonist activation 
properties consistent with changes to channel gating. Representative raw data 
traces showing maximal evoked responses to A, Gly, and then in the same cell 
B, taurine revealing the maxima for both agonists was reduced in R IalT151N and
T151A E192ARial ’ though to a greater degree for the less efficacious and potent 
agonist taurine. C, and D, Corresponding dose response curves to demonstrate 
decreased potency of agonists in a series of a l  T151 mutants; a l  » R ial >
,  T151A O T  1 T l5 l  A . O T  - T151R . n T  -T 1 5 1 N  ,1 1 5 1 a ,E 192A , ra l  » R ial > R ial > R ial » R ial are shown for
Gly (C) and taurine (D). Taurine lm2iX data were always measured as a 
percentage of the maximal Gly response in the same cell. N= 4 - 11.
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Figure 5.10 Further studies on T151 mutated GlyR a l  receptors. A, 
Sensitivity to inhibition by the competitive antagonist strychnine of 50 % 
maximal Gly responses remained comparable across a series of a l  T151 
mutants. B, Typical 50 % maximal glycine responses in the absence and 
presence of 10 nM strychnine (St) and after recovery for R ial and R Ia lT151N. 
Further characterisation of the effect of T151 mutated receptors on dose response
r  ^  i • j  • r  , 1 1 5 1 0  , T151E ,T 1 5 1 F  , ,T 1 5 1 Scurves for C, glycine and D, taunne for a l  , a l  , a l  and a l
T151Cmutated GlyRs. Despite retaining polar electronegative groups at a l
T151E T151Sa l  and a l  , all three receptors exhibited a 2 -  4 fold increase in EC50 for 
both agonists and a minor reduction in taurine relative efficacy, assessed in 
comparison to the maximal Gly response in the same cell. Introduction of a 
large hydrophobic group in the form of an a l T151F did not cause a further 
increase in agonist EC50s relative to its polar electronegative counterparts. 
N  = 3 -4 .
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Figure 5.11 Agonist properties for Gly and taurine activating R ia l1151A 
receptors carrying additional mutations in the nearby potentiating Zn2^  binding site 
region. A, Gly EC50 values increased and taurine efficacy B, and Gly maximal 
currents C, were both decreased when mutations from the Zn2+ binding region 
were introduced into R ia l1131A. The greatest perturbation to receptor function 
coincided with the axis of the predicted Zn2+ binding site with R ia l1151A’D194A and 
Rial n51A' H215A producing effectively non-functional receptors with Gly maximal 
currents less than 200 pA. Asterisks (*) denote significant (P < 0.05) divergence in 
receptor property from RIa 11151A. N=  4 -7 .
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Discussion
Evidence for a discrete Zn2+ potentiation site in GlyR a l
The Zn2+ potentiation site elucidated here in the form of GlyR a l  D194, H215 and
"?+E l92 fits the criteria for a Zn binding site. Each of these residues is chemically 
adept at interacting with Zn2+, and the structural GlyR a l  model, based on AChBP, 
predicts these three residues are in close proximity and ideal for presentation in a
“7+ • • • •Zn binding site. In addition, alanine substitution of these residues equally reduced 
Zn potentiation of currents activated by two different agonists, Gly and taurine, 
strongly suggesting that these residues exert their effect from a single source or site 
of action such as a binding site. Finally, experiments using MTSEA demonstrate that 
this site is accessible to water and therefore also to Zn via all three residues. 
Moreover, the analysis of an a l E192p mutated receptor suggested that E l92 may be 
exerting its effect on Zn2+ binding through the peptide backbone. This site only 
requires a fourth coordinating point to complete the Zn2+ binding site and in the case 
of catalytic sites, this is predominantly provided by an activated water molecule 
(Auld, 2001).
Comparison of the GlyR a l inhibition and potentiation sites
This potentiation site features a histidine residue as a likely Zn2+ coordinating partner 
and thus has some similarity with the GlyR inhibitory site. However, even without a 
precise atomic structural guide for the potentiating site it is still possible to predict 
that the exact chemical nature and structural properties of this site will be quite
different from the Zn2+ inhibitory site. This is because the other main candidate
• 2+residue for Zn coordination features an acidic carboxylic acid group donated by an
Asp, a residue not present in the inhibitory site. In addition there may be an unusual 
• • 2+contribution to Zn coordination, at the potentiation site, from the peptide backbone, 
the organisation of which is important for Zn2+ sensitivity. These coordinating 
groups could account for the higher sensitivity of the potentiation site to Zn2+ 
(EC50 « 1 pM) compared with the inhibitory site (IC50 « 20 pM), as acidic groups are 
stronger Zn2+ coordinators than polar hydroxyl groups such as those of the inhibitory 
site, e.g. a l  T133 (Auld, 2001). Finally, this potentiation site differs critically from 
the inhibitory site in that its predicted location suggests the site exists as a discrete 
unit on each subunit rather than as a cross-bridge between adjacent subunit
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interfaces. This means that in contrast to the mechanism of action of the inhibitory 
site, which could act by stabilising communication between two neighbouring 
subunits and preventing the subunits rotating to activate the receptor (Chapter 3), 
each potentiation site must communicate its effect initially within the confines of a 
single subunit before any downstream global consequences on receptor function 
could be imposed.
Transduction roles for residues at the GlyR a l  Zn2+ potentiation site
Although the three residues identified here, GlyR a l  E l92, D194 and H215, are all 
potential contributors to the potentiating Zn2+ site, it appears that the contribution of 
these residues to the site is not equal, as was previously shown to be the case for 
residues at the GlyR a l  inhibitory site (Chapter 3 - 4 ) .  In the case of an H215 
substitution, an Ala residue attenuated but did not ablate the sensitivity to 
potentiating Zn2+. The a l H215A receptor also did not have any obvious effect on the
'Si
maximum level of Zn enhancement or alter the function of the potentiating site. 
This suggested that H215 may contribute a pure binding role to the potentiating site.
In contrast, introduction of Ala at either E l92 or D194 produced a receptor with no
2+detectable Zn enhancement. Furthermore these substitutions appeared to create an 
extra Zn2+ inhibition site suggesting this region could influence the function and 
transduction of potentiation. However, in accord with a role in direct cation 
coordination for E l92 and D194 the potency of Zn2+ at the new inhibitory site was 
always of the order 1 5 - 5 0  fold less than at the original potentiation site. 
Substitution of the prime Zn2+ coordinating candidate D194 with a Lys residue, also 
a non-Zn2+ binding moiety but of larger volume than Ala, still ablated potentiation 
but did not induce any secondary functional effects. It is conceivable that the effect 
of a l D194A on transduction may simply be due to the insertion of an alanine at this 
position. In the case of E l92 this residue does appear to be able to specifically 
influence the transduction that is induced from the potentiating site. The data 
support the supposition that the organisation of the backbone at this locus is critical 
both for the potency of the site and also for the polarity of the site. In order for Zn2+ 
to bind and potentiate glycine currents, it must increase the propensity of the receptor 
to open in response to agonist binding. From the evidence presented here and given 
that the region surrounding the E192/D194/H215 site did not influence Zn2+
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potentiation, it can be speculated that the movement required is most likely linked to 
the backbone region at E l92, though this cannot be validated without 
thermodynamic and structural data.
A link between the GlyR a l Zn2+ potentiation site and the channel gating 
domain
In addition to those residues thought to line the Zn2+ binding site, T151 was also 
identified as a vital ‘control element5 for this site. Threonine 151 appears to be an 
important transduction component since its replacement by other residues altered the 
phenotype of the potentiation site reversing its polarity to create a high sensitivity 
inhibitory site. More profoundly, the sensitivity of the novel inhibitory site was
94-comparable to that of the original potentiating site for Zn , suggesting this residue 
was not affecting the affinity of the site. Instead the alternative residues inserted at 
position 151 varied the extent of inhibition in agreement with a transduction role. 
Threonine 151, located in the critical cys-loop gating domain (Kash et al., 
2003;Schofield et al., 2003;Schofield et al., 2004), was also important in determining 
agonist potencies since mutation to Ala, Arg and Asn reduced the GlyR sensitivity to 
agonists. This clear dual function of T151 suggested a mechanism of action for the 
Zn2+ potentiation site. The effect of Zn2+ binding appears to communicate 
downstream to T151 to increase the efficacy of the agonist-induced channel opening. 
This is supported by mutations introduced in the extracellular domain outer face 
around the Zn2+ binding site, which compounded the effect on agonist potencies of 
a l T151A mutated receptors, even though these mutations alone were innocuous. 
Importantly,the putative Zn2+ binding locus, E l92, D194 and H215, when replaced 
with Ala residues, all strongly reduced agonist relative efficacies on the a l T151A 
background. This supported the supposition that for the wild-type receptor, Zn2+ 
binding at this location could induce a downstream effect onto the cys-loop at T151 
enabling potentiation. In accordance with Zn2+ potentiation increasing agonist 
efficacy, the partial agonism of taurine on GlyR a l  in oocytes is enhanced to nearly 
a full agonist by potentiating doses of Zn2+ (Laube et al., 2000). Furthermore, 
residues located in the M2-3 extracellular loop, which are predicted to be closely 
opposed and to interact with the cys-loop gating domain (Brejc et al.,
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2001;Miyazawa et al., 2003), also affect Zn2+ mediated potentiation (Lynch et al., 
1998) as would be expected if there is interplay between these two domains.
Recently it has been shown that in the case of anaesthetics operating on GlyRs 
perturbation of a selection of residues in the proposed cys-loop domain, not only 
reduced glycine potency but also diminished the potentiation caused by certain 
anaesthetics (Schofield et al., 2004). Though T151 was not one of the residues 
concerned, the authors did replicate a reduction in agonist potency for a GlyR 
a l T151A mutation as is reported here. This supports a potential scheme in which 
positive modulators that increase the receptor efficacy may operate by feeding into 
the critical receptor gating domain comprising the cys-loop and M2-3 loop, even if 
originally the input is derived from distinct sources such as the extracellular or 
transmembrane domains. Also of interest is the recent observation that when 1307 in 
the TM2 domain of the GABAa p receptor is substituted with a Gin residue the 
polarity of an inhibitory 5P-pregnane-3a-ol-20-one neurosteroid is reversed to now 
induce potentiation (Morris and Amin, 2004). This is comparable to the reversal of 
the Zn potentiation site polarity observed here upon perturbation of a l  E l92 or 
T151 suggesting that modulation site polarity reversals may be a common side effect 
of interfering with the transduction machinery of a binding site.
Implications for Zn2+ potentiation at other GlyR subtypes
The structure-function study reported here focused primarily on determinants of Zn2+ 
mediated potentiation in GlyR a l .  However the implications for properties of Zn2+ 
enhancement at GlyR a2-4, GlyR p and the 5-HT3A receptor were also investigated. 
Accurate comparisons of the potency of potentiating Zn2+ at GlyR a l  and a2 and 
their respective heteromers revealed that both receptors have a submicromolar high 
sensitivity to Zn enhancement, though the potency is 10 -  fold less for a2 due to a
•n i
subsitution at the Zn binding residue, a l  D194, with another acidic moiety, a l
E201. The remaining two residues a l  E l92 and H215 as well as the control element
T151 all remain the same in a2 (Fig 5.2Q suggesting the properties of Zn2+
potentiation at the a l  subtype have the same molecular basis. Though no studies
were carried out to measure the potency of Zn2+ enhancement at GlyR a3 and 4 these
two receptors retain the exact same molecular composition as a l  for Zn2+
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potentiation and are therefore likely to retain comparable properties, an assumption 
supported by a significant potentiation of GlyR a3 by 1 pM Zn2+ (Chapter 3).
Studies to investigate a contribution from the p-subunit to Zn2+ potentiation 
suggested its role is unimportant in this process. Incorporation of the P subunit 
forming heteromeric GlyR a lp  and a2p did not in any way influence the potency of
^ i a
Zn enhancement and co-expression of the p-subunit with an a l  mutant devoid 
of Zn2+ potentiation did not enable the recovery of a positive allosteric action by
^ I  ^ i
Zn . The molecular basis of this apparent lack of sensitivity to Zn enhancement 
by the p-subunit could be attributed at least in part to the identification of a variant 
residue at the equivalent position to a l  T151. Introduction of the corresponding 
p-subunit residue, an Arg, into the GlyR rendered the a  11151R mutant insensitive to 
Zn2+ enhancement such that the potentiating site now seemed to support an inhibitory 
influence. This is supported by a previous observation where an a l  chimera that 
suffered a partial replacement of the region encoding the cys-loop and therefore 
T151 with the p-subunit sequence also generated a GlyR a l  subunit insensitive to 
Zn2+ potentiation (Laube et al., 1995).
Implications for Zn2+ enhancement of §-HT3ARs and nAChRs
Characterisation of the 5-HT3AR for modulation by Zn has also previously revealed 
a biphasic profile with comparable sensitivities for Zn2+ potentiation and inhibition to 
those measured for the GlyR (Hubbard and Lummis, 2000). The possibility though 
that these two receptors share the same molecular basis for Zn2+ potentiation now 
seems unlikely as replacing GlyR a l  T151 with the Asn present in the 5-HT3AR did 
not retain Zn2+ potentiation at the GlyR. In addition substitution of the 5-HT3AR Asn 
residue with an Ala, which when introduced to create GlyR a l T151A ablates 
enhancement, did not cause any apparent effect on Zn2+ potentiation at 5-HT3ARs. 
Though the other specific molecular correlates of the GlyR a l  binding site E l92, 
D194 and H215 did align with potential Zn2+ binding partners in the mouse 5-HT3AR 
variant tested here (Fig 5.&4), alignment analysis with the human 5-HT3AR did not 
provide the same results (data not shown). As the regions around the actual Zn2+ 
binding site residues are poorly conserved between GlyRs and the 5-HT3AR it was 
not possible to gage whether these acidic residues in the 5-HT3AR were homologous
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to those of the GlyR and an in depth structure-function study to investigate this was 
not undertaken. Overall the evidence presented here suggests that the 5 -HT3AR is
9 ^unlikely to possess a homologous Zn potentiation site compared to that of the 
GlyR. This is further supported by the fact that the 5 -HT3AR does not maintain the 
same degree of specificity for cation enhancement (Hubbard and Lummis, 2000). At 
5 -HT3ARs the Zn2+ enhancement effect can be displaced by other cations including 
Ca2+ and Mg2+ making it necessary to carry out the Zn2+ modulation curves in the 
absence of these ions, which is not required when measuring Zn2+ enhancement at 
the GlyR.
 ^ I
There is also no molecular basis for the potentiation by Zn of some subtypes of the 
nAChR (Hsiao et al., 2001). Though it may be possible that nAChRs retain a 
comparable site for Zn enhancement to the GlyR, the properties of this nAChR 
site(s), are likely to be quite different. Whilst Zn2+ potentiation of GlyRs is a very 
robust process occurring with comparable sensitivities and maximal enhancements 
across GlyR a  1-3 and their respective ap heteromers, Zn2+ potentiation at various 
nAChRs is more complex. Both the subtype of the a  and p-subunit are able to 
influence the extent and maximal level of Zn2+ mediated potentiation at nAChRs 
(Hsiao et al., 2001). Furthermore the sensitivity to Zn2+ enhancement in normal 
saline across all these nAChR variants, a2-4 and p2 and P4, was substantially lower 
with EC50S in the range 15-100 pM compared to the 0.8 pM value reported here for 
GlyR a l .
The nAChR potentiation site does however share a higher level of selectivity like the
9+GlyR (Laube et al., 1995) when compared to the 5 -HT3AR, with significant Zn 
potentiation occurring even in the presence of Ca2+ and Mg2+ ions and only Cd2+ 
being able to partially compensate for Zn enhancement (Hsiao et al., 2001). A
9 1
study using chimeras has demonstrated that the most important contribution to Zn 
mediated potentiation in nAChRs comes from the extracellular N-terminal domain of 
the receptor similar to the GlyR. However, there are no obvious correlates between 
the GlyR residues, T151, E l92, D194 and H215, in the nAChR a  and p subunits 
(alignment not shown) that could account for Zn2+ modulation.
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Physiological significance of GlyR Zn2+ potentiation
The high sensitivity to Zn2+ enhancement reported here for homomeric a l  and 2 and 
heteromeric al(3 and a2p GlyRs, along with the rapid onset of Zn2+ potentiation 
previously reported (Chapter 3), make Zn2+ an ideal endogenous co-modulator at 
glycinergic synapses. This is relevant especially as Zn2+ is concentrated into selected 
nerve terminals and packaged into synaptic vesicles throughout the CNS including 
those present within glycinergic boutons of the spinal cord (Birinyi et al., 2001 ;Jo et 
al., 2000;Velazquez et al., 1999;Wang et al., 2001). Additionally, Zn2+ ions may be 
released into the synaptic cleft or from a thin Zn veneer following nerve fibre 
stimulation (Assaf and Chung, 1984;Howell et al., 1984;Kay, 2003) resulting in 
multiple effects on neuronal excitability by modulating ligand-gated and voltage- 
operated ion channels (Smart et al., 1994;Harrison and Gibbons, 1994). Experiments 
measuring zebrafish glycinergic IPSC kinetics in the presence and absence of the 
Zn chelators, tricine and TPEN, revealed that these synaptic receptors are sensitive 
enough to be potentiated even by Zn2+ contamination in the extracellular saline 
solution (Suwa et al., 2001). Thus it would appear likely that GlyRs can at least
 ^ I
undergo a basal level of modulation by released Zn though whether this extends to 
the specific action of Zn as a rapidly released and removed synaptic co-modulator 
will require further studies.
Conclusion
 ^ I
I report here the identification of the Zn potentiation site for the GlyR and a 
possible mechanism of action for Zn potentiation via the cys-loop channel-gating 
domain. This site has a high sensitivity to Zn2+, with the EC50 estimated at less than 
1 pM, well within the current range of estimates for putative physiological levels of 
released Zn2+ (Frederickson et al., 2000). Importantly, this mutagenesis study 
supports the supposition that the AChBP is a powerful model for use in GlyR 
structure-function studies and strengthens the recent precedent linking the GlyR cys- 
loop region to channel gating (Kash et al., 2003;Schofield et al., 2003;Schofield et 
al., 2004), by identifying a novel regulatory component in GlyR function in the form 
of T151. This study provides novel insight into the function of a cys-loop ligand-
 ^1
gated ion channel Zn binding site.
182
Glycine
Max current EC5o (pM) 
(nA)
n EC5o (pM)
Taurine
t%GlyI™*)
n ECS0 (pM)
Zni+ (on Gly)
Max(%) IC50(pM) 
increase*
n
Zn2+ binding residues
a l 4.5 ±0.5 16 ± 2 5 90 ± 10 i © o 5 0.8 ± 0.3 39 ± 8 20 ±5 4
R ial 5.9 ± 0.3 25 ± 4 4 130 ±30 -100 4 0.8 ± 0.2 42 ± 6 >3000 4
R IalE192A 3.6 ±0.7 19 ± 4 3 190 ±60 i © o 3 None None 710± 100 7
R IalDl94A 4.8 ± 0.4 48 ± 4 3 310 ±70 -100 3 None None 270 ± 50 3
Rlal**21^ 3.7 ±0.2 21 ±3 3 100 ±30 i © o 3 22 ± 4 28 ± 12 1320 ±210 4
Acidic non-binding residues
R IalD141A 2.9 ± 1.1 46 ± 7 2 240 ± 80 © o 2 * 1 0.5 ± 0.2 41 ±21 >3000 3
R IalD148A <0.04 — 10 --- __ 3 — — — —
R IalE19,A 4.8 ±0.6 22 ±5 3 190 ±40 -100 3 0.8 ± 0.4 80 ±50 >3000 3
Residues surrounding Zn2+ binding site
R ial 4.5 ±0.3 9 ± 2 3 80 ±20 i © o 3 0.9 ± 0.7 29 ± 6 n.e 3
R IalR196A—. - DOHA 5.0 ±0.5 27 ± 6 4 150 ±50 I © o 4 0.6 ± 0.1 34 ± 7 n.e 4
R ial 5.3 ± 0.2 9 ± 7 3 60 ± 10 -100 3 0.5 ± 0.3 58 ±30 n.e 3
R IalE2,7A 4.2 ±0.8 21 ± 5 3 120 ±50 -100 3 0.9 ± 0.3 37 ± 3 n.e 4
Cys mutated receptors
R IalE192C 5.8 ±0.8 110 ± 10 4 n.e n.e 1.9 ±0.2 59 ± 15 -  1000 4
R IalD194C 5.6 ±0.8 99 ±24 4 n.e n.e 3.6 ± 0.6 40 ± 12 2000 ± 300 5
R IalH215C 4.0 ± 0.6 71 ± 10 3 n.e n.e 0.44 35 ± 8 1100 2^ja jEt92C, H215C < 0.1 6 — __ __
RIa 1D,94C.H215C < 0.1 — 6 — — — — — —
Table 5.1 Agonist potency data and Zn2+ modulation data for mutagenesis studies to elucidate the Zn2+ potentiation site of
GlyR a l.
Definitions: n.e. -  not evaluated, ‘— ’ represents receptors where maximal Gly currents were too small to accurately evaluate Zn2+ 
modulation, none -  denotes circumstances where the attribute under evaluation was not present.
* The maximum percentage increase of a 50 % maximal agonist induced response. ** _ This error is a standard deviation.
Max current 
(nA)
Glycine
ECsoCpM) n EC50 (pM)
Znz+ (on Gly)
Max (%)* IC50 (pM) 
increase
n
H 109F m utated receptors
R ial 5.9 ±0.3 25 ± 4 4 0.8 ± 0.2 42 ± 6 >3000 4
R IalH109F 5.1 ±0.2 28 ± 5 3 ~1 67 ± 14 >10000 7
R IalE,92A 3.6 ±0.7 19 ± 4 3 None None 710± 100 6
R IalH,09F* E192A 6.0 ± 0.5 51 ± 4 4 None None 660 ± 90 4
W a l“ ,SA 3.7 ±0.2 21 ±3 3 22 ± 4 28 ± 12 1320 ±210 4
R IalHl09F* ® 15A 1.2 ±0.3 150 ± 15 3 40 ± 11 34 ± 11 3200 ± 600 4
Pro &  Lys m utated receptors
R IalE,92P 7.0 ± 0.2 48 ± 4 3 4.2 ±0.8 50 ± 11 > 1000 3
R IalD194K 6.4 ± 0.8 140 ±30 6 None None 640 ± 80 6
RfcjHlWF. D194K 1.9 ±0.5 200 ± 30 3 None None 1270 ±110 6
Zn2+ IC50A*1 IC50A Max*2 Znz+ IC50B*3 n
(pM) (%) inhibition W )
H 109F m utated receptors (biphasic inhibition)
R ial 4.8 ± 0.4 48 ± 4 3 270 ± 50 100 n.a. 3
j^ j HIWF.DIWA
2.5 ±0.6 290 ± 70 3 79 ±28 45 ± 4 820 ± 80 4
Pro & Lys m utated receptors (biphasic inhibition)
R ial 7.0 ± 0.2 60 ± 6 3 32 ± 14 52 ± 8 1000± 100 3
R IalD,94P 5.2 ±0.9 43 ± 9 4 8.2 ± 1.3 42 ± 7 150 ±28 3
Table 5.2 Agonist potency data and Zn2+ modulation data for mutagenesis studies to determine 
effects on transduction from the Zn2+ potentiation site.
Definitions: n.a. -  not applicable as this receptor exhibited only one distinguishable inhibitory phase, 
none -  denotes circumstances where the attribute under evaluation was not present.
* The maximum percentage increase of a 50 % maximal agonist induced response.
i ^
* First high sensitivity IC 50  component, * Maximum achievable percentage reduction by the first 
inhibitory component of 50 % maximal Gly responses, *3 Second low sensitivity IC 50  component.
Max current 
(nA)
Glycine 
EC50 (pM) n EC50 (pM)
Taurine
itntx
(%GlyUJ
n Zn2+
IC50A* 1
(pM)
Zn'+ (on Gly)
IC50A ZnJ* ICjoB*3 
Max*2 (%) (pM) 
inhibition
n
Agonist and Znl+ transduction T151 residue mutations
a l T15.A 4.7 ± 0.6 53 ± 9 4 330 ± 60 -100 4 2.9 ±2.0 68 ± 7 160 ±60 4
R IalT,51A 4.0 ± 0.4 63 ± 12 5 380 ± 80 97 ± 4 4 1.6 ±0.6 73 ± 8 1040 ±290 5
R IalT15,N 2.9 ± 0.5 180 ±30 7 2060 ± 230 46 ± 6 5 1.6 ±0.7 7 ±0.4 1410 ± 210 4
R IalT151R 3.8 ± 0.9 95 ± 7 3 560± 130 93 ± 3 4 3.6 ± 0.4 39 ± 3 710 ± 130 4
T151 combined with residues both within and surround ng the Zn2+binding site
R I( x1T.51A.K«90A 0.4 ±0.1 180 ± 10 4 1810± 140 32 ± 3 4 n.e n.e n.e
R IalT!51A*E,92A 1.9 ±0.5 170 ± 10 7 9 6 0 ± 160 65 ± 4 7 16 ± 3 32 ± 4 390 ± 60 3
R I a l T15IA.Dl 94A 0.15 ±0.07 220 ± 20 20 n.e 33 ± 6 20 n.e n.e n.e
R I a l T151A.Rl96A 1.2 ±0.3 130 ± 10 4 1810 ± 450 35 ± 7 4 n.e n.e n.e
Rlfll^^A1 R213A 2.1 ±0.8 52 ± 10 5 4 0 0 ± 120 85 ± 2 5 n.e n.e n.eR I a l T151A.H215A
0.1 ±0.04 380 ± 30 15 n.e 4 0 + 1 0 15 n.e n.e n.eR I a l T15JA.E217A
1.2 ±0.4 120 ± 6 4 900 ± 70 71 ± 3 3 n.e n.e n.e
Further T151 residue mutations
RI<xlT,5,c 4.6 ± 1.6 52 ± 8 3 370± 130 94 ± 4 3 n.e n.e n.e
R IalTl5lD <0.05 n.e 10 <0.05 n.e 10 n.e n.e n.e
R IalT,5IE 5.0 ± 1.5 50 ± 7 3 390 ± 70 94 ± 1 3 n.e n.e n.e
R IalT,5,F 5.7 ± 0.6 100 ±20 4 600 ± 240 88 ± 5 4 n.e n.e n.e
RIalT151s 5.3 ±0.8 73 ± 7 3 620 ± 190 90 ± 4 3 n.e n.e n.e
Table 5.3 Glycine, taurine and Zn2+ potencies for GlyR a l carrying mutations at threonine 151.
Definitions: n.e. -  not evaluated, ‘— ’ represents receptors where maximal Gly currents were too small to accurately 
evaluate Zn2+ modulation.i • • •«« 2 , ,* First high sensitivity IC 5 0  component, * Maximum achievable percentage reduction by the first inhibitory component of 50 % 
maximal Gly responses, *3 Second low sensitivity IC 50  component.
Chapter 6 
Summary and Final Thoughts
The 1960s represented a critical landmark in the optimisation of techniques to 
elucidate protein structure. This holy grail was of fundamental importance as 
scientists believed that knowledge of a protein’s structure was key to its functional 
secrets. Clearly, since the deduction of crystal structures such as insulin and 
haemoglobin, this has proved to be an unfounded assumption, largely because the 
structure of a protein is not the sole source of functional information. Another vital 
component is also required, that of protein dynamics. In contrast to structural 
techniques, such as NMR and X-ray crystallography, there is as yet no formal 
process for obtaining the dynamic information possessed by a protein. Strategies to 
monitor real-time equilibrium fluctuations within a protein’s structure and to 
measure the movements that are undertaken in response to ‘stimuli’, i.e. binding 
events, will be key to determining this information. The standardisation of such 
techniques, however, is most likely decades away and in the mean-time functional 
diagnoses rely predominantly on covalent modifications, whether this be in the form 
of site-directed mutagenesis or covalent labelling strategies.
The work described in this thesis demonstrates that with appropriate interpretation, 
covalent modification is remarkably powerful at determining the locations involved 
in binding events and even at elucidating potential mechanisms of communication 
between different protein domains. The data presented reveal that an unequivocal 
picture of amino acid function is almost never forthcoming. This supports the 
assertion above that a protein is not merely a static image where residues can be 
pigeon-holed into their specific functional roles, but that instead a protein is a 
dynamic structure, constantly in a state of physical flux, where amino acids 
contribute to multiple processes and work together as an inseparable team. Even 
attempts to assess the importance of residues at potential Zn2+ binding sites, where 
the coordinating moieties can be chemically predicted and might be expected to have 
a fairly specific role in coordination, proved remarkably complex with a wide range 
of functional consequences for the GlyR. The functional interpretations of such data
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are beyond that which can be determined from the structural model alone and instead 
require an appreciation of, as yet, completely absent dynamic information.
Previous studies on GlyR a l  pointed to four residues with a potential involvement in 
Zn2+ coordination at the inhibitory Zn2+ binding site, HI07 from the subunit ‘+* face 
and H I09, El 10 and T112 from the face of a neighbouring subunit (Harvey et al., 
1999;Laube et al., 2000; Fig 6.1). The work here identifies two further polar 
residues exposed at the surface of the GlyR a l  Zn2+ inhibitory face, which also
influence Zn2+ mediated inhibition, N61 and T133 (Fig 6.1). All these residues are
2+
predicted to reside in the same region and therefore may influence Zn coordination 
at the predicted inhibitory site, either directly or indirectly. The primary sequence 
arrangement for the original three identified residues on the Zn inhibitory site 
face means that these residues are all spatially close to one another. However given 
that H I09 marks the end of the predicted p-sheet 5 with its immediate neighbour 
El 10 marking the start of a loop region it is unlikely that the peptide psi bond angles 
would permit both residues to be similarly orientated to contribute to Zn2+ 
coordination (Auld, 2001;Vallee and Auld, 1990). Such a situation where two 
neighbouring residues on a P-strand contribute to Zn2+ coordination of the same ion 
has not yet been reported (Auld, 2001;Vallee and Auld, 1990). Furthermore, GlyR 
a l  N61 and T133, which from a structural perspective are predicted to reside on two
*y,
separate nearby loops ideal for contributing to Zn binding, represent relatively less 
favoured Zn2+ binding moieties (Auld, 2001;Vallee and Auld, 1990). The results 
from the functional site-directed mutagenesis studies were also not unequivocal. The 
evidence for H I07 as a direct binding partner in the site is the strongest, as ablation 
of the Zn coordination property of this residue gives a dramatic reduction in the
‘ji
potency of Zn inhibition without affecting the efficacy (maximal level of 
inhibition) or inducing other Zn2+ related phenomena such as ZAG activity. 
Furthermore, only the residue at the equivalent position to HI 07 can be donated from 
what is considered to be a neighbouring non-functional P-subunit and return 
functionality to the inhibitory site. The data suggest that this is because the 
inhibitory signal can then be mediated through the a  subunit face, therefore 
suggesting that the ‘+* face H I07 is required for binding but not transduction. 
Perhaps also of consequence, the data presented here reveal that the HI 07 equivalent
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is also responsible for differential sensitivity to Zn2+ inhibition between GlyR 
subtypes. From an evolutionary perspective, if it were desirable to select for 
receptors with varying sensitivities to Zn2+ then it would be most effective to target a 
residue with a pure role in Zn2+ coordination so as not to induce other effects on the 
properties of the receptor.
Concerning the residues residing on the inhibitory Zn2+ site face it is more 
difficult to distinguish specific roles for each moiety. Previous data and the evidence 
presented in this report favours Zn2+ binding at the intersubunit interface, between 
the *+’ and subunit domains, to stabilise the receptor in a closed conformation 
(Nevin et al., 2003). From this standpoint H I09 and El 10 chemically represent the 
strongest candidates to mediate the Zn binding process at the interface. 
However alanine substitution of El 10 induced a relatively small 5-fold reduction in 
the potency of Zn2+ mediated inhibition, while an a l H109A mutated GlyR has an even 
smaller reduction in potency, just 2-fold, and also affects the efficacy of this process 
by reducing the maximal amount of inhibition that Zn can induce. The structural 
model of the GlyR presents H I09 in a more favourable orientation for direct 
coordination with Zn2+ across to H I07. However the AChBP has a low sequence 
homology with GlyRs (approximately 20 %) and the region for H I09 and El 10 falls 
across the start of a peptide loop within the receptor, which classically retains the 
least structural similarity between homologues. Therefor^, it is not possible to place
•"y 1
complete confidence in this prediction that H I09 is the primary face Zn 
coordinating partner. The remaining three residues, N61, T112 and T133 do not 
represent classical Zn2+ coordination partners, though these moieties have been 
reported as binding partners in some instances (Auld, 2001). All three of these 
residues, along with HI09, can clearly influence Zn2+ transduction when substituted 
with alanines, as Zn2+ mediated inhibition is ablated and ZAG activity is conferred. 
Plus these residues exert other complicating effects on GlyR properties, including 
some modest reductions in the potency of glycine and a decrease in the macroscopic 
activation rates by non-saturating doses of glycine. The clear similarities exhibited 
between these residues, despite their discrete locations along the primary sequence, 
demonstrates the usefulness of the structural model as a reliable predictor of 
approximate amino acid positions. It is also worth mentioning that alanine
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substitution at N61, H I09 and T133 generated low potency ZAGs but at T112, high 
potency ZAG activity was induced, not dissimilar in sensitivity to the original 
potency of Zn mediated inhibition. As the evidence suggests the ZAG induced by 
disruption at the subunit face, relies on the same Zn2+ binding components as the 
original Zn2+ inhibitory site this implies that disruption at N61, H I09 and T133 
affects the site potency whilst disruption at T112 affects only the transduction. This 
would agree with previous studies where substitutions of T il 2 have induced effects 
on the relative efficacy of partial agonists and so T112 may have a general role in 
multiple aspects of GlyR function (Schmieden et al., 1999), rather than a specific 
role in Zn2+ coordination.
i
This report also identified a novel site for Zn potentiation. The evidence for
'j,
residues specifically involved in direct coordination of Zn at this location is clearer 
perhaps due to its predicted intrasubunit nature. Site directed mutagenesis studies 
identified a discrete region, composed of three residues, GlyR a l  E l92, D194 and 
H215 (Fig 6.2) that when substituted with alanine either ablated, or reduced, 
sensitivity to Zn2+ enhancement. Other potential Zn2+ coordinating amino acids in 
the vicinity and neighbouring residues did not exert any influence over Zn2+ 
potentiation when substituted, demonstrating the specificity of this location. 
Furthermore, the evidence that two of these residues, D194 and H215, were direct
 ^ I
coordinators of Zn was strengthened by demonstrating their apparent accessible 
nature at the surface of the protein using a cys-modifying reagent, a requirement for 
any dynamic Zn2+ binding site. As with the studies on the Zn2+ inhibitory site, the
94-results were not always unequivocal. The alanine substitution at E l92 ablated Zn
94-potentiation but also induced the formation of a low potency Zn inhibition site. 
The evidence indicated that this occurred through a reversal of the function of the 
potentiation site suggesting E l92 can influence transduction from this site. The 
inhibition was also of a lower potency than the original potentiation implying that 
manipulation of E l92 also reduced the affinity of the site, though decreasing the 
efficiency of transduction can also cause such an effect. Interestingly, side chain 
modification of E l92 using a cys-modifying reagent did not ablate potentiation. 
Furthermore substitution with a proline, known to influence the peptide backbone 
geometry (Chou and Fasman, 1974;Yohannan et al., 2004), also retained the capacity
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for Zn2+ potentiation with only a modest reduction in potency. This suggests it is the 
trajectory of the backbone at this loci that is of vital consequence for Zn2+ 
potentiation rather than the side chain identity. It was not possible from these studies 
to determine if the peptide backbone is involved directly in binding, but dynamic 
Zn2+ binding sites are predicted to retain at least three coordinating residues and an 
activated water molecule (Auld, 2001). As there are no other obvious candidate 
binding residue for the third coordinating partner in this region, then currently, the 
peptide backbone presents the most plausible explanation.
The mutagenesis experiments presented in this report not only investigated the 
relatively simple prospect of dissecting true components of Zn binding but also 
attempted to divulge possible mechanisms by which the two sites could propagate 
their effects. This strategy proved surprisingly powerful in divulging useful
^ i
information regarding such transduction mechanisms. In the case of Zn 
potentiation, an element in the cys-loop gating domain of the GlyR, T151, was 
isolated that could determine the extent by which the potentiation site was able to 
exert an effect on receptor function. This suggested that Zn might exert 
potentiation by acting on the gating process, a hypothesis also supported by the
synergistic effect that disrupting the gating element, T151, in combination with
• • • *)+ • • residues in the vicinity of the Zn potentiation site had on reducing the efficacy of
agonist action. Such synergy was not observed between T151 and HI07 at the
'y,
inhibitory site suggesting this effect is selective to the region of Zn enhancement.
A previous study in oocytes also showed that Zn2+ increased the relative efficacy of
the partial agonist taurine (Laube et al., 2000). Furthermore, certain residues in the
M2-3 loop, an important component of the gating process (Lynch et al., 1997) ablate
Zn2+ potentiation (Lynch et al., 1998) as would be expected if Zn2+ potentiation
interacts with this process. Though this study has not proved that T151 is the
exclusive element from the cys-loop in order for the Zn2+ potentiation site to mediate
its effect, disruption of two acidic residues, and Q150 in this domain, did not affect
enhancement by Zn2+. Moreover C l52, an immediate neighbour of T151, is
involved in formation of the cys-loop bridge, critical for receptor gating and
assembly, making it an unlikely mediator in the Zn enhancement process. Thus
T151 would appear to be a specific control element that transduces the binding of
Zn2+ at the potentiation site to increase the efficacy of the receptor.
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Figure 6.1 Homology model presenting 
the molecular basis of the inhibitory Zn2+ 
site and its transduction apparatus 
(viewed from the inside aspect; see inset).
A, The intersubunit nature of the 
inhibitory Zn2+ site (expanded in (C), red 
dashed box) between the *+' and 
interfaces is presented, as is the
hydrophobic Zn2r inhibition transduction domain (expanded in (B), blue dashed 
box), which leads to the agonist binding site (Top picture, green residues. A more in 
depth view of the proposed agonist binding site can be viewed in Fig 1.6B,C).
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Figure 6.2 The GlyR Zn2+ potentiation site.
Above in (A) is a presentation of the residues in the 
Zn2+ potentiation site viewed from above (see inset).
The comparative locations of the agonist binding site 
(green) and the Zn2+ inhibition site (orange) are also 
shown. Note the clear intersubunit nature of the 
inhibitory site on the inside face compared to the 
intrasubunit location of the Zn“^  potentiation site on the external face. B, Side view 
(see inset) of the Zn2 potentiation site with labels for the three potential Zn“ 
coordinating residues, E l92, D194 and H215 and the control element T151 (blue). 
This highlights the location of T151 on the gating element cys-loop (blue) in close 
proximity to the p i-2 loop (green) and M2-3 loop (red) gating elements. The four 
transmembrane domains are also shown, with the pore lining helix, M2, in yellow.
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Perhaps the most revelatory discovery to result from the site directed mutagenesis 
studies reported here, was the determination of an entire hydrophobic transduction 
pathway required for allosteric interplay between the Zn2+ inhibition site and the 
agonist binding site. The ability to determine a genuine and selective role for these 
residues in transduction, something that is notoriously hard to do, was a fortuitous 
consequence of ZAG induction (Chapter 4) upon substitution of hydrophobic 
residues, L98, F99, F100, F108,1132 and L134 with alanine. These residues were all 
predicted from the structural GlyR model to line up in a pathway from the inhibitory 
Zn2+ site face across to the agonist-binding site (Fig 6.1). Other hydrophobic 
residues surrounding the pathway did not induce such an effect. Previously, 
transduction had been predicted to occur from the face of the Zn inhibition site 
due to the unique ability of the GlyR (3 subunit to only donate a Zn2+ binding site 
residue from its *+’ face (Chapter 3). This ZAG formation was linked to the original 
inhibitory Zn2+ site, as not only was Zn2+ inhibition ablated upon substitution of the 
hydrophobic residues in question but also these ZAG receptors relied on H I09, 
formerly of the inhibitory Zn2+ site, to elicit Zn2+ activated currents. This suggested 
that in ZAG receptors the function of the inhibitory site had been switched to induce 
activation and therefore these hydrophobic residues were important in the 
transduction process of the Zn2+ inhibition site. To confirm this discovery really 
requires dynamic protein data. In this case, the dynamic data was elucidated using 
functional mutagenesis studies to modify the protein, and therefore its energetics, 
then observe the consequences. Though this pathway marks an apparent allosteric 
transduction route across the protein, it may be that such a communication event also 
represents a more significant role in the general function of the receptor itself. 
Despite a model structure of the extracellular domain of cys-loop receptors, based on 
AChBP, it has, as yet, not proved possible to decipher the order and importance of 
downstream transduction events that mediate the communication between the agonist 
binding loops and the three base loops, the p i -2 loop, cys-loop and the P8-9 loop so 
that agonist binding can induce channel opening. The mechanism of action of the 
inhibitory Zn2+ site clearly suggests that Zn2+ stabilises the closed conformation of 
the receptor by fixing the inhibitory site face in a set orientation with the 
inhibitory site *+’ face of a neighbouring subunit (Chapter 3). Clearly then, binding 
of agonist to open the receptor results in movement of the inhibitory site face such
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that Zn2+ can no longer bind and inhibit the receptor, a process that the evidence 
reported here suggests is mediated via a hydrophobic transduction domain. 
Reorganisation of the receptor’s hydrophobic pathway and inhibitory Zn2+ site 
face may therefore be part of the GlyR activation procedure. How important this 
event is in activation of the receptor, i.e. whether it is a driving force for receptor 
activation or a side effect of receptor activation, remains to be seen, but undoubtedly 
this will come under scrutiny in the near future.
The data presented in this study represents a significant contribution to understanding 
the molecular basis of Zn2+ modulation of GlyRs. Where an understanding is
9 -4-currently lacking is in the appreciation of any physiological role Zn may be 
exerting over GlyRs. The hippocampus, an ideal preparation to study NMDA
9 -4-receptors, is also the favoured preparation for research on synaptic Zn release and 
several studies have attained indirect evidence that Zn2+ can endogenously modulate 
NMDA receptors (Ueno et al., 2002;Vogt et al., 2000). Furthermore pathways by 
which Zn2+ can be released in the hippocampus have been characterised 
(Frederickson et al., 2000) and due to the very high affinity of NR2A containing 
NMDA receptors it would seem likely that these receptors experience a significant 
level of background modulation by Zn2+ (Paoletti et al., 1997). Unfortunately the 
hippocampus appears to express only extrasynaptic GlyRs (Mori et al., 2002) and 
these are less prominent than NMDA and GABAaRs, therefore limiting the extent to
9 .
which studies, especially dynamic endogenous Zn modulation studies on GlyRs, 
can be carried out. Spinal cord, the ideal preparation to acquire information about 
synaptic GlyR modulation, has yet to become the subject of any study addressing
9 i
endogenous release of Zn as a neuromodulator. Though studies in Xenopus do
9 -4-suggest that background concentrations of Zn may be sufficient to elicit 
potentiation of GlyRs and therefore have physiological significance (Suwa et al., 
2001). With regards to future progress in this field it may prove possible to use the 
high potency ZAG receptors developed in this report as probes for Zn2+ release. 
Transfection of such receptors into neuronal preparations to be expressed at synapses 
could provide an exciting opportunity, to detect for the first time, direct release of 
Zn2+ at the synapse.
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In conclusion, the data reported here provide a tantalising insight into some of the 
complex interactions that can occur in the extracellular portion of the GlyR. To 
dissect the processes that occur in a novel protein merely from a structural image is 
as futile as attempting to appreciate the picture of a face without any understanding 
of expressions. The dynamic information dissected in this report offer a glimpse into 
two expressions, Zn2+ potentiation and inhibition, available to the GlyR during the 
course of its routine role to process activation in response to the binding of an 
agonist.
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